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Chapter 1. Introduction 
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Parts of this introduction have been adapted from 
 Maltha J, Jacobs J. Clinical practice: The diagnosis of imported malaria in children Eur J Pediatr
2011, 170: 821-829.
 Maltha J, Gillet P, Jacobs J. Malaria rapid diagnostic tests in endemic settings. Clin Microbiol
Infect 2013, 19: 399-407.
 Maltha J, Gillet P, Jacobs J. Malaria rapid diagnostic tests in travel medicine. Clin Microbiol
Infect 2013, 19: 408-415.
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Burden of malaria 
Approximately half of the world’s population is at risk of acquiring malaria [1]. An estimated 219 
million persons get infected annually and 600,000 people die [1]. Children are mostly affected: 86% 
of deaths occurs in children <5 years of age, most of them in Sub-Saharan Africa. Other vulnerable 
groups are pregnant women and  non-immune travelers.  
What is malaria? [2] 
The parasite 
Malaria is caused by a parasite called Plasmodium, which is transmitted through the bites of the 
infected Anopheles mosquito. There are four human Plasmodium species: Plasmodium falciparum, 
Plasmodium vivax, Plasmodium ovale and Plasmodium malariae. Recently, human infections with a 
fifth species, Plasmodium knowlesi, which is usually found in monkeys, have been reported (48). 
Figure 1 depicts the life cycle of malaria parasites in humans.  
Figure 1. Plasmodium life cycle 
The Plasmodium life cycle in humans (right, blue arrows) and mosquitos (left, red arrows). 
Retrieved from Centers for Disease Control and Prevention (CDC). Available at http://www.cdc.gov/malaria/about/biology/ 
The cycle in the human host: from liver to blood, hypnozoites, relapse and recrudescence 
Plasmodium has a sexual cycle inside the mosquito and an asexual cycle inside man. During the bite 
of an infected female mosquito, Plasmodium sporozoites are injected in the dermis, they migrate 
into the blood and move to liver cells where they develop into liver schizonts. After the rupture of 
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the schizonts (approximately one week after infection), merozoites are released into the 
bloodstream and each of them will invade a red blood cell (RBC). There they develop into ring forms 
(trophozoites) which mature into schizonts that divide into merozoites which invade new RBCs. The 
rupture of the schizont and release of merozoites give rise to the so-called malaria paroxysms with 
spiking fever and rigors. The time required to complete the RBC cycle (from invading merozoites 
over trophozoites to rupturing schizont) depends on the species: for P. falciparum, P. vivax and P. 
ovale, the cycle takes 48 hours, for P. malariae and P. knowlesi it takes 72 hours and 24 hours 
respectively. In non-immune patients however, particularly when infected with P. falciparum, 
parasites tend to mature asynchronously, resulting in irregular fever patterns [3].    
After one or two weeks, gametocytes, the sexual form of Plasmodium, will be produced. These 
gametocytes continue the sexual cycle when taken up by a mosquito during a next blood meal. The 
sexual cycle will be completed over a period of two weeks, where after the mosquito can infect 
another human host.  
In case of P. vivax and P. ovale infections, dormant liver stages (hypnozoites) may cause infections 
(so-called relapses) weeks to months after adequate prophylaxis or effective blood-stage therapy of 
a primary infection. P. malariae may persist in the blood at undetectable levels without causing 
symptoms for many years and may subsequently develop into clinical illness in patients under 
immunosuppressive drugs or after splenectomy (also called recrudescence) [3]. Although rare, 
recrudescence has been reported for P. falciparum as well [4–7].
Geographic distribution of Plasmodium species 
Figure 2 displays the countries and areas where malaria transmission occurs. P. falciparum is the 
predominant species in sub-Saharan Africa, where P. vivax is virtually absent, except for some areas 
in Eastern Africa, as  most black Africans lack the Duffy blood group antigen which enables P. vivax to 
enter the RBC. P. ovale is mainly restricted to Africa, New Guinea and the eastern parts of Indonesia 
and the Philippines, but rare cases have been observed in the Middle East and Asia [8]. P. malariae is 
the second most common species in Africa and is also distributed in other geographic areas [3,8]. 
South-America is predominated by P. vivax though P. falciparum is present as well. The same goes 
for the Indian sub-continent and Southeast Asia where P. malariae is also prevalent. Most 
Plasmodium knowlesi infections have been reported from Malaysian Borneo [9], but have also been 
observed in other Southeast Asian countries [10,11].
Clinical symptoms  
Children with uncomplicated malaria may present with symptoms mimicking other diseases. Fever is 
common, is often intermittent and may be absent upon presentation. Other symptoms may include 
vomiting, headaches, chills, muscle aches and anorexia, abdominal pain and diarrhea and in the case 
of Plasmodium vivax intense rigors may occur [12]. The clinical picture may be indistinguishable from
many other common childhood infections like gastroenteritis (vomiting + diarrhea), respiratory 
infection or influenzae.  
In the case of P. falciparum, severe malaria may develop rapidly if no adequate treatment is started. 
Symptoms and signs of severe malaria include severe anemia, convulsions, coma, respiratory 
distress and shock [13], symptoms that may also be present in other life-threatening diseases like
bacterial sepsis or meningitis [12,14]. P. vivax and P. knowlesi can also cause severe malaria though
to a lesser extent [15,16].
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Figure 2. Countries or areas at risk of malaria transmission 
Retrieved from WHO. Malaria, countries or areas at risk of transmission, 2010. 
Treatment of malaria [17]
Artemisinin-based combination therapy (ACT) is recommended for uncomplicated falciparum 
malaria. For severe P. falciparum malaria intravenous artesunate is recommended, alternatively 
intravenous quinine can be given. P. vivax should be treated with chloroquine, or when resistance 
has been observed, with an ACT. In addition, primaquine should be administered to eradicate the 
liver hypnozoites. P. ovale should be treated with chloroquine and primaquine. P. malariae can be 
treated with chloroquine alone.  
Parasite based diagnosis 
In the past, patients in endemic countries were treated based on clinical symptoms alone. In view of 
the emergent resistance of P. falciparum to choloroquine and the need for more expensive 
artemisinin-based combination therapy (ACT), the World Health Organization (WHO) recommends 
treatment only after parasite based confirmation of the diagnosis, i.e. demonstration and 
identification of the parasite [17]. Microscopy or malaria rapid diagnostic tests (RDTs) can be 
used. Microscopy has the advantage of species identification and determination of parasite density. 
However, as microscopy is often unavailable in many malaria endemic settings or of low quality [18–
21], malaria rapid diagnostic tests (RDTs) are recommended as the diagnostic method of choice [17]. 
In 2006, in high endemic areas it was still recommended to treat children under 5 presumptively as 
malaria was thought to be the most common cause of illness. More recent studies have however 
shown that a decreasing proportion of children presenting with fever are ill due to malaria [22], and 
that parasite-based treatment in children is safe [23]. Therefore, since March 2010, WHO extended 
the recommendation for the parasite-based treatment to children below five years old [17].
Malaria rapid diagnostic tests  
Mechanisms of action 
RDTs are handheld devices in which malaria is visualized by a colored line on a nitrocellulose strip 
(Figure 3).The nitrocellulose strip is mostly embedded in a plastic cassette; occasionally, this strip 
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may present as a dipstick (self-standing strip to be dipped in a tube) or be enclosed in a cardboard 
format (Figure 4). When applying only 5 microliter of human blood, malaria can be detected by an 
antigen-antibody reaction on the test strip. The mechanism of action is explained in Figure 3.  
Figure 3. Schematic drawing of a malaria rapid diagnostic test  
Sequence of events when performing a malaria RDT. Blood and buffer are applied to the sample and buffer pad 
respectively. They are attracted by the capillary action of the absorption pad and start to migrate. First, they 
pass the conjugate pad, which contains a detection antibody targeting a Plasmodium antigen, such as PfHRP2, 
Pf-pLDH, Pv-pLDH, pan-pLDH or aldolase (for abbreviations see text). This detection antibody is a mouse-
antibody that is conjugated to a signal, mostly colloidal gold. If present in the sample, the Plasmodium antigen 
is bound to this detection antibody-conjugate. Next, the antigen-antibody-conjugate complex migrates further 
until it is bound to the capture antibody, which binds to another site of the Plasmodium target antigen. As the 
capture antibody is applied on a narrow section of the strip, the complex with the conjugated signal will be 
concentrated and by virtue of the colloidal gold will become visible as a colored line. The excess of detection 
antibody-conjugate that was not bound by the antigen and the capture antibody moves further until it is bound 
to a goat-raised anti-mouse antibody, thereby generating a control line [2]. 
Figure 4. Different platforms of RDTs 
From right to left: dipstick, cassette, hybrid and 
cardboard. [32] 
Plasmodium antigens  
The following antigens may be detected by RDTs: P. falciparum-specific histidine-rich protein-2 
(PfHRP2), parasite lactate dehydrogenase (pLDH) which can be specific to P. falciparum (Pf-pLDH), P. 
vivax (Pv-pLDH) or common to all Plasmodium species (pan-pLDH) or aldolase. 
The first antigen used for development of RDTs was PfHRP2, a protein produced by asexual forms 
and young gametocytes of P. falciparum [24,25]. It is expressed on the RBC membrane and readily
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diffuses into plasma [26]. Due to its slow clearance it may persist in the blood for more than 5 weeks
after effective treatment of infection [27–30], which leads to low specificity in high endemic areas.
The enzyme pLDH is used in the glycolytic pathway of all Plasmodium species and is produced by 
both sexual and asexual forms [31]. Aldolase is another enzyme of the glycolytic pathway of the
malaria parasite, it is common to all Plasmodium species and has also been incorporated as 
detection antigen in some of the commercial available RDT products.     
Malaria RDTs are available in different formats using different combinations of detection antigens. 
Two-band RDTs consist of a control line and one test line. Three-band RDTs contain two test lines, 
usually targeting P. falciparum (PfHRP2 or Pf-pLDH) and a pan-malaria antigen (pan-pLDH or 
aldolase). Four-band RDTs detect P. falciparum, a pan-malaria antigen and Pv-pLDH (Figure 5).  
Figure 5. Two-, three- and four-band malaria RDTs (above, middle and below respectively) run 
with a P. falciparum sample (left) and a P. vivax sample (right). 
The two-band RDT shows the control line and a P. falciparum (PfHRP2)-line for the P. falciparum sample and 
only a control line for the P. vivax sample: correct reporting is “P. falciparum” and “no P. falciparum detected” 
respectively. The three-band RDT shows - apart from the control line - PfHRP2 and pan-pLDH test lines for P. 
falciparum: correct reporting is “P. falciparum, mixed infection with non-falciparum species not excluded”. The 
P. vivax sample shows only a pan-pLDH test line; correct reporting is “non-falciparum species”. For the P. 
falciparum sample, the four-band RDT shows test lines for the pan-pLDH and PfHRP2 test lines: correct 
reporting is “P. falciparum, mixed infection with P. ovale/P. malariae not excluded”. For the P. vivax sample, 
pan-pLDH and Pv-pLDH test lines are visible; correct reporting is “P. vivax, mixed infection with P. ovale/P. 
malariae not excluded”. 
P. falciparum diagnosis: PfHRP2 versus Pf-pLDH 
Most commercially available RDTs detect PfHRP2 for the diagnosis of P. falciparum. Reported 
advantages of PfHRP2 over Pf-pLDH-detection are higher sensitivity at low parasite density (< 
100/microliter) [33] and lower susceptibility to environmental conditions like heat and humidity [34].
Pf-pLDH may however have other advantages, such as not being affected by the prozone effect, i.e. 
test lines of low intensity or absent test lines at high parasite densities [35]. Furthermore, no
sequence variation of the encoding gene has been observed [36,37] in contrast to PfHRP2 [38–40].
However, the impact of PfHRP2 sequence variation on RDT accuracy remains under debate [32,38].
Finally, Pf-pLDH-detecting RDTs may perform better in areas where pfhrp2 gene deletions have been 
observed [41].
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Use and regulation of RDTs 
From less than 200,000 RDTs used worldwide in 2005, this has rapidly expanded to 88,000,000 in 
2010 and an annual need of 1.5 billion RDTs has been forecasted (Roll Back Malaria, 
http://www.rollbackmalaria.org/psm/index.html). Currently more than 200 products from 60 
manufacturers are available [42]. Substandard RDTs are widespread in resource-limited settings
[43,44] and lot-to-lot variations may affect performance of RDTs [45]. WHO provides quality control
by inspection of manufacturing sites, systematic assessment of RDT products and their performance, 
a region based lot control program and provision of job aids and training material. There are 
however no controls at the bench and, except for a few brands 
(http://www.finddiagnostics.org/programs/malaria-afs/malaria/rdt-job-aids/), the provided job aids 
are generic whereas the RDT products on site may have different design and procedures.   
RDTs for the diagnosis of severe malaria 
In 2011, 87 out of 99 countries with on-going malaria transmission had adopted the policy of 
universal testing of malaria before start of treatment [1]. Several studies have shown safety of this 
strategy in uncomplicated malaria [23,46,47] although others debate this [48,49]. For children with 
signs of severe malaria this strategy has however not been extensively evaluated. In many remote 
settings, children may be diagnosed with malaria at health center level (provided RDTs are available) 
without further referral because of economic and geographic accessibility. As except for RDTs no 
other diagnostic method is available at the health center, further exploration to alternative causes of 
illness are limited and treatment decisions are based on clinical suspicion and malaria diagnosis by 
RDT. At the hospital level, malaria RDTs may be used rather than microscopy, because of lower 
workload and faster diagnosis, particularly at night. The RDT product most appropriate in this setting 
should be identified (PfHRP2 versus Pf-pLDH), high sensitivity is needed but also high specificity as 
other life-threatening diseases may be missed. PfHRP2-detecting RDTs are reported to have high 
sensitivity, also at very low parasite densities, but low specificity in high endemic settings in contrast 
to Pf-pLDH-detecting RDTs [33]. To refine the diagnostic algorithm in children with severe illness it is
important to know how often malaria and other life-threatening diseases with similar symptoms like 
bacteremia and meningitis occur.  
Malaria in travelers 
Yearly more than 125 million travelers visit a malaria endemic country [50]. Approximately 10,000
cases of imported malaria are reported annually, i.e. infection  acquired in endemic setting but 
symptoms appearing after return to home country, but this may be as high as 30,000 [50]. Children
account for 10-15% of all imported malaria cases [2]. Travelers or expats who stay abroad for a 
longer time may fall ill during their stay abroad. As malaria diagnosis is not always within reach or of 
low quality and counterfeit medications are not uncommon, the use of standby emergency 
treatment is increasingly recommended [51], and would ideally be preceded by a high quality self-
diagnostic test. This idea has been abandoned 10-15 years ago as several studies showed poor 
performance of RDTs in the hands of sick travelers [52–55]. Since then, RDTs have undergone
improvements and self-use by travelers may be reconsidered. RDTs are now widely available 
through the internet without need of consultation or prescription. Internet-sold RDTs are however 
of unknown quality and there is currently no regulation of RDT products sold online [43].
              8
Study objectives 
Although malaria RDTs have been studied extensively, during evaluations of malaria RDTs and visits 
to field settings we observed shortcomings in the accuracy of RDTs, at the level of end-user 
performance as well as to their use in the diagnostic algorithm. The shortcomings observed have led 
to research questions that have been addressed in this thesis.  
P. falciparum samples generating false positive P. vivax specific test lines (Chapter 2) 
First of all, we observed anecdotal false positive Pv-pLDH lines in case of P. falciparum samples with 
high parasite densities. We assessed the degree to which this occurs and addressed the question 
whether all Pv-pLDH RDT products are affected in Chapter 2.  
Which RDT for the Peruvian Amazon? (Chapter 3) 
Colleagues in Peru recently described existence of pfhrp2 gene deletions, the gene encoding the 
protein PfHRP2 which is detected by most malaria RDTs, in P. falciparum field isolates. This 
observation incited us to do an extensive evaluation of different RDT products in the Peruvian 
Amazon, where most malaria cases occur. RDTs – if chosen appropriately -  could highly  contribute 
to malaria case management in this area where the majority of people at risk of acquiring malaria 
have no access to health facilities with a microscope.  
End-user friendliness of RDTs (Chapter 4) 
Accurate instructions for use (IFU) are crucial for RDT performance and interpretation. During field 
visits we occasionally observed shortcomings in RDT IFUs and content. Moreover, a study on the 
external quality assessment of malaria RDTs revealed that some of the errors in interpretation were 
embedded in the IFUs supplied with the RDT. Therefore we assessed a large panel of RDT products 
for correctness and completeness of their IFU, the quality of packaging and labeling of the RDT box, 
device and buffer vial.   
RDTs for self-use by travelers? (Chapter 5) 
Malaria RDTs are now freely available through the internet and may be of interest to expats and 
long-term travelers. There is no strict regulation of RDT sale through internet and while the RDT 
products promise excellent performance, diagnostic accuracy as well as quality of instructions of 
these products are not known. We addressed this in Chapter 5. 
MALARIA SELF-TEST? Source: www.lonelyplanet.com 
Hi, 
I'm going to be spending 3-4months cycling through Kenya, Tanzania and Mozambique solo. 
My travel clinic doctor has suggested i might want to take a malaria self-test kit with me as well as 
some treatment medication in case i find myself with malaria symptoms away from a clinic with the 
necessary medication. The latter sounds like a good idea, but is the test kit really worth it? 
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RDTs for children suspected of severe malaria (Chapters 6 and 7) 
In malaria endemic areas, children with severe febrile illness are often diagnosed as having severe 
malaria. Bacterial infections are however not uncommon and co-infections with malaria may occur. 
In Burkina Faso there are hardly any data about the prevalence of bacterial infections. In Chapter 6 
we assessed the proportions of severe malaria versus bacteremia in children presenting with severe 
febrile illness as well as the frequency of co-infections. In Chapter 7 we compare the diagnostic 
accuracy of PfHRP2 versus Pf-pLDH-detection in children presenting with severe febrile illness in a 
rural area with seasonal P. falciparum transmission. Few studies addressed the use of malaria RDTs 
in children suspected of severe malaria and those who did recommend PfHRP2-detecting RDTs 
which we expect to be less useful in high endemic settings.   
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Abstract
Background: Most malaria rapid diagnostic tests (RDTs) detect Plasmodium falciparum and an antigen common to the 
four species. Plasmodium vivax-specific RDTs target P. vivax-specific parasite lactate dehydrogenase (Pv-pLDH). Previous 
observations of false positive Pv-pLDH test lines in P. falciparum samples incited to the present study, which assessed P. 
vivax-specific RDTs for the occurrence of false positive Pv-pLDH lines in P. falciparum samples.
Methods: Nine P. vivax-specific RDTs were tested with 85 P. falciparum samples of high (≥2%) parasite density. Mixed P. 
falciparum/P. vivax infections were ruled out by real-time PCR. The RDTs included two-band (detecting Pv-pLDH), three-
band (detecting P. falciparum-antigen and Pv-pLDH) and four-band RDTs (detecting P. falciparum, Pv-pLDH and pan-
pLDH).
Results: False positive Pv-pLDH lines were observed in 6/9 RDTs (including two- three- and four-band RDTs). They 
occurred in the individual RDT brands at frequencies ranging from 8.2% to 29.1%. For 19/85 samples, at least two RDT 
brands generated a false positive Pv-pLDH line. Sixteen of 85 (18.8%) false positive lines were of medium or strong line 
intensity. There was no significant relation between false positive results and parasite density or geographic origin of 
the samples.
Conclusion: False positive Pv-pLDH lines in P. falciparum samples with high parasite density occurred in 6/9 P. vivax-
specific RDTs. This is of concern as P. falciparum and P. vivax are co-circulating in many regions. The diagnosis of life-
threatening P. falciparum malaria may be missed (two-band Pv-pLDH RDT), or the patient may be treated incorrectly 
with primaquine (three- or four-band RDTs).
Background
Malaria rapid diagnostic tests (RDTs) are immunochro-
matographic tests targeting antigens of one or more Plas-
modium species. Signals are visible as cherry-red to
purple coloured lines, comprising a control line (which
indicates that the test has been performed well) and one
or two test lines. The initially developed two band tests
generate a test line that targets P. falciparum by detecting
either histidine-rich protein 2 (HRP-2) or P. falciparum-
specific parasite lactate dehydrogenase (Pf-pLDH). The
later developed three band tests include a second target
that is common to the four Plasmodium species, such as
aldolase or pan-specific parasite lactate dehydrogenase
(pan-pLDH). However, the conventional three-band
RDTs, detecting a P. falciparum-specific antigen and a
pan-Plasmodium antigen, cannot distinguish between a
P. falciparum infection and a mixed infection with P.
vivax when both test lines are observed. Differentiation
between the non-falciparum species is neither possible. P.
falciparum and P. vivax infections require different treat-
ment, which makes discrimination between the two spe-
cies important. RDTs specific to P. vivax could be useful.
There are two-band RDTs that detect Plasmodium vivax-
specific pLDH (Pv-pLDH), three-band RDTs in which
Pv-pLDH is combined with HRP-2 or Pf-pLDH, and so-
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Page 2 of 7called four-band tests that combine detection of HRP-2,
pan-pLDH and Pv-pLDH. The Pv-pLDH tests have
undergone limited evaluation [1-3].
In previous evaluations of RDTs targeting Pv-pLDH,
rare but consistent false positive Pv-pLDH test lines were
observed among P. falciparum samples, especially at high
parasite densities [2-4]. These observations are of con-
cern as this limits the potential use of the Pv-pLDH
directed RDTs, both in endemic and non-endemic set-
tings. In order to study the extent of this phenomenon
among other RDTs, the present study was undertaken to
challenge available RDT brands with a Pv-pLDH test line
to a panel of P. falciparum samples with high parasite
densities.
Methods
Study design
Several RDTs were retrospectively evaluated in a refer-
ence laboratory on a panel of stored whole blood samples
obtained in patients suspected of malaria. The reference
method was microscopy corrected by polymerase chain
reaction (PCR).
Patient samples
In this study stored whole blood samples (-70°C) were
used, obtained in returned international travelers sus-
pected of malaria presenting at the outpatient depart-
ment of the Institute of Tropical Medicine (ITM),
Antwerp, Belgium, or submitted by other Belgian labora-
tories to ITM in its function of National Reference Cen-
ter. Samples had been obtained between 1996 and 2009
and were classified in regions of travel destinations
according to the United Nations classification of geo-
graphical region and composition [5]. All samples were
evaluated by microscopy and real-time PCR for species
identification (ruling out mixed infections) and determi-
nation of parasite density, as described previously [6,7].
For the purpose of this study, the more convenient para-
site density expressed by % of infected red blood cells was
applied, thereby assuming 50,000/μl to be equal to 1% of
red blood cells parasitized [8]. P. falciparum-infected
samples with parasite densities ≥2% (≥100,000/μl) were
selected.
Malaria rapid diagnostic tests
RDTs containing a P. vivax-specific test line were
selected, including those published on the World Health
Organization (WHO) list of RDT manufacturers with
adequate evidence of good manufacturing [9] as well as
others available on the international market. We checked
the package inserts to ensure the antigen used was P.
vivax-specific. In line with other comparative evaluations
[7,10] it was decided not to display individual RDT brand
names because of the wide lot-to-lot variability and the
frequent changes in composition and brand names and
types [1].
Test procedures
Tests were performed according to the manufacturers'
instructions, except that a pipette (Finnpipette, Helsinki,
Finland) was used instead of the transfer devices supplied
by the manufacturer. The laboratory technicians involved
in the study have received a detailed training and their
performance and agreement are monitored by participa-
tion to internal and external quality control assessments.
Readings were done by three subsequent observers, of
whom the first always was the one performing the test,
and carried out at daylight assisted by an electric bulb.
The observers were blinded to each others readings and
to the results of microscopy and PCR. In case no control
line was observed the test was considered invalid and
repeated. Test line intensities were scored according to a
system of five categories as described previously [6]: none
(no line visible), faint (barely visible line), weak (paler
than the control line), medium (equal to the control line)
and strong (stronger than the control line). Test results
were based on consensus agreement: the same test result
observed by at least two out of three readers. In case of no
consensus the result of the first reader was considered.
Pv-pLDH lines generated by P. falciparum samples will be
further referred to as false positive Pv-pLDH lines.
Statistical analysis
The nonparametric Spearman's rank correlation coeffi-
cient rs was used to measure the strength of association
between parasite density and the number of RDTs with a
false positive Pv-pLDH test line. Associations were con-
sidered significant at a p-value < 0.05. Inter-observer
agreement for line intensities and positive and negative
test results were expressed by kappa values for each pair
of observers and by the percentage of overall agreement
between the three observers.
Ethical review
The study was reviewed and approved by the Institutional
Review Board of ITM and by the Ethical Committee of
Antwerp University, Belgium.
Results
Collection of samples and RDTs
Eighty-five P. falciparum samples with a parasite density
≥2% (100,000/μl) were selected. The parasite densities
ranged from 2-35%, with 30 samples of at least 20% para-
site density.
The male:female ratio was 3:1, with a median age of 40
years (range 3-98 years) and three children were under
the age of five years. Samples were obtained in West
Africa (n = 34), Middle Africa (n = 22), East Africa (n =              15
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Page 3 of 75), Southern Africa (n = 4) and West Asia (n = 1). Of 19
samples no data on the geographic origin were known
and could not be retrieved. Four RDT brands (numbers.
1, 4, 7 and 9) were tested with less than 85 samples, due to
either a lack of RDTs or a lack of sample.
Twenty different RDT brands were selected. Although
their product name referred to P. vivax-specificity (for
instance, by adding the epithet "Pf/Pv"), two of them in
fact targeted pan-pLDH instead of Pv-pLDH: these RDTs
were not considered for evaluation. Seven companies
marketing eight RDT brands did not reply to the order of
RDTs, despite several reminders via email contact. One P.
vivax-specific three-band RDT was not included in this
study because of bad clearance of the background, which
made reading results impossible. The final panel con-
sisted of nine different RDT brands from seven manufac-
turers, including one two-band (single Pv-pLDH test
line), three three-band (Pv-pLDH and HRP-2 test line)
and five four-band RDTs (Pv-pLDH, HRP-2 and pan-
pLDH test line). Five RDTs had CE mark compliance and
two were included in the WHO list of good manufactur-
ing practices.
Three different four-band RDT brands (numbers 6, 7
and 8) had similar package inserts and the cassettes had
identical morphology. Two three-band RDTs (numbers. 2
and 3) also had identical cassettes and similar package
inserts. RDT numbers 1 and 4 were from the same manu-
facturer, as well as RDT numbers 2 and 5.
Test characteristics
There were no invalid test results. As expected, all the P.
falciparum samples showed positive test lines for the
HRP-2 and the pan-pLDH test lines, if present on the cas-
sette. Table 1 lists the results for the Pv-pLDH test lines,
expressed by line intensities. In total there were 85 false
positive Pv-pLDH lines in six RDT brands, caused by a
total of 42 samples. In the individual RDT brands they
occurred at frequencies of 8.2% (7/85 samples) up to
29.1% (23/79 samples), among two-, three- and four-band
tests. There was no difference between RDTs that were
CE-marked or WHO-listed and those which were not.
Table 2 lists the details of consensus readings of line
intensities for the false positive Pv-pLDH test lines,
according to parasite densities and region of infection. In
2/736 readings there was no consensus and the results of
the first reader were considered. Nineteen samples gener-
ated a false positive line in at least two RDTs. There was
no apparent relation between parasite density of samples
and the occurrence of false positive Pv-pLDH lines (rs =
0,155, p = 0,153). False-positive Pv-pLDH lines occurred
exclusively in samples from patients returning from Mid-
dle or West Africa (Table 3), but there was no significant
relation between geographic origin of samples and false-
positive results.
Most (69/85, 81.2%) false-positive Pv-pLDH readings
were faint or weak (Table 1), but strong line intensities
were observed in two RDT brands (Tables 1 and 2). Taken
all readings together, inter-observer agreements for line
intensity readings were good for HRP-2, pan-pLDH and
Pv-pLDH test lines. For the Pv-pLDH line, in terms of
positive and negative readings for all brands together,
kappa values between pairs of observers were good (0.79,
0.70, 0.77) and overall agreement was excellent (88.0%).
For the RDT brands considered separately, overall agree-
ment for the Pv-pLDH line ranged from 75.9% to 100%.
Discussion
In this study, six out of nine P. vivax-specific RDTs
showed false positive Pv-pLDH lines when challenged to
a panel of 85 P. falciparum samples with high (≥2%) para-
site densities, in which mixed infections with P. vivax
Table 1: Line intensity reading for Pv-pLDH lines in P. falciparum samples with parasite densities ≥2%
Line intensity readings, number of samples
Nr Type Nr of samples tested Faint Weak Medium Strong Total positive (% of total samples)
1 Two-band 84 7 4 1 4 16 (19.0%)
2 Three-band 85 0
3 Three-band 85 0
4 Three-band 66 2 5 4 11 (16.7%)
5 Four-band 85 0
6 Four-band 85 8 13 21 (24.7%)
7 Four-band 79 19 3 1 23 (29.1%)
8 Four-band 85 2 5 7 (8.2%)
9 Four-band 82 1 5 1 7 (8.5%)
Two-band: Pv-pLDH test line; Three-band: Pv-pLDH and HRP-2 test line; Four-band: Pv-pLDH, HRP-2 and pan-pLDH test line.              16
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Page 4 of 7Table 2: False positive Pv-pLDH lines in 42 P. falciparum samples with parasite densities ≥2%
Samples RDT number and type
Nr % parasite 
density
Origin 1. Two-band 4. Three-band 6. Four-band 7. Four-band 8. Four-band 9. Four-band Total RDTs 
positive
1 2,0 MAF - - - - - W 1
2 2,2 MAF - * F - - - 1
3 2,3 MAF - * W - - - 1
4 2,8 WAF F F - - - - 2
5 3,2 MAF W S W W W W 6
6 3,2 MAF - * - F F - 2
7 3,3 WAF - * F - - - 1
8 3,7 ND S * - F - - 2
9 3,8 ND - - - F - - 1
10 3,9 ND - - W F - - 2
11 4,0 WAF S S W F W - 5
12 4,2 WAF W M - - - - 2
13 4,5 WAF F F - - - - 2
14 4,6 MAF - - F - - - 1
15 5,3 WAF M M W F - - 4
16 5,5 WAF - - - F - - 1
17 5,7 MAF S S W W - F 5
18 6,6 MAF F * - - - - 1
19 7,0 ND - - W F - - 2
20 7,2 WAF S * W M W M 5
21 7,4 WAF - - - F - - 1
22 7,6 MAF - - - F - - 1
23 9,1 ND - - - - - W 1
24 9,6 ND * M W F - - 3
25 20,0 ND - - - F - - 1
26 20,0 WAF F - - F - - 2
27 20,0 WAF - - W - - - 1
28 20,0 WAF W S W F W - 5
29 20,0 WAF W M F F - W 5
30 20,0 WAF - - F F - - 2
31 20,0 ND F - - - - - 1
32 20,0 ND F - - F - - 2
33 20,0 WAF - - - F - - 1
34 20,0 MAF - * - - - W 1
35 20,0 ND - * F - - - 1
36 20,0 MAF F * - - - - 1
37 20,0 WAF - * W - - - 1
38 20,0 WAF - * F - - - 1
39 20,0 WAF - * F - - - 1
40 20,0 MAF - - - F - - 1
41 20,0 WAF - M W W W - 4
              17
Maltha et al. Malaria Journal 2010, 9:198
http://www.malariajournal.com/content/9/1/198
Page 5 of 7were excluded by PCR analysis. Frequencies for individ-
ual brands ranged from 8.2% (7/85 samples) to 29.1% (23/
79 samples).
Plasmodium vivax accounts for almost half of the
malaria infections worldwide and is no longer considered
as a mild infection: complicated infections have been
demonstrated in both endemic countries and in returned
travelers [11,12]. In addition, P. vivax malaria may be
chloroquine resistant and has a tendency to relapse [13].
To eradicate the dormant liver stages, primaquine treat-
ment is needed. Primaquine is contraindicated in case of
glucose-6-phosphate dehydrogenase (G6PD) deficiency,
due to the risk of hemolysis [14,15]. G6PD deficiency is
common in most P. vivax malaria areas; moreover, in
these areas G6PD testing is impractical due to a lack of
funds, equipments or expertise [16].
RDTs detecting P. vivax-specific pLDH are of addi-
tional value for the diagnosis of malaria in both P. vivax
endemic areas and in the setting of travel medicine. The
conventional three-band RDTs detecting a P. falciparum-
specific antigen and a pan-Plasmodium antigen cannot
distinguish between a P. falciparum infection and a mixed
infection with P. vivax when both test lines are observed.
Differentiation between the non-falciparum species is
neither possible. Three- or four-band RDTs that target
Pv-pLDH have the advantage that they can detect P. vivax
in mixed infections: they are an adjunct to microscopy as
P. vivax is often microscopically under diagnosed in
mixed infections [13]. In addition they can be used to dis-
tinguish between Plasmodium ovale and P. vivax [2]. This
is an advantage in the non-endemic setting, where micro-
scopic differentiation between P. ovale and P. vivax is
notoriously difficult [17].
Plasmodium vivax-specific RDTs have hardly been
evaluated [18-22], and are not discussed in any of the
recent reviews on malaria RDTs [1,8,17,23]. The present
findings are of concern particularly in areas where P. fal-
ciparum and P. vivax are co-circulating: in case of a two-
band Pv-pLDH test, the diagnosis of life-threatening P.
falciparum malaria may be missed, which is especially of
concern in remote areas among less experienced staff and
without backup of microscopy. In case of a three- or four-
band RDT, the patient may be treated incorrectly with
primaquine, leading to severe hemolysis in patients with
G6PD-deficiency.
Among the limitations of the present study, we should
mention its retrospective nature (precluding further
work-up of samples), the test conditions in a reference
laboratory (which are more favorable than those in field
settings) and the fact that all but one P. falciparum sam-
ples were obtained in travelers returning from Africa. In
addition, the present study explored false positive Pv-
42 35,0 WAF - * - - F - 1
Total false positive Pv-
pLDH lines
16 11 21 23 7 7 85
MAF = Middle Africa; WAF = West Africa; ND = No Data
F = faint; W = weak; M = medium; S = strong; - = negative; * = sample not tested due to lack of RDT or sample
Table 2: False positive Pv-pLDH lines in 42 P. falciparum samples with parasite densities ≥2% (Continued)
Table 3: Numbers of P. falciparum samples generating false positive Pv-pLDH lines according to geographic origin
Numbers of samples tested*
Origin (region) Total Negative Positive** (% of total 
samples)
East Africa 5 5 0
Middle Africa 22 10 12 (54.5)
Southern Africa 4 4 0
West Africa 34 14 20 (58.8)
West Asia 1 1 0
No data 19 9 10 (52.6)
All samples 85 43 42 (49.4)
* Nine RDT brands were tested with a panel of 85 samples
** Defined as a sample with a false positive Pv-pLDH line in ≥1 RDT brand              18
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Page 6 of 7pLDH lines exclusively in samples with high P. falciparum
parasite densities, in line with the previous observations
[2-4]. However, the inclusion of P. falciparum samples of
lower parasite density and Plasmodium negative samples
would have completed the picture. A prospective study in
an area with P. falciparum and P. vivax coexistence
should be performed to assess the relevance of the false
positive Pv-pLDH lines in a field setting.
False-positive reactions of P. vivax samples with the
HRP-2 line and the Pf-pLDH line have been described
previously [24-26], but the presently observed false-posi-
tive Pv-pLDH lines in P. falciparum samples have only
been reported anecdotally [2-4,22]. Among the panel of
RDTs tested in the WHO and Foundation for Innovative
New Diagnostics (FIND) study, there were two RDTs
with a Pv-pLDH line: according to the tables, one of them
generated false positive Pv-pLDH lines in 1.9% (6/316) of
the P. falciparum samples tested.
Without exact knowledge of the antibodies targeting
the Pv-pLDH antigen, it is difficult to explain the phe-
nomenon, especially since false positive Pv-pLDH lines in
the present study occurred not consistently among the
different samples and brands. Weak cross-reactions may
also be facilitated by slight differences in the composition
of the nitrocellulose membrane and the diluent. It is
known that several companies use the same pLDH anti-
bodies in their RDT brands [27] and this may also be the
case for Pv-pLDH: this is reflected by the identical prod-
uct presentations and similar false positive rates of RDT
brands numbers 6 and 7 and numbers 2 and 3 respec-
tively. In the present study, there was no apparent relation
between the false positive Pv-pLDH lines and the geo-
graphic origin of the infection, but it should be noted that
mainly samples from sub-Saharan Africa were included.
The present study also revealed problems in RDT avail-
ability and communication with the supplier in the inter-
national market, as eight brands were not delivered
despite several reminders. Furthermore, two of the RDTs
that claimed to be P. vivax-specific by their label and
name proved to detect pan-pLDH according to their
package insert. Similar confusing names have been noted
previously, also for the antibodies targeting aldolase [28].
Conclusion
The occurrence of false positive Pv-pLDH lines in P. falci-
parum samples with high parasite densities was observed
in six out of nine P. vivax-specific RDTs, in two-, three-
and four-band RDTs. The false positive Pv-pLDH lines
are of concern because the diagnosis of life-threatening P.
falciparum malaria may be missed (two-band Pv-pLDH
RDT), or the patient will be treated incorrectly with pri-
maquine (three- or four-band RDT), which may cause
severe hemolysis in patients with G6PD-deficiency. A
prospective study in an area with P. falciparum and P.
vivax coexistence should be performed to assess the rele-
vance of the false positive Pv-pLDH lines in a field set-
ting.
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Abstract
Background: In the Peruvian Amazon, Plasmodium falciparum and Plasmodium vivax malaria are endemic in rural areas,
where microscopy is not available. Malaria rapid diagnostic tests (RDTs) provide quick and accurate diagnosis. However,
pfhrp2 gene deletions may limit the use of histidine-rich protein-2 (PfHRP2) detecting RDTs. Further, cross-reactions of P.
falciparum with P. vivax-specific test lines and vice versa may impair diagnostic specificity.
Methods: Thirteen RDT products were evaluated on 179 prospectively collected malaria positive samples. Species diagnosis
was performed by microscopy and confirmed by PCR. Pfhrp2 gene deletions were assessed by PCR.
Results: Sensitivity for P. falciparum diagnosis was lower for PfHRP2 compared to P. falciparum-specific Plasmodium lactate
dehydrogenase (Pf-pLDH)- detecting RDTs (71.6% vs. 98.7%, p,0.001). Most (19/21) false negative PfHRP2 results were
associated with pfhrp2 gene deletions (25.7% of 74 P. falciparum samples). Diagnostic sensitivity for P. vivax (101 samples)
was excellent, except for two products. In 10/12 P. vivax-detecting RDT products, cross-reactions with the PfHRP2 or Pf-
pLDH line occurred at a median frequency of 2.5% (range 0%–10.9%) of P. vivax samples assessed. In two RDT products, two
and one P. falciparum samples respectively cross-reacted with the Pv-pLDH line. Two Pf-pLDH/pan-pLDH-detecting RDTs
showed excellent sensitivity with few (1.0%) cross-reactions but showed faint Pf-pLDH lines in 24.7% and 38.9% of P.
falciparum samples.
Conclusion: PfHRP2-detecting RDTs are not suitable in the Peruvian Amazon due to pfhrp2 gene deletions. Two Pf-pLDH-
detecting RDTs performed excellently and are promising RDTs for this region although faint test lines are of concern.
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Introduction
In Peru, malaria is mainly endemic in the Amazon region,
where it is the primary cause of morbidity in adults and the fourth
in children [1]. According to the recommendations of the World
Health Organization (WHO), diagnosis and treatment should be
based on parasitological confirmation by either microscopy or
malaria rapid diagnostic tests (RDTs) [2]. In Peru, most cases
occur in rural areas where no microscopy is available. Currently,
thick blood films (TBFs) of malaria suspected patients are sent for
analysis to the most nearby health center, but this process takes
several days and patients are often treated presumptively [3]. In
such conditions RDTs could be useful, providing quick and
accurate diagnosis, thereby leading to timely and correct treatment
and reducing the severity and economic burden of disease.
Besides, use of RDTs in the Peruvian Amazon has been
demonstrated to be cost-effective [4].
RDTs are handheld cassettes detecting malaria parasites by an
antigen-antibody reaction on a nitrocellulose strip which become
visible as blue or cherry-red test lines. There are several detection
antibodies, directed to different antigens: histidine-rich protein-2
(PfHRP2) and Plasmodium falciparum-specific Plasmodium lactate
dehydrogenase (Pf-pLDH) for P. falciparum; Plasmodium vivax-
specific pLDH (Pv-pLDH) for P. vivax, and pan-pLDH and
aldolase which are common to all four Plasmodium species.
The occurrence of both P. vivax and P. falciparum in Peru
requires an RDT type that detects and differentiates between both
species as they require different treatment [2]. However, cross-
reactions may occur, i.e. the presence of a visible P. falciparum test
line among P. vivax samples and vice versa [5,6], due to genuine
antigen-antibody interactions or non-specific bindings [7]. In
addition, P. falciparum parasites lacking the pfhrp2 and pfhrp3 genes,
-encoding PfHRP2 and the related protein PfHRP3 respectively-
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have been recently described in Peru [8] indicating that the use of
PfHRP2 detecting RDTs may be limited [8]. Previous evaluations
of two PfHRP2 detecting RDTs in Peru demonstrated sensitivity
for P. falciparum diagnosis of 95% [9] and 53.5% [10].
The aims of the present study were to assess diagnostic accuracy
of a panel of different RDT products for malaria diagnosis in the
Peruvian Amazon, with particular focus on the impact of pfhrp2
and pfhrp3 gene deletions on diagnostic sensitivity and of cross-
reactions on diagnostic specificity.
Methods
Ethics statement
The study was approved by the Ethical Review Board of the
Universidad Peruana Cayetano Heredia, Lima, Peru (Code
SIDISI: 55587 and 55239). All patients with a positive TBF,
performed as part of routine patient care, were included after
signing informed consent. Written informed consent was obtained
from the patient himself in the case of adults or from the parent/
guardian in case of a minor (,18 years).
Study site and population
Several health centers around Iquitos (Figure 1) were included.
Malaria in the Peruvian Amazon is perennial with a peak during
the rainy season (November – May) and an incidence of 10–50
malaria cases per 1000 inhabitants per year [11]. Patients were
included by either passive case detection (symptomatic patients
presenting at the health centers) or active case detection (outreach
teams performing malaria screening in epidemic communities). All
patients with a positive TBF were included after signing informed
consent. Previous antimalarial treatment, symptoms and travel
history were recorded.
Samples
EDTA anti-coagulated venous blood samples were drawn and
transported to the laboratory of San Juan where RDTs were
performed. After RDT performance, samples were aliquoted and
stored at 220uC, usually within 24 hours (range 2–72 hours) after
sample collection, pending further analysis.
Malaria rapid diagnostic tests
Thirteen RDT products detecting several target antigens were
selected (Table 1), based on good performance as documented by
the WHO/Foundation for Innovative New Diagnostics (FIND)
malaria RDT evaluation program [12,13] or recent release on the
market.
Both SDFK90 and Paracheck detect only P. falciparum and were
included for evaluation of P. falciparum diagnosis. SDFK90 was
only performed on P. falciparum samples and mixed infections.
RDTs were purchased at the Institute of Tropical Medicine
(ITM), Belgium and shipped to Peru. For logistic reasons (delays of
delivery and shipment), some RDTs had to be performed on
stored samples, in these cases median period of sample storage was
51 days (range 29–131 days).
Test procedures
RDTs were performed according to the manufacturer’s
instructions except that the supplied transfer device was replaced
by a micropipette. The first observer read test results within the
specified reading time, the second and, when available, third
observer within 10 additional minutes. Observers were blinded to
each other’s readings. In case of absence of the control line the test
was repeated. A scoring system of five categories was used to assess
line intensities [14]. Test results were based on consensus
agreement in case of three observers. In all other cases, the result
of the first observer was considered.
Microscopy
At the laboratory of San Juan, species and parasite density were
determined by TBF microscopy, assuming a white blood cell count
of 8,000/ml [15]. For quality control (QC), 20% randomly selected
slides, including those with interpretive problems, discordant RDT
results, negative slides and suspected mixed infections were
reexamined by two blinded expert microscopists at ITM. For
parasite density the results of the first microscopist were considered
except when QC indicated a density of more than two fold
difference with the original count, in such cases mean of the two
QC readings was considered.
DNA extraction
DNA was extracted from 200 ml whole blood using QIAamp
DNA blood Mini kit (QIAGEN, Venlo, The Netherlands),
according to the manufacturer’s instructions except for a dilution
in 100 ml instead of 200 ml elution buffer.
Species-specific PCR
In case of discordances between RDT and microscopy or
between initial and QC microscopy, real-time PCR (P. falciparum/
P. vivax) was performed [16] which was considered conclusive.
Assessment of pfhrp2 and pfhrp3 gene deletions
Confirmed P. falciparum samples were assessed for pfhrp2 and
pfhrp3 gene deletions by conventional PCR using primers and
conditions as described elsewhere [8,17]. For pfhrp2, two
amplifications were performed: one of entire exon 2 (encoding
PfHRP2) and another across exon 1 and exon 2 (exon1–2).
Samples were considered lacking the pfhrp2 gene when both
amplifications failed to generate a PCR product. For pfhrp3, a
single amplification of entire exon 2 was performed.
PfHRP2 ELISA
The presence of PfHRP2 protein in whole blood samples was
determined by enzyme linked immune sorbent assay (ELISA,
Figure 1. Map of included health centers. The village of Atalaya
(23.58, 273.75), located 59 km to the West of Iquitos, is not displayed
on the map.
doi:10.1371/journal.pone.0043094.g001
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Standard Diagnostic, Hagal-Dong, Korea) according to the
manufacturer’s instructions. ELISA was performed in all samples
with P. falciparum infection, mixed infections and in P. vivax samples
generating visible PfHRP2 lines.
Statistical analysis
Diagnostic sensitivity (calculated with 95% confidence intervals
(C.I.)) of the RDT products was defined as the number of P.
falciparum or P. vivax samples with a visible P. falciparum-specific or
Pv-/pan-pLDH test line respectively (regardless of the presence of
another test line), divided by the total number of P. falciparum or P.
vivax samples respectively. Mixed infections were not included for
calculation. Cross-reactions were defined as P. falciparum samples
generating a visible Pv-pLDH line or P. vivax samples generating a
visible PfHRP2 or Pf-pLDH line.
Proportions were assessed for statistical significance using the
Chi-square test or, in case of small sample size, the Fisher-exact
test. A p-value,0.05 was considered significant.
Interobserver agreement was determined by kappa values (k) for
positive and negative readings and line intensity readings between
the first pair of observers.
Additional analysis
All microscopically confirmed P. falciparum samples that did not
show a visible PfHRP2 line in more than one RDT product were
repeated two times with all PfHRP2-detecting RDTs.
Results
Patients and samples
From December 2010–July 2011, 182 patients were included, in
three patients malaria was not confirmed by microscopy nor by PCR.
Final sample collection consisted of P. falciparum (n = 74), P. vivax
(n = 101) and four mixed infections. The collected samples comprised
5% of all P. falciparum and P. vivax infections reported in Loreto region
in that time period [1,18]. Data of demography and parasite density
are shown in Table 2. Nineteen patients, including the two
asymptomatic cases, were included through active case detection
performed once in Tarapoto (n = 5) and once in Atalaya (n = 14).
Diagnostic sensitivity of the RDT products
PfHRP2-detecting RDTs had significantly lower sensitivity for
P. falciparum diagnosis compared to Pf-pLDH-detecting RDTs
(p,0.0001, Table 3), due to a subset of samples that consequently
failed to generate a PfHRP2 line in all PfHRP2 RDT products
tested, see results below.
For P. vivax diagnosis, most RDTs performed equally well,
except for AZOG (detecting Pv-pLDH) and Parascreen (detecting
pan-pLDH) (Table 3), which failed to detect P. vivax samples at a
median parasite density of 1,075/ml (range 255–4,532/ml) and
600.5/ml (range 255–10,720/ml) respectively.
The mixed infections were detected by all RDT products except
for AZOG which displayed a single PfHRP2 line for a sample
consisting predominantly of P. falciparum parasites.
Table 1. Overview of RDT products and their lot numbers.
Product name Manufacturer/distributor
Further
referred to as
Target
antigen Pf
Target antigen
pan/Pv Lot numbers
Recommended
storage temperature
ADVANTAGE Mal Card J. Mitra & Co., New Dehli,
India
Advantage Pf-pLDH pan-pLDH ACM171110 4–30uC
AZOG Malaria Pf/Pv AZOG, Inc. New Jersey, USA AZOG PfHRP2 Pv-pLDH 58LAB017 2–30uC
CareStartTM Malaria Pf-
pLDH/pLDH (Pf/PAN)
Combo
Access Bio, Inc. New Jersey,
USA
CareStart pLDH Pf-pLDH pan-pLDH A10IL 4–30uC
CareStartTM Malaria
HRP2/Pv-pLDH (Pf/Pv)
Combo
Access Bio, Inc. New Jersey,
USA
CareStart Pf/Pv PfHRP2 Pv-pLDH J10IV 4–30uC
Falcivax Rapid Test for
Malaria Pv/Pf
Zephyr Biomedicals, Verna,
India
Falcivax PfHRP2 Pv-pLDH 81098 4–30uC
First Response Ag
malaria pLDH/HRP2
combo test
Premier Medical Corporation
Daman, India
First Response PfHRP2 pan-pLDH 69I0610 4–30uC
Onsite Pf/Pv Ag rapid
test
CTK Biotech, Inc. San Diego,
USA
Onsite PfHRP2 Pv-pLDH F0810G2 2–30uC
PARACHECK PfH
(device)
Orchid Biomedical Systems
Verna, India
Paracheck PfHRP2 - 31795, 31797 4–45uC
Parascreen Rapid Test
for Malaria Pan/Pf
Zephyr Biomedicals, Verna,
India
Parascreen PfHRP2 pan-pLDH 101176 4–30uC
SD Bioline Malaria
Antigen test
Standard diagnostic, Hagal-
dong, Korea
SDFK40 Pf-pLDH pan-pLDH MLRDT1001,
MLRDT1002
1–40uC
SD Bioline Malaria
Antigen P.f/pan
Standard diagnostic, Hagal-
dong, Korea
SDFK60 PfHRP2 pan-pLDH 90026, 90017,
90096
1–40uC
SD Bioline Malaria
Antigen P.f/P.v
Standard diagnostic, Hagal-
dong, Korea
SDFK80 PfHRP2 Pv-pLDH 145015, 145016 1–40uC
SD Bioline Malaria
Antigen P.f
Standard diagnostic, Hagal-
dong, Korea
SDFK90 PfHRP2 and Pf-
pLDH*
- MFRDT1001,
MFRDT1002
1–40uC
*SDFK90 contains 2 test lines specific for P. falciparum.
doi:10.1371/journal.pone.0043094.t001
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For P. falciparum, faint test line intensities occurred more
frequently among Pf-pLDH compared to PfHRP2-detecting
RDTs (p,0.001, Table 3). For P. vivax, no overall difference in
proportion of faint test lines was observed between Pv-pLDH
versus pan-pLDH-detecting RDTs.
Failure of P. falciparum diagnosis by PfHRP2-detecting
RDTs and pfhrp2 gene deletions
All PfHRP2-detecting RDTs failed to diagnose 21 P. falciparum
samples (Table 4), whereas the Pf-pLDH-detecting RDTs detected
all of them. Most samples (19/21) were lacking pfhrp2 (no
amplification of exon1–2 and exon2). The remaining two samples
(PI151 and PI156) generated PCR products for pfhrp2 exon1–2 and
exon2. Pfhrp2 gene deletions occurred at both low and high parasite
densities (Table 4) and all patients were symptomatic. PfHRP2
ELISA of the 21 samples confirmed the absence of PfHRP2, with
only one sample (PI26) showing a weak positive result (optical
density ten-fold lower than other ELISA positive samples).
Pfhrp2: percentage of samples with gene deletions and
geographic origin
Pfhrp2 gene deletions occurred among 19 (25.7%) P. falciparum
samples. Thirteen (68.4%) were obtained from patients presenting
at the health center of Santa Clara (Figure 2), with most patients
Table 2. Patient data and parasite density of the final sample collection.
P. falciparum (n = 74) P. vivax (n = 101) Mixed infection (n=4)
Sample collection period Dec 2010–Jul 2011 Dec 2010–Mar 2011 Dec 2010–Mar 2011
Male gender 41 (55.4%) 52 (51.5%) 4 (100%)
Age, median years (range) 27.5 (4–74) 29 (2–76) 31.5 (4–47)
Children ,15 years, number (%) 16 (21.6%) 24 (23.8%) 1 (25%)
Median parasite density/ml (range) 4,971.5 (0–78,208) 5,080 (255–58,880) 9,527.5 (5,204–22,321)
Asymptomatic patients (number) 1 (1.4%) 1 (1.0%) 0 (0.0%)
Antimalarial treatment past 2 weeks 4 (5.4%)* 0 (0.0%) 0 (0.0%)
*artesunate + mefloquine since 2 days (n = 1), chloroquine since 2 days (n = 2), full course of chloroquine/primaquine (n = 1) at least .1 week ago (exact date not
known).
doi:10.1371/journal.pone.0043094.t002
Table 3. Sensitivity, faint line intensity and cross-reactions of the different RDT products for detection of P. falciparum and P. vivax.
% Sensitivity (95% C.I.)
% of positive test lines with faint
intensity* Number of cross-reactions (%)
RDT product
P. falciparum
(n = 74) P. vivax (n = 101)
PfHRP2
/Pf-pLDH Pv-/pan-pLDH{
P. vivax with
PfHRP2/Pf-pLDH
test line
P. falciparum with
Pv-pLDH test line
PfHRP2-detecting RDT
Paracheck 70.3 (58.5–80.3) - 5.8 - 0 (0.0) -
PfHRP2 and pan-pLDH detecting RDTs
First Response 71.6 (60.0–81.5) 100.0 (94.6–100.0) 3.8 2.0 3 (3.0) -
Parascreen 71.6 (60.0–81.5) 89.1 (81.4–94.4) 1.9 21.1 7 (6.9) -
SDFK60 71.6 (60.0–81.5) 100.0 (94.6–100.0) 7.1 4.0 5 (5.0) -
PfHRP2and Pv-pLDH detecting RDTs
AZOG 71.6 (60.0–81.5) 87.1 (79.0–93.0) 17.0 79.5 2 (2.0) 0 (0.0)
CareStart Pf/Pv 71.6 (60.0–81.5) 100.0 (94.6–100.0) 5.7 10.9 11 (10.9) 0 (0.0)
Falcivax 71.6 (60.0–81.5) 100.0 (94.6–100.0) 1.9 7.9 5 (5.0) 0 (0.0)
Onsite 71.6 (60.0–81.5) 100.0 (94.6–100.0) 5.7 4.0 0 (0.0) 2 (2.7)
SDFK80 71.6 (60.0–81.5) 100.0 (94.6–100.0) 1.9 0.0 1 (1.0) 1 (1.4)
Pf-pLDH and pan-pLDH detecting RDTs
Advantage 98.7 (92.7–100.0) 100.0 (94.6–100.0) 24.7 4.0 1 (1.0) -
CareStart pLDH 98.7 (92.7–100.0) 99.0 (94.6–100.0) 9.6 8.0 10 (9.9) -
SDFK40 97.3 (90.6–99.7) 100.0 (94.6–100.0) 38.9 1.0 1 (1.0) -
PfHRP2 and Pf-pLDH detecting RDT
SDFK90 PfHRP2 line 71.6 (60.0–81.5) - 1.9 - - -
SDFK90 Pf-pLDH line 98.7 (92.7–100.0) - 40.5 - - -
*cross-reactions excluded.
{only P. vivax samples were considered.
doi:10.1371/journal.pone.0043094.t003
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living in Tarapoto (8/13, 61.5%). The remaining six were
distributed among three other health centers (Figure 2). Pfhrp2
gene deletions were found throughout the study period and
sometimes P. falciparum samples with and without pfhrp2 gene
deletions were found simultaneously in the same village. One
patient with a pfhrp2 gene deletion diagnosed at Morona Cocha
had been travelling to Angamos (close to the Brazilian border)
during the month previous to sampling.
Pfhrp3 gene deletion
In total 34 (43.6%) P. falciparum samples lacked the pfhrp3 gene:
they included all samples lacking the pfhrp2 gene (n = 19) as well as
15 additional samples which contained pfhrp2, and which were
correctly diagnosed by all PfHRP2-detecting RDTs.
Occurrence of cross reactions
In most (10/12) RDT products that were assessed with P. vivax
samples, P. falciparum test lines (either PfHRP2 or Pf-pLDH) were
visible at a median frequency of 2.5% (range 1.0%–10.9%). In
total, 27 (26.7%) P. vivax samples were involved. In all of these
samples, mixed infection with P. falciparum was excluded by PCR
and none of the patients had reported P. falciparum infection in the
month prior to sampling. In six of these samples however, HRP2
ELISA yielded a weak positive result. There was no apparent
relation between parasite density and the occurrence of cross-
reactions (range 255–58,880/ml).
In two RDT products, P. falciparum samples generated a visible
Pv-pLDH line: one faint line for SDFK80 (parasite density
78,208/ml); and a faint and medium line for Onsite (parasite
density 53,333/ml and 3,480/ml). Mixed infection with P. vivax was
excluded by PCR and none of the patients reported recent P. vivax
infection.
Interobserver agreement
For positive/negative readings, median k per RDT product was
1.00 (range 0.84–1.00). For line intensity readings, median k was
0.87 (range 0.62–0.99).
Discussion
The present study evaluated a panel of RDT products for
malaria diagnosis in the Peruvian Amazon. It showed that Pf-
pLDH-detecting RDTs performed significantly better for P.
falciparum diagnosis compared to PfHRP2-detecting RDTs in this
geographical region. The low sensitivity of PfHRP2-detecting
RDTs was related to pfhrp2 gene deletions which invariably leaded
to false negative PfHRP2 results irrespective of the parasite
density. For P. vivax diagnosis all but two RDT products performed
well with no overall difference in sensitivity and line intensity
between Pv-pLDH and pan-pLDH detecting RDTs. Cross-
reactions with the P. falciparum line were observed in 10/12 P.
vivax-detecting RDT products at a median frequency of 2.5%
(range 1.0%–10.9%) of P. vivax samples assessed. In two RDT
products, false positive Pv-pLDH lines were observed in up to
2.7% of P. falciparum samples.
Table 4. P. falciparum samples not detected by PfHRP2-detecting RDTs: pfhrp2 and pfhrp3 PCR results and PfHRP2 ELISA results.
Sample and patient information
Sample number Sex Age Parasite density (/ml) pfhrp2 exon 1–2 pfhrp2 exon 2 pfhrp3 exon 2 PfHRP2 ELISA
PI138 f 56 0* 2 2 2 2
PI139 m 6 79 2 2 2 2
PI137 m 41 80 2 2 2 2
PI136 m 53 270 2 2 2 2
PI 24 f 20 752 2 2 2 2
PI113 f 30 876 2 2 2 2
PI142 m 21 1,000 2 2 2 2
PI151 m 28 1,222 + + 2 2
PI 18 f 12 1,400 2 2 2 2
PI 78 m 37 2,808 2 2 2 2
PI156 f 36 3,480 + + + 2
PI135 m 7 4,784 2 2 2 2
PI153 m 70 5,080 2 2 2 2
PI140 f 20 5,640 2 2 2 2
PI 26 m 48 7,227 2 2 2 +/2
PI 27 f 67 7,840 2 2 2 2
PI163 m 65 16,552 2 2 2 2
PI 81 m 46 18,800 2 2 2 2
PI148 f 34 19,600 2 2 2 2
PI 74 m 38 22,560 2 2 2 2
PI 65 m 27 43,089 2 2 2 2
+=positive, 2=negative, +/2=weak positive.
*This sample contained only gametocytes.
doi:10.1371/journal.pone.0043094.t004
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Impact of pfhrp2 gene deletions
The exact incidence of pfhrp2 gene deletions in the Peruvian
Amazon is not known. We presently found 25.7% of P. falciparum
samples lacking pfhrp2, in a previous study this was 41.0% [8]. In
the present study pfhrp2 gene deletions were found at different sites,
but not at all health centers. Pfhrp2 gene deletions have however
been reported throughout the Peruvian Amazon [8] as well as in
Brazil [19] and one of the presently included patients might have
acquired infection near the Brazilian border. By consequence, the
findings as currently described may be applicable to the whole
Amazon region.
The impact of pfhrp2 gene deletions is further highlighted by the
fact that all samples lacking pfhrp2 were not detected by any of the
PfHRP2-detecting RDT products. In addition, all samples lacking
pfhrp2 were found in symptomatic patients and occurred at both
high and low parasite densities, in contrast to a previous study [20]
which demonstrated pfhrp2 gene deletions only in asymptomatic
patients and at low parasite densities. Of note is that in 1998–1999
an evaluation of the PfHRP2-detecting RDT Parasight-F around
Iquitos showed sensitivity for P. falciparum diagnosis of 95% [9].
Possibly, pfhrp2 gene deletions have become common in this area
only recently.
Discordances between pfhrp2 PCR and PfHRP2 RDT
results
For samples PI151 and PI156, the presence of pfhrp2 exon2 was
demonstrated by both PCRs but PfHRP2 RDT and ELISA results
were negative. Parasite density of both samples was far above the
RDT detection threshold and does not explain failure of detection.
A mutation or deletion may have occurred, leading to failure of
production of the antigen or production of an antigen that is not
recognized. Failure of detection of both samples may also be due
to errors in transcription or translation, causing low parasite
protein expression and consequently failure of detection by RDTs
and ELISA [21]. Further research is needed to investigate the
occurrence and cause of this phenomenon.
Role of pfhrp3
It has been postulated that PfHRP3 might compensate for
absence of PfHRP2 in PfHRP2-detecting diagnosis, due to cross-
reaction of PfHRP3 with PfHRP2 antibodies [8,17]. In the present
study this could not be assessed since all pfhrp2 negative samples
lacked the pfhrp3 gene as well.
Cross-reactions
In all samples showing cross-reactions, mixed infections were
excluded and Plasmodium infection during the month previous to
sampling was not reported. In the case of P. vivax samples
generating a PfHRP2 line, past subclinical infection with PfHRP2
persistence (caused by slow clearance of PfHRP2 [22]) may have
occurred in at least part of the samples, as supported by the weak
positive ELISA results in six samples. However, optical density
values in these samples were low and PfHRP2 lines were only
visible in few RDT products, which makes non-specific reactions a
more plausible explanation. In the case of visible Pf-pLDH lines
among P. vivax samples and Pv-pLDH lines among P. falciparum
samples, genuine antigen-antibody reactions [23] or non-specific
reactions [7] may have occurred. Cross-reactions (false positive P.
falciparum test lines) among P. vivax samples are particularly
relevant in RDTs detecting pan-pLDH: in these cases RDT results
are interpreted as P. falciparum infection and the patient will not be
treated with primaquine, which is needed to eradicate the liver
stages. Conversely, false positive Pv-pLDH test lines among P.
Figure 2. Number of P. falciparum samples containing or lacking the pfhrp2 gene per health center. The village of Atalaya is not a health
center, but is displayed separately as all samples in Atalaya were collected by an outreach team during an epidemic.
doi:10.1371/journal.pone.0043094.g002
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falciparum samples indicate mixed P. falciparum/P. vivax infection,
which will lead to unnecessary treatment with primaquine.
Limitations
The present study did not include Plasmodium negative patients,
precluding calculation of specificity and positive and negative
predictive values. However, it provides relevant data about RDT
diagnostic sensitivity and its relation with pfhrp2 gene deletions,
based upon which suitable RDTs can be selected. Further, we
included a large panel of simple one-step RDT products but did
not include RDTs with a more complex procedure such as the
previously evaluated OptiMAL [24]. Not all RDTs could be
performed on fresh samples, though samples had been stored for a
short period and had not been exposed to repeated freezing and
thawing. Besides, no apparent differences were found between
RDT results on stored versus fresh samples. Finally, observers of
RDT results were not always blinded to microscopy results
provided by the health center.
Which RDT for the Peruvian Amazon?
From the present study it is clear that PfHRP2-detecting RDTs
are not suitable for the Peruvian Amazon, due to the high
prevalence of P. falciparum samples lacking the pfhrp2 gene which
was invariably associated with false negative results. Pfhrp2 gene
deletions occurred at all parasite densities and all patients were
symptomatic. The three Pf-pLDH-detecting RDTs - all combining
pan-pLDH - performed excellently for P. falciparum and P. vivax
diagnosis. Among one of them however, an unacceptably high
proportion of P. vivax samples generated cross-reactions with the
Pf-pLDH line, impeding its use. For the remaining two, the high
number of faint test lines is of concern as especially in field settings
faint lines tend to be overlooked or disregarded as negative
[25,26,27]. Besides, general limitations of Pf-pLDH-detecting
RDTs are a lower sensitivity at low parasite densities [7,12,14] and
less heat stability, although the latter is currently less important
than originally described [7,14] and SDFK40 reports heat stability
up to 40uC (Table 1).
Despite the excellent diagnostic accuracy of SDFK40 and
Advantage in the present study, prospective field evaluation on all
malaria suspected patients is needed to determine positive and
negative predictive values and end user performance. In the long
term, the development of an RDT targeting both Pf-pLDH and
Pv-pLDH could be considered. Such a combination could, besides
diagnosing each of both species, also differentiate between P.
falciparum and mixed P. falciparum/P. vivax infections, but is not yet
commercially available.
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Malaria rapid diagnostic kits: quality of
packaging, design and labelling of boxes and
components and readability and accuracy of
information inserts
Philippe Gillet1*, Jessica Maltha2, Veerle Hermans1, Raffaella Ravinetto3, Cathrien Bruggeman4, Jan Jacobs1,2
Abstract
Background: The present study assessed malaria RDT kits for adequate and correct packaging, design and
labelling of boxes and components. Information inserts were studied for readability and accuracy of information.
Methods: Criteria for packaging, design, labelling and information were compiled from Directive 98/79 of the
European Community (EC), relevant World Health Organization (WHO) documents and studies on end-users’
performance of RDTs. Typography and readability level (Flesch-Kincaid grade level) were assessed.
Results: Forty-two RDT kits from 22 manufacturers were assessed, 35 of which had evidence of good manufacturing
practice according to available information (i.e. CE-label affixed or inclusion in the WHO list of ISO13485:2003 certified
manufacturers). Shortcomings in devices were (i) insufficient place for writing sample identification (n = 40) and (ii)
ambiguous labelling of the reading window (n = 6). Buffer vial labels were lacking essential information (n = 24) or
were of poor quality (n = 16). Information inserts had elevated readability levels (median Flesch Kincaid grade 8.9,
range 7.1 - 12.9) and user-unfriendly typography (median font size 8, range 5 - 10). Inadequacies included (i) no
referral to biosafety (n = 18), (ii) critical differences between depicted and real devices (n = 8), (iii) figures with
unrealistic colours (n = 4), (iv) incomplete information about RDT line interpretations (n = 31) and no data on test
characteristics (n = 8). Other problems included (i) kit names that referred to Plasmodium vivax although targeting a
pan-species Plasmodium antigen (n = 4), (ii) not stating the identity of the pan-species antigen (n = 2) and (iii) slight
but numerous differences in names displayed on boxes, device packages and information inserts. Three CE labelled
RDT kits produced outside the EC had no authorized representative affixed and the shape and relative dimensions of
the CE symbol affixed did not comply with the Directive 98/79/EC. Overall, RDTs with evidence of GMP scored better
compared to those without but inadequacies were observed in both groups.
Conclusion: Overall, malaria RDTs showed shortcomings in quality of construction, design and labelling of boxes,
device packages, devices and buffers. Information inserts were difficult to read and lacked relevant information.
Background
The use of malaria RDTs is rapidly expanding
Prompt parasitological confirmation by microscopy or
alternatively by RDTs is recommended in all patients
suspected of malaria before treatment is started [1].
As a consequence, malaria rapid diagnostic tests (RDTs)
are increasingly used as a diagnostic tool in both malaria
endemic and non-endemic settings: in 2007, more than
70,000,000 tests were performed [2].
Malaria RDTs are so-called immunochromatographic
tests that detect Plasmodium antigens in the blood by
an antigen-antibody reaction on a nitrocellulose strip.
The antigen-antibody complex is conjugated to colloidal
gold, and a positive result is visible as a cherry- or pur-
ple-red coloured line. Apart from a control line, there
are one, two or three test lines: the so-called two-band
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tests comprise a control line and a single test line, and
are mostly designed to diagnose Plasmodium falci-
parum. Their targets are either histidine-rich protein-2
(HRP-2) or P. falciparum-specific parasite lactate dehy-
drogenase (Pf-pLDH). Three-band RDTs display a
second test line mostly targeting antigens common to
the four species such as pan-Plasmodium-specific para-
site lactate dehydrogenase (pan-pLDH) or aldolase. The
four-band RDTs have an additional third test line target-
ing Plasmodium vivax-specific pLDH (Pv-pLDH).
Written instructions add to the correct performance and
interpretation of RDTs
RDTs are accurate and robust but they have limitations
linked to design, production and distribution [3-8]. In
addition, there are errors at the level of the end-user,
which apply to both laboratory staff and field workers
and are related to sampling, testing and interpretation
of RDTs [9,10]. Clearly written instructions can add to
the comprehensibility and maximize RDT kit perfor-
mance [9,10]. On this basis, the World Health Organiza-
tion (WHO) designed easy-to-read generic job aids [11].
During field visits in Africa, teams of the Institute of
Tropical Medicine (ITM) occasionally noted shortcom-
ings in RDT kit boxes, content and instructions. In addi-
tion, part of the interpretation errors that were observed
during a recent external quality assessment (EQA) on
RDTs were shown to be related to errors in the infor-
mation inserts of the RDT kits used [4]. Inspection of
these information inserts also revealed a large variety in
layout and readability, as well as variations in the ade-
quacy of labelling of RDT boxes and devices.
Objectives of the present study
In view of the observations above, it was decided (i) to
assess malaria RDT kits for adequate and correct design,
construction and labelling of boxes and components,
and (ii) to study the readability and accuracy of their
information inserts.
Methods
Selection of RDT kits
Malaria RDTs marketed as devices consisting of cas-
settes, cardboard boxes and hybrids (nitrocellulose strips
to be dipped into plastic wells) were selected. They were
checked for the presence of the CE label and evidence
of good manufacturing practice (GMP) based on their
inclusion in the WHO lists of RDT manufacturers and
distributors complying with ISO13485:2003 or US FDA
21 CFR 820 production norms [12].
As this study was not intended to score RDTs indivi-
dually, it was decided not to display the RDT brand and
kit names, in line with previous comparative studies
assessing RDTs [3-5,13].
Criteria used for RDT kit assessment and procedure
For packaging, design and labelling, assessment criteria
were compiled from requirements listed in regulatory
documents such as the Directive 98/79/EC and the
European Community (EC) as well as relevant WHO
documents [14-17]. Criteria for information inserts and
device design from studies on end-users’ performance
and RDT instructions were pooled [5,7,9,10,18-24].
Inadequacies were defined as listed in Table 1.
RDT kit package, device package, device and buffer vial
The RDT kit packages were assessed for type (box ver-
sus plastic bag), material (simple and plasticized card-
board) and the presence and quality of the printed
information. Information displayed on the package con-
sidered as essential included the RDT kits and manufac-
turer’s names, expiry date, number of tests included,
storage requirements and a reminder to read the
instructions before use. A referral to the intended use
of the RDT kit was looked for, either by the RDT kit
name or by an additional text. The expiry date men-
tioned on the box was matched with those of the other
RDT kit components. For CE labelled RDT kits pro-
duced by companies outside the European Economic
Area, the affixing of the so-called authorized representa-
tive of the company in the EC (EC-REP) was assessed.
Kits were assessed for sampling material needed
included or not.
The package of the test device was checked for quality
(humidity-proof material) and essential information
including RDT kit name, lot number and expiry date. In
addition, the desiccant was checked for composition,
warning label and presence of colour indicator.
The RDT devices (cassette or cardboard housing the
nitrocellulose strip) were assessed for clearness of design
and construction including referral to the RDT kit’s
name. The space allocated for sample identification was
evaluated for dimensions and ease of writing. A space of
minimal 0.5 cm height and 4 cm wide was considered as
adequate for handwriting of sample identification. The
labelling of buffer wells, sample wells and reading win-
dows including the places of appearance of the control
and test lines (further referred to as reading label) were
assessed for visibility and unambiguous interpretation.
The buffer vials were assessed for leak-proof closure,
and their labels for quality of adherence and print. The
information displayed on the label was assessed for the
presence of RDT kit name, lot number, expiry date and
storage conditions.
RDT information insert
RDT kits were checked for the presence of an informa-
tion insert and a job aids (short procedure version), of
which date of release and version number were assessed.
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Layout and figures
The figures were counted and their dimensions mea-
sured. Their total surface area was calculated and
expressed as a percentage of the total surface of the
information insert. The figures were assessed for their
concept (pure black and white versus use of colours)
and conformity with the real devices.
Typography
The font size of the predominant letter type used
(excluding the bibliography section) was measured in
Cicero using a typometer (Rotring-werke Riepe KG,
Hamburg, Germany) as the “kp” distance from the top
of the highest ascender (top of the lower case letter k)
to the bottom of the lowest descender (bottom of the
lower case letter p). The opening of the characters was
visually assessed for the characters “c, o and a”, by cov-
ering them for their lower two-thirds and checking
whether they were still correctly readable (open letter
type) versus read as an “o” (closed letter type). The
interline spacing was assessed by measuring in Cicero
with a typometer the distance between the base line of
two successive rows and then subtracting the font size.
Table 1 Number of RDTs (n = 42) with inadequacies in malaria RDT boxes, device packages, devices, buffer vials and
package inserts*
Items considered to be inadequate Number (%)
Box: construction and design
Materials: plastic bag or simple cardboard (not humidity-resistant) 9 (21.4)
No labels, no printed information or labels not humidity-resistant 6 (14.3)
Differences in name on device packaging, device, buffer and information insert 27 (64.3)
Box: information displayed
No EC-REP mentioned on CE labelled RDTs, although required (n = 25) 3 (12.0)
RDT kit’s name nor additional information refer to intended use 3 (7.1)
RDT kit’s name incorrectly refers to P. vivax instead of non-falciparum species (n = 29) 4 (13.8)
Kit components not displayed 26 (62%)
Essential information lacking: expiry date, numbers of tests included, storage conditions 12 (28.6)
Kit contents:
Capillary sampling system (lancet and alcohol swap) not included or not optionally included 24 (57%)
Blood transfer system (capillary, pipette or tube) not included 3 (7.1%)
Device package and content: construction and design
Material not humidity-resistant 4 (9.5)
No desiccant or desiccant without saturation indicator 18 (42.9)
Device package and content: information displayed
Essential information lacking: expiry date, lot number, test kit name 9 (21.4)
No warning label “do not swallow” on desiccant 6 (14.3)
Device: construction and design
Space for sample identification too small or not writable with standard pen (felt pen needed) 40 (95.2)
No or incomplete RDT name on the device 29 (69.0)
No reading label or simultaneous presence two reading labels consisting of symbols only 6 (14.3)
Buffer: construction and design
Buffer vial not leak proof 2 (4.8)
Label does not stick well to the vial, prints are not humidity-resistant (n = 40) 16 (40.0)
Buffer: information displayed
Essential information lacking: expiry date, lot number, storage conditions, correct RDT kit’s name (n = 41) 24 (58.5)
No instructions included on how to pierce the buffer vial dropper (n = 15) 5 (33.3)
Package insert: information
Absence of date of release or version number 20 (47.6)
Package insert: content
Identity of target antigens not clearly mentioned 2 (4.8)
No referral to biosafety precautions (gloves, safe waste disposal, etc.) 18 (42.9)
Major differences between depicted and real device (n = 40) 8 (20.0)
Use of figures with unrealistic colours (e.g. control and test lines depicted as green) 4 (9.5)
No data on test characteristics (sensitivity, specificity) 8 (19.0)
*Total number of RDT kits = 42 unless otherwise stated.
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Fonts of open letter types and interline spacing equal or
larger than 2 are better readable compared to fonts of
closed letter types and interline spacing smaller than 2,
especially at larger text columns. For patient education
materials and health instructions, font sizes of 12 or lar-
ger are recommended [25,26].
Readability level
For assessment of the readability level, the sessions
about blood sampling, procedure and interpretation in
the English text version were copied or retyped in
Microsoft Word (Microsoft Corp., Redmond, WA,
U.S.A.) and checked for correct spelling and syntax con-
struction. Follow-up editing was performed as described
elsewhere [27]. Next, the text fragments were copied
into an on-line readability assessment tool, which gener-
ates different reading indices [28]. The Flesch-Kincaid
grade level [29] was calculated. This grade-level
expresses the U.S. grade-level equivalency of the skills
required to read a particular document. For patient edu-
cation materials and health related information, the
recommended level is ≤ 6th grade level [25,30].
Accuracy and relevance of information
The following items were actively looked for: description
of the RDT test principle, target antigens, listing of
required materials provided and not, description of sam-
pling procedures and biosafety precautions. The RDT
test procedures were studied with reference to common
errors made by end-users in the field (Table 2)
[5,9-11,18,19,23]. The interpretation section was
assessed for the complete description of invalid results
and Plasmodium species differentiation as well as for
listing causes of false negative and false positive results.
The description of test characteristics was assessed for
mentioning the diagnostic accuracies related to the dif-
ferent Plasmodium species and parasite densities. Biblio-
graphic references were checked for relevance with
regard to RDT performance in general and information
on the RDT kit’s performance in particular.
Assessment, data registration and statistical analysis
Two observers trained in the use of RDTs independently
assessed the RDTs according to the described criteria.
Discrepant observations were discussed together with
the other investigators and a consensus was reached.
Data were registered in an Excel sheet (Microsoft Corp.,
Redmond, WA, U.S.A.).
Results
Panel of RDT kits
For the purpose of this study, 51 RDT kits were ordered
at 29 companies. Seven companies (representing nine
RDT kits) did not reply despite several reminders. The
final panel consisted of 42 RDT kits from 22 companies.
Nearly all (39/42, 93%) RDT kit formats were cassettes,
further there were one cardboard and two hybrid kits.
Two RDT kits consisted of individually wrapped RDT
packages containing all materials for a single test (cas-
sette, disinfectant, lancet and buffer). They will be
further referred to as “Single RDT kits”. Table 3 lists the
RDTs according to their evidence of GMP. Table 1 lists
the number of the RDTs with inadequacies in boxes,
devices, buffer vials and information inserts.
RTD kit package, device and buffer vial
RDT kit package
Thirty-eight RDT kits arrived as cardboard boxes; four
kits arrived in plastic bags. Two of these plastic bags
contained a cardboard box to be folded by the end-user,
resulting in a total of 40 boxes and two plastic bags as
the package of use on the bench. All but one box dis-
played an indication in the RDT kit’s name or in the
test description that the RDT kit was intended for
malaria diagnosis. The two plastic bags did not display
Table 2 Number of RDT information inserts (n = 40)
addressing critical steps in procedure and interpretation
Items addressed in procedure section Number
(%)
Bring the RDT device and buffer to room temperature 32 (80.0)
Check the integrity of the device package 9 (22.5)
Check expiry date 27 (67.5)
Use the device immediately after opening 28 (70.0)
Place the device on a level surface 0 (0.0)
Check the desiccant for signs of exposure to humidity 11 (27.5)
Write down sample identification 3 (7.5)
Wipe finger with alcohol 26 (65.0)
Allow the finger to dry before pricking 12 (30.0)
Hold the transfer device (loop, straw) vertical 8 (20.0)
Hold the buffer vial vertical 12 (30.0)
Do not to use another buffer than the one provided with
the kit
9 (22.5)
Use an adequate light source for reading 3 (7.5)
Items addressed in interpretation section Number
(%)
All possible line combinations for invalid test results are
mentioned
12 (30.0)
All possible test line combinations for positive test results
are mentioned
31 (77.5)
Interpretation of a faint test line as positive is mentioned 8 (20.0)
Causes of false negative results are mentioned, in particular
low parasite densities
11 (27.5)
Causes of false positive results are mentioned, e.g. presence
of the rheumatoid factor
3 (7.5)
Persistence of HRP-2 is mentioned 19 (47.5)
To repeat the test in case of a negative RDT result and
persistent suspicion of malaria is mentioned
1 (2.5)
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any information. A company name was listed on all the
40 boxes, but for 12 kits, it was not clearly mentioned
whether this name represented the manufacturer or the
distributor.
The lot number and expiry date were listed on all
boxes. One of the Single RDT kits showed both lot
number and expiry date on the outer box containing the
single packages, but not on the single packages them-
selves. There were no discrepancies between the expiry
dates on the RDT kit box and those of the contents
except for two buffer vials with expiry dates extending
those printed on the RDT kit box.
The number of tests included and a reminder to read
the instructions before use were not displayed on four
and ten boxes respectively. All the 40 boxes showed
information on storage temperature requirements, by
written text, symbols or both. Apart from a single sym-
bol, i.e. a penguin expressing “do not freeze”, all symbols
were internationally recognized symbols complying with
EN 980:2008 or FDA 2004, 21 CFR 809.10 and 21 CFR
Parts 610 and 660. Capillary blood sampling systems
were included in eight kits and proposed as optional in
ten other kits. Blood transfer systems were missing in
three kits.
Device packages
Four of 42 device packages were not made of humidity-
resistant material. Most of the packages were easy to
open by tearing a pre-cut lid of the package. However,
for three packages, scissors had to be used to open the
packages properly.
A desiccant was present in all but one package. Three
of the 41 desiccants did not show a warning that
the desiccant was harmful: two of them (from one man-
ufacturer) were tablets looking like drug pills. Seventeen
desiccants (including the two tablets) had no colour
indicator of humidity saturation.
RDT devices
Space for writing was too small in 40 of the 42 devices
(Figure 1). For two cassettes, a felt pen was required as
a standard pen failed to mark.
Most cassettes (35/39) had separate wells for sample
and buffer application, four had a single well for sample
and buffer application. There was no uniform labelling of
the wells: for instance characters “S” and “A” were used
randomly for the sample well, buffer well and combined
sample/buffer well (Figure 2). Fifteen cassettes showed at
the distal end a window or holes that might be confused
with a sample or buffer well (Figures 1 and 2).
The reading label was indicated with acronyms (n = 20),
characters or numbers. Acronyms included abbreviations
such as “Pf” or “pan”, they were printed on the plastic
housing or on a label and were well readable. Characters
such as “C” (control line) and “T” and numbers were
embedded in the plastic housings and were more difficult
to distinguish (Figure 2). In one cassette, characters were
printed on a label, which was not well fixed (Figure 1). In
14 cassettes, two labels were displayed at either side of the
reading window (Figure 2), and one three-band cassette
had no reading label at all (Figure 2).
RDT buffer vials
The two Single kit RDTs contained a small buffer plastic
ampoule in each device package, which were too small
to display information. Fifteen buffer vials required
clockwise tightening the vial cap to pierce the dropper
vial nozzle, but for five of them, this was not mentioned
in the information insert. For 13 vials, the label was not
well fixed and the printed information on three of these
labels was not humidity-resistant. Lot number and
expiry date were not listed on five vials and storage con-
ditions were missing on 10 vials.
Table 3 Overview of the RDT kits evaluated in the
present study
Evidence of GMP
RDT
format
Plasmodium antigens
targeted
Number CE
mark
WHO
list†
Total
Two
band
HRP-2 7 4 5 7
pan-pLDH 1 1 0 1
Pv-pLDH 1 1 0 1
Three
band
HRP-2, pan-pLDH 11 5 7 9
HRP-2, aldolase‡ 5 5* 5 5
HRP-2, Pv-pLDH 4 1 1 2
Pf-pLDH, pan-pLDH 6 5 6 6
Four
band
HRP-2, Pv-pLDH, pan-
pLDH
7 3 5 6
*One three-band test (HRP-2, aldolase) is FDA approved.
†WHO list of ISO:13485:2003 certified manufacturers and their RDT products
(list of known commercially available antigen detecting malaria RDTs) [12].
‡One of these RDTs used both aldolase and pan-pLDH as pan-malarial
antigen.
Figure 1 Four-band RDT. The allocated place for writing sample
identification is too small. The grid at the left hand may be
confused with a sample well. There are two different reading labels
at each side of the reading window, of which the lower one is
printed on a label that is not well fixed.
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RDT information insert
The information inserts of the two Single RDT kits were
not considered: one of them contained a simple job aids
explaining the procedure by figures only, the other con-
tained a shortened version of the information insert of
the same RDT marketed as laboratory kit. All of the
remaining 40 RDT kits contained an information insert
of which seven had an additional job aids. Either version
number or date of issue was missing in 11 and 13 of
them; in five, both were missing.
Layout and figures
All 40 inserts included figures. The median number of
figures per information insert was 8.5 (range 2 - 25) and
figures accounted for a median surface ratio of 7.2%
(range 0.4% - 33%) of the entire insert. The median size of
the figures was 2.4 × 2.0 cm, the smallest and largest figure
measured respectively 1.0 × 0.3 cm and 6.7 × 8.0 cm.
All inserts used figures to illustrate the interpretation
section. Other figures depicted blood sampling (n = 17),
application of sample and buffer (n = 21) and a clock
indicating the correct reading delay (n = 10). Fourteen
inserts used red colour to indicate control and test lines
but in four, they were pictured green or blue. Most
inserts (n = 35) showed differences between depicted
and real devices of which some were major, such as dis-
crepancies between characters used for sample and buf-
fer well identification (n = 4) and differences in labelling
of the reading window (n = 5) (Figures 3 and 4). One
insert mentioned a reading delay of 15 minutes, but the
illustration mentioned a reading delay of 20 minutes
(Figure 5).
Typographic features and readability
Figure 6 displays the font size and line spacing of the
information inserts. Median font size was 8 ± 1.3,
none of them exceeded 10. User-unfriendly typo-
graphic features included combinations of font sizes of
eight or smaller with a closed letter type (n = 10) or
with line spacing lower than two and more than 12
words per line (n = 14) (Figure 7). Median readability
level was grade 8.9 (range 7.1 - 12.9) and 18 and four
of the inserts’ readability levels were above grade 9 and
10 respectively (Figure 8). Readability levels of the job
Figure 2 Example of RDT cassettes. Most of the cassettes have separated wells for sample and buffer application. There is no uniform
labelling of the wells: different characters (e.g. “S”, “A”) are used randomly for the sample well, buffer well and combined sample/buffer well. The
reading labels are indicated with acronyms, characters or numbers.
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aids were also high (median 8.5, range 5.1 - 9.4), and
six out of seven exceeded the readability level of the
most recent WHO job aids. Five inserts showed prints
of very poor quality hindering reading of the text
(Figure 9).
Accuracy and relevance of information
The RDT kit’s principle was described in all 40 informa-
tion inserts. All but two inserts mentioned the materials
provided in the RDT kit, and seven inserts provided a
complete list of the materials required.
All RDT kit inserts mentioned the required specimen
(in all cases both capillary and venous blood), all but
one mentioned the anticoagulant to be used. Capillary
blood sampling through finger prick was described in 35
inserts, of which one also added sampling by venipunc-
ture. By contrast, the heel prick was not described in
any information insert.
Biosafety precautions included the use of gloves
(depicted or mentioned in 21 inserts, Figure 10) and
safe waste disposal (addressed in 16 inserts), but 18
inserts did not mention any information on biosafety.
From Table 2 it is clear that a number of critical steps
in RDT procedures were addressed by only part of the
RDT inserts. Among them, there were relevant steps
such as writing down sample identification, correct posi-
tioning of the transfer and buffer vial and the need for
an adequate light source.
The complete array of all control and test line combi-
nations was listed by only nine inserts. Fourteen inserts
mentioned the absence of all lines as an invalid result
but not the presence of a test line in the absence of a
control line (Figure 9). In addition, errors in the inter-
pretation of test lines were observed. For instance, the
combination of a Pf-specific and a pan-specific test line
was interpreted as P. falciparum without mentioning the
possibility of a mixed infection (12/34 three- and four-
band RDTs). Likewise, the combination of a Pv-specific
and a pan-specific test line in case of a four-band RDT
was interpreted as a Plasmodium vivax infection without
mentioning the possibility of a mixed infection with
Plasmodium ovale and Plasmodium malariae (6/7
RDTs). In addition, a visible pan-pLDH line was
Figure 3 Interpretation section of the information insert and cassette of a Plasmodium falciparum/Plasmodium vivax RDT. The real
device has a single sample/buffer whereas the depicted one displays separate wells. The characters used for the reading label on the illustration
are inverted compared to the real device.
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interpreted as a P. vivax infection (instead of non-falci-
parum species) in two inserts.
Few inserts mentioned causes of false positive and false
negative results (Table 2). One insert recommended to
repeat the test in case of a negative RDT result and per-
sistent suspicion of malaria, another warned about
the prozone effect as a cause of a false negative result
(Figure 4). RDT test results during treatment follow-up
were addressed in 13 inserts, but the information listed
in nine inserts was presented in a scattered way and only
one insert clearly mentioned that HRP-2 persistence does
not indicate a failed therapeutic response.
RDT test characteristics
Eight inserts did not provide information on sensitivity
or specificity. Diagnostic characteristics were mostly
expressed for P. falciparum and P. vivax (n = 31 and
n = 22 respectively), only one insert mentioned test
characteristics for P. ovale and P. malariae. Sensitivity
for P. falciparum was expressed by parasite density
range in 10 inserts.
Bibliography cited in the information inserts
In total, 45 different references were used in the biblio-
graphy of the information inserts. One third of them
referred to the original description of the target antigens,
another 12 referred to general information on malaria
and its diagnosis. Thirteen inserts cited evaluation studies
of RDTs, but only three RDT kits referred to product-
related studies. Two panels of identical references were
shared by nine and eight inserts respectively.
Figure 4 Interpretation section of the information insert and cassette of a P. falciparum/P. vivax RDT. Shape and labels of wells and
reading window are different between the real and the depicted device. Characters are embedded in the plastic housing and poorly
discernable. The text is correct and complete (even the prozone effect and how to deal with it) but less readable (Flesch-Kincaid grade level 9.1).
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RDT kits’ names
Inconsistencies in the RDT kit names and referrals to
target antigens were observed. For instance, four RDT
kits had names referring to P. vivax although they used
a pan-species Plasmodium antigen. Two other inserts
did not mention the identity of the pan-species antigen
(aldolase versus pan-pLDH). Five RDT kits from one
manufacturer were supplied in identical boxes, carrying
the same names and identical prints. Furthermore, there
were slight but numerous differences between names as
displayed on boxes versus those noted on device
packages (eight had no brand name affixed), devices
(15 differences) and information inserts (eight differ-
ences). Similar observations were made for buffer vials:
five vials displayed only the manufacturer’s name and
one vial did not show brand nor manufacturer’s name.
RDT kits’ duplicates
During assessment of the RDT kits, apparent similarities
between different RDT brands were observed. These
similarities concerned, amongst others, design and shape
of the device and content and layout of the information
insert (e.g. numbers of samples used for calculation of
test characteristics). In that way, six products were
assumed to represent a common design and production
platform for 16 different RDT brands.
Relation with CE marking and WHO listing
Overall, RDTs with evidence of GMP (n = 35) scored
better compared to those without (n = 5), although
inadequacies, errors and omissions were observed
between both groups. Three CE labelled RDT kits pro-
duced outside European Economic Area (EEA) had no
EC-REP indicated neither on the box nor in the infor-
mation insert. For these kits, the CE symbol as displayed
Figure 5 Information insert of a three-band RDT, procedure
section. There is a discrepancy between the reading time
mentioned in the text compared to that showed on the illustration.
Figure 6 Typographic features of RDT information inserts (n =
40): font sizes and line spacing.
Figure 7 Example of typography used in RDT information
inserts: the package insert on the top is user-unfriendly (font
size 6, line spacing 0,5, close letter type, average number of
words per line 21, Flesch-Kincaid grade 9,5). The package insert
on the background, from the same company but for another RDT
uses a better typography (font size 8, line spacing 2, open letter
type, average number of words per line 14), but the readability is
still elevated (Flesch-Kincaid grade 9,8).
Figure 8 Readability of the RDT information inserts (n = 40)
and job aids (n = 7) expressed as Flesch-Kincaid grade level.
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on the package had not the shape and relative dimen-
sions of the 98/79/EC directive (Figure 11). Six of the
eight RDT kits that did not mention data on sensitivity
and specificity were CE labelled.
Discussion
Previous studies demonstrated that RDT manufacturers’
instructions are insufficient to ensure accurate test
performance by community health care workers, and
well-designed instructions such as the WHO generic job
aids have proven to increase performance [9,10,19,31].
In practice however, such job aids still need to be adapted
to the particular RDT brand used on site and, depending
on the chains of supply, different RDT brands and ver-
sions may be available. For market exploration and
choice of RDTs, laboratory managers will orient to RDT
kits’ names and labelling. Clear design and labelling of
RDT kit components will contribute to correct storage
and use; and laboratory staff will rely on RDT inserts for
background information, adaptations of the generic pro-
cedures, interpretation and trouble-shooting.
The design of the present study has its limitations. For
instance, mainly RDTs marketed as cassettes were con-
sidered. However, cassettes are the mostly used platform
and preferred by end-users over the strip format [9].
Besides, only a part of the marketed brands was evalu-
ated; however, this evaluation studied about half of the
80 brands worldwide-marketed [2] including those fre-
quently used in endemic and non-endemic settings.
With regard to the assessment of the information
inserts, it should further be noted that the Flesch-Kincaid
label (as discussed below) is only a proxy measure of
readability. In addition, the layout of the inserts was
assessed for typography but not for other features such
as adequate use of headings, bullets, boldfacing, and
amount of white space [32,33]. Finally, although RDTs
were presently assessed against compiled criteria based
on relevant documents, they were not evaluated by end-
users in a real-life setting. On the other hand, as far as
Figure 9 Interpretation section of the information insert of a
three-band P. falciparum/pan-species RDT. For invalid tests, only
the absence of all lines is mentioned, not the possibility of a visible
test line without a control line. The invalid results are not depicted.
The print quality is poor, no colours are used for the control and
test lines.
Figure 10 Illustration depicting sampling of capillary blood.
The health care worker’s hand is depicted without gloves. The
simultaneous presence of English and French text may be difficult
for a non-experienced reader.
Figure 11 CE-label displayed on a RDT kit box. The shape and
relative dimensions of the characters do not comply with the
requirements as mentioned in the EC Directive 98/79 (depicted in
the insert, upper right corner). There is no authorized representative
(EC-REP) affixed, although required.
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known, this is the first time that in vitro diagnostic medi-
cal devices (IVDs) were assessed for these characteristics.
Problems in design and labelling of the RDT kits’
components
Despite these limitations, much information was gener-
ated on the quality and appropriateness of RDT packa-
ging, labels and inserts. Apart from two exceptions (the
plastic bags), boxes were well labelled, but shortcomings
in labelling of device packages and buffer vials were
more numerous. The absence of blood sampling and
transfer system which was observed in nearly a quarter
of RDT kits may create logistical problems when used
in field settings. The problems in device design were of
most concern. Characters indicating wells and reading
labels that were embedded in the plastic cassette hous-
ings are difficult to distinguish and the simultaneous
presence of two reading labels may cause confusion.
Standardized and unequivocal characters or acronyms
should be used for designating wells and reading labels
and clear labelling with contrasting print should be
ensured.
Some design issues were not compiled from previous
studies but originated from ITM observations. Some of
them may look trivial but have consequences in daily
practice. For instance, device packages without pre-cut
lids require scissors to open, which is neither safe nor
practical in busy and remote settings. The space allo-
cated for sample identification on most cassettes was
large enough for writing down a sample number but not
a patient name: this may meet the requirements in com-
puterized settings but not those in a non-computerized
field setting, where full names are written as recom-
mended by WHO job aids instructions [16]. Likewise, it
is evident that use of a felt pen for writing down sample
identification is inappropriate for a field setting. Another
example was the clockwise tightening of the buffer vial’s
cap for piercing the dropper bottle nozzle: ITM teams
observed that laboratory staff unaware of this procedure
simply cut off the distal end from the nozzle. The
resulting opening tended to be very wide resulting in a
too large volume of buffer added to each test and early
emptying of the buffer vial. The RDT cassettes that
remained without buffer were run with other buffers or
with injection water, at the risk of causing false positive
results [5].
Readability level and typography of the information
insert
The Flesch-Kincaid grade level used in the present study
has been demonstrated to be reliable and valid and is fre-
quently used in health care issues such as consumer medi-
cal information (CMI) and patient education materials
[27,30]. Its use in the present context should be
interpreted with caution. Like any other reading formula,
the Flesch-Kincaid readability tool assesses text structure
but does not take into account the content. It further
refers only to US grade levels and applies to English lan-
guage. Other factors such as motivation and previous
experience may influence comprehension, and linguistic
and cultural issues may interfere [33]. Despite these limita-
tions, it is of note that readability levels of all inserts
exceeded the 6th grade level, while the recommended level
for health related information is equal or lower than this
level [27,30]. The readability level of the job aids scored
slightly better, but still higher compared to the WHO gen-
eric job aids. Too elevated reading levels have been consis-
tently demonstrated in CMI documents such as those of
home pregnancy tests, blood glucose monitoring and
home blood pressure monitor equipment as well as in
patient education brochures [25-27,32,34,35]. It should
also be taken into account that end-users in endemic set-
tings are likely to be non-native speakers of the language
of the information insert (e.g. English, French, Portuguese),
and may operate in stressful situations such as environ-
mental disasters and war [36,37] which decrease actual
reading levels [38]. Apart from the bad quality prints and
small figures, the observed user-unfriendly typographic
features may add to the decreased readability of the
inserts, which were consistent with those documented for
CMI materials [25,30,32,34,35].
Content of the information insert
The lack of referral to biosafety procedures in nearly
half of the inserts was striking and unacceptable, in par-
ticular because this is clearly mentioned in the WHO
generic job aids [11]. Likewise were the differences
between depicted and real devices and the use of non-
realistic colours for depicting test lines which do not
comply with WHO recommendations [16]. Numbers
and sizes of illustrations did not comply with the estab-
lished standards for patient education materials and
CMI [25,35,39].
The shortcomings in the RDT test interpretation ses-
sion were in line with observations made during a
recent external quality assessment on RDTs in a non-
endemic setting. During that session, not reporting a
mixed infection in case of the simultaneous presence of
P. falciparum- and pan-specific test lines was demon-
strated to be linked to the information inserts of the
RDT kits used [18]. Although extremely rare in the
experience at ITM, the presence of a visible test line in
the absence of a control line points to invalid test
results and should be added to the spectrum of possible
line combinations, preferably with a picture. In addition,
the persistence of HRP-2 after successful treatment and
the production of pLDH by gametocytes should be
clearly mentioned.
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The poor description of diagnostic characteristics in the
information inserts was another concern. Although cur-
rent directives and recommendations do not specify details
about origin, numbers and statistical validity of these test
characteristics, manufacturers should be encouraged to
provide as detailed and sound data as possible, including
data on sensitivity in relation to parasite density and Plas-
modium species. The low diagnostic sensitivity for
P. malariae and P. ovale is well known [40]: few studies
have included enough samples to provide reliable data for
both species. Those that did mostly found a poor sensitiv-
ity, in particular for P. malariae [40-44]. In the absence of
a thorough evaluation for both species, one could consider
adding a statement mentioning the low overall diagnostic
sensitivity for both species to the information insert, in
order to avoid unrealistic expectations by the end-user
relying on the pan-Plasmodium species nature of the
targeted antigen [40].
The cited bibliography mainly referred to the original
papers on the description of the antigens or general
RDT evaluations. In addition to references addressing
the RDT kit itself, references to one or more of the
recent reviews on RDTs or WHO/FIND documents
could be added, as they contain relevant information on
the use and limitations of RDTs.
Names and duplicates of RDTs, relation to GMP and CE
labelling
Among the inadequacies, erratic and inconsistent names
were a frequent finding: they ranged from minor differ-
ences in RDT brand names as displayed on boxes, devices
and their packages and information inserts to brand
names suggesting P. vivax despite using a pan-pLDH tar-
get. In addition, shortcomings with regard to clear speci-
fication of target antigens were noted. For a laboratory
manager finding his way among many other diagnostics
and supplies, it is essential to get a quick and reliable
idea about the intended use and the target antigens of
RDTs. An unequivocal code for naming and short test
descriptions should be considered, with mentioning of
the (abbreviated) antigens as a requisite (e.g. Pf-pLDH,
HRP-2 etc.).
With regard to the presumed RDT kit duplicates (kits
presenting with similar presentation suggesting a shared
design and production), it should be noted that WHO
and FIND recognize this phenomenon [45]. WHO
defines so-called “re-branded” products as products man-
ufactured under identical conditions at the same manu-
facturing site as the original product, but labelled with a
different product name and identifier. WHO encourages,
in such case, joint application for the prequalification
program or test evaluations [45-47]. The CE recognizes
also the “re-branding” for commercial interests. The
coexistence of multiple names for the same product
however may create difficulties for instance in retrieving
published information on test evaluations and may add
to the complexity of post marketing surveillance, includ-
ing traceability in case of batch recalls. To prevent these
problems, the requirement of “re-branded” RDT kits to
mention the original manufacturer should be considered.
In addition, any RDT kit label (whether original or
re-branded) should clearly distinguish the names of the
manufacturer from that of the local distributor.
Shortcomings and errors were observed among CE-la-
belled and WHO-listed RDTs. Not affixing the EC-REP
when required and not mentioning information on RDT
test characteristics do not conform the 98/79/EC Direc-
tive [48]. It should further be noted that in case of
malaria RDTs, the CE-label by itself is not a guarantee
for intrinsic quality of performance. The 98/79/EC
Directive includes the “Annex II”, which lists diagnostics
for which market release of any new lot has to be pre-
ceded by testing and approval by a competent authority,
the so-called notified body. For diagnostics that are not
listed in the “Annex II” (such as malaria RDTs), such
testing and authorization are not required. Acquisition
of the CE-label for these diagnostics is a purely adminis-
trative process, in which the manufacturer himself
draws up the EC declaration of conformity. Unfortu-
nately, the majority of laboratory and medical staff are
unaware of this procedure. This can create a sense of
“over-confidence” in CE-labelled products, based on the
perception of quality associated with European labels.
The inclusion of RDTs for malaria and other tropical
diseases in the “Annex II” could represent a significant
support for countries with weak regulatory overview.
What can be done to improve the quality of RDT package
and information inserts?
Many shortcomings such as incomplete and incorrect
labelling of boxes, device packages, cassettes and buffer
vials can be easily remediated at minimal costs. End-
users and manufactures should reach consensus on uni-
form codes for labelling wells and reading windows and
gradually reinforce the requirements for inserts and
packaging. Generic recommendations as how to layout
and how to appropriately design information inserts as
well as use of figures can be found in the literature on
CMI [25,35,39], RDT specific guidelines have been
issued by the WHO [16]. Readability, cultural and lin-
guistic backgrounds should be taken into account [23],
and all texts and figures should be assessed for appro-
priateness and comprehension among the targeted end-
users [10,49]. For the content of RDTs, the reference
documents that were used to compile Tables 1 and 2
can give guidance. Examples of such checklists are
added as additional files (Additional file 1 Table S1 and
Additional file 2 Table S2). The information inserts
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should highlight key points in performance and inter-
pretation in order to reduce the likelihood of potential
errors.
With regard to user-friendliness and adequacy of RDT
presentation and instructions, interesting features not
listed on the compiled criteria were noted. For instance,
some device packages carried short instructions for use
based upon the generic WHO job aids [16], witch may
increase the test performance [9,10,19,31]. The availabil-
ity of job aids for the different brands on the company
websites in an adaptable text format may help Malaria
National Programs to translate it in the end-user lan-
guage and to adapt it on the local context. In addition,
some RDT kits provided a glossary with explanation of
the affixed symbols, which may help in their compre-
hension and acquisition and another five had all essen-
tial information printed on a single (lateral) side of the
box, contributing to easy storage (Figure 12). Another
asset was the presence of more than one buffer vial per
RDT box, as shortage and replacement of buffer vials is
a common problem in resource limited settings [5].
Likewise, the above described observations and correc-
tive measures could be extended to other IVDs, such as
human immunodeficiency virus RDTs.
Of course, it should be noted that adequate packages
and information inserts by themselves are not a guaran-
tee for competent use of RDTs. Simply distributing the
RDTs and instructions does not work, and RDT instruc-
tions on their own will not change professional beha-
viours [20]. Thorough training and performance
monitoring are needed for correct performance [16].
Conclusion
In conclusion, malaria RDTs showed shortcomings with
regard to quality of construction, design and labelling of
boxes, device packages, devices and buffers. Information
inserts were difficult to read and lacked relevant
information. Particular problems were observed in the
consistency and appropriateness of RDT brand names
and in the referral to the antigens used. In general,
CE-labelled and WHO-listed RDTs scored better com-
pared to those without but inadequacies were observed
among these RDTs. Addressing the quality of RTD pack-
age and information inserts in evaluation programs such
as the WHO/FIND products testing program could sti-
mulate the manufacturers to remediate these shortcom-
ings. Likewise, inclusion of malaria RDTs in the “Annex”
II of the 98/79/EC directive might represent a powerful
support from the European Community towards the
quality of in-vitro diagnostics in tropical countries.
Additional material
Additional file 1: Example of operational checklist for packaging,
labelling and instructions of RDTs.
Additional file 2: Example of a checklist for the content of the
information inserts.
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Abstract
Introduction: In the past malaria rapid diagnostic tests (RDTs) for self-diagnosis by travelers were considered suboptimal
due to poor performance. Nowadays RDTs for self-diagnosis are marketed and available through the internet. The present
study assessed RDT products marketed for self-diagnosis for diagnostic accuracy and quality of labeling, content and
instructions for use (IFU).
Methods: Diagnostic accuracy of eight RDT products was assessed with a panel of stored whole blood samples comprising
the four Plasmodium species (n = 90) as well as Plasmodium negative samples (n = 10). IFUs were assessed for quality of
description of procedure and interpretation and for lay-out and readability level. Errors in packaging and content were
recorded.
Results: Two products gave false-positive test lines in 70% and 80% of Plasmodium negative samples, precluding their use.
Of the remaining products, 4/6 had good to excellent sensitivity for the diagnosis of Plasmodium falciparum (98.2%–100.0%)
and Plasmodium vivax (93.3%–100.0%). Sensitivity for Plasmodium ovale and Plasmodium malariae diagnosis was poor
(6.7%–80.0%). All but one product yielded false-positive test lines after reading beyond the recommended reading time.
Problems with labeling (not specifying target antigens (n = 3), and content (desiccant with no humidity indicator (n = 6))
were observed. IFUs had major shortcomings in description of test procedure and interpretation, poor readability and lay-
out and user-unfriendly typography. Strategic issues (e.g. the need for repeat testing and reasons for false-negative tests)
were not addressed in any of the IFUs.
Conclusion: Diagnostic accuracy of RDTs for self-diagnosis was variable, with only 4/8 RDT products being reliable for the
diagnosis of P. falciparum and P. vivax, and none for P. ovale and P. malariae. RDTs for self-diagnosis need improvements in
IFUs (content and user-friendliness), labeling and content before they can be considered for self-diagnosis by the traveler.
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Introduction
In the nineties, malaria rapid diagnostic tests (RDTs) were
suggested for self-diagnosis by travelers [1]. The idea was however
abandoned after several studies had shown poor test performance
and difficulties in interpretation of test results by the ill traveler [1–
4]. Since then, major progresses have been made in RDT design
and performance. Most of the currently marketed RDTs are so-
called one-step RDTs that are more simple and user-friendly [5]
compared to the multi-step RDT products evaluated in previous
studies. Malaria RDTs are now easy to use handheld cassettes
detecting antigens produced by the Plasmodium parasite which
become visible as colored (mostly red) test lines within 20 minutes
[6].
Recently, the decline in malaria burden in many parts of the
world has made stand-by emergency treatment (SBET) more
attractive for many travelers than the classic chemoprophylaxis. In
the SBET strategy, travelers and expatriates to low-resource
endemic settings carry an emergency malaria treatment (with
reliable activity against P. falciparum) for self-administration when
no medical attention is rapidly available. This option may be
considered where the risk of adverse reaction to malaria
chemoprophylaxis outweighs the risk of malaria infection [7,8]
and is increasingly promoted by some experts in travel medicine
[9]. Self-diagnosis of febrile illness with reliable malaria RDTs
could accelerate early therapy (with the standby treatment),
preventing complications and death, or avoid unnecessary use of
antimalarials [10,11].
Nowadays, RDTs for malaria self-diagnosis are available
through the internet, but their diagnostic accuracy and ease of
use have not yet been studied. Also, the quality of instructions for
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use (IFU) – which assure correct performance and interpretation
of the RDT results [4] - can vary widely [12]. Therefore, the
present study assessed both diagnostic accuracy and quality of
packaging, labeling and IFU of RDT products marketed for self-
diagnosis by travelers.
Methods
Ethics Statement
The study was approved by the Institutional Review Board of
ITM and by the Ethical Committee of Antwerp University,
Belgium. RDTs were performed on stored blood samples
(‘‘leftovers’’) obtained as part of routine diagnostic work-up in
international travelers suspected of malaria. In view of the absence
of risk and the anonymous data processing, IRB deemed informed
consent obsolete.
Study Design
RDT products for self-diagnosis were evaluated for diagnostic
accuracy against a panel of 100 stored blood samples obtained in
travelers suspected of malaria and for the quality of packaging and
their IFU.
Patients and Samples
A total of 100 stored EDTA blood samples (including the four
human Plasmodium species as well as malaria negative samples,
Table 1) obtained from returned international travelers clinically
suspected of malaria were selected. Samples were collected
between October 2007 and September 2011 and were stored at
270uC at the Institute of Tropical Medicine (ITM), Antwerp,
Belgium. Species identification was done by expert microscopy,
corrected by four-primer real-time PCR [13].
Malaria Rapid Diagnostic Tests
Availability of RDT products for self-diagnosis on the internet
was assessed using the search engine ‘Google’. The following terms
were used in both English and French: ‘Malaria self-diagnosis’,
‘Malaria self-test’, ‘Malaria survival kit’, ‘Malaria home testing’,
‘Malaria autotest’. Three times a search was performed (January,
April and June 2011). In addition, two manufacturers were
contacted directly for availability of RDT products marketed for
self-diagnosis (Standard Diagnostics and Access Bio Inc.). Another
manufacturer (TODA PHARMA) had contacted himself ITM to
inform that he had RDTs available for self-diagnosis.
Test Procedures
Tests were performed according to the manufacturer’s instruc-
tions, except that a transfer pipette (Finnpipette, Helsinki, Finland)
was used instead of the transfer device supplied with the RDT
products. The first observer was the one who performed the test
and read test results within the specified reading time. The second
observer read test results within 5 additional minutes and was
blinded to the results of the first observer. Both observers were
blinded to the results of microscopy and PCR. The results of the
first observer were considered and compared to the second
observer to determine interobserver agreement. Test lines were
scored for line intensity as described previously [14]. Faint
intensity implies a barely visible test line which risks being
interpreted as negative. In case of absence of the control line, the
result was invalid and considered negative because it was assumed
that travelers will not always have a second RDT available. In
order to assess false positive results occurring upon reading beyond
the recommended reading time (so-called ‘‘back-flow phenome-
non’’ [15], the first observer scored test lines again at the end of
the day, between 2 and 8 hours after initial reading.
RDT Packaging and Instructions for Use
RDTs’ packaging and instructions for use (IFU) were assessed
using a checklist adapted from a previous study [12]. In addition,
typography, lay-out and readability level of the IFUs was assessed
as previously described [12]. Font size was measured in Cicero as
the ‘kp’ distance. For health instructions in general, font sizes .12
are recommended, interline spacing $2 and fonts of open letter
types [16]. The readability level was expressed as Flesh Kincaid
grade level. There are no criteria of readability levels for IFUs but
for patient education files, a level #6th grade is recommended
[16].
Some RDT products (OptiMAL and TODA) were delivered as
boxes containing multiple single-use RDT packages with IFUs
supplied in the boxes as well as in the individual packages. In these
cases only the IFUs included in the individual packages were
considered, as this IFU will most likely be the one available to the
traveler.
Statistical Analysis
For P. falciparum diagnosis, sensitivity was defined as follows: the
number of P. falciparum samples with a visible P. falciparum specific
test line, divided by the total number of P. falciparum samples. For
the non-falciparum species, sensitivity was defined as the number of
non-falciparum samples with a visible pan-pLDH test line, divided
by the total number of non-falciparum samples. As one product
(OneStep, Table 2) detects P. vivax instead of all non-falciparum
species, sensitivity was defined as all P. vivax samples with a visible
P. vivax test line divided by the total number of P. vivax samples.
Sensitivity was calculated with 95% confidence intervals (C.I.).
Table 1. Panel of clinical samples used to assess the test characteristics of the RDT products.
Region of travel
Species
Parasite density/ml median
(range) Africa Asia Caribbean/South-America No data
P. falciparum (n = 55) 2,928 (21–1,750,000) 51 3 1
P. vivax (n = 15) 1,068.5 (15–14,228) 6 6 1 2
P. ovale (n = 15) 817.5 (51–5,930) 14 1
P. malariae (n = 5) 382 (26–1,920) 5 1
Negative for malaria (n = 10) – 8 1 1
doi:10.1371/journal.pone.0053102.t001
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False positive test lines were defined as any visible test line
among the Plasmodium negative samples, non-falciparum samples
generating a visible P. falciparum-specific test line and in addition
for OneStep a visible P. vivax test line generated by P. falciparum, P.
ovale or P. malariae samples.
Inter-observer agreement for positive and negative readings and
line intensity was expressed by kappa values (k). In line with
previous RDT evaluations k 0.60–0.80 was considered good and k
.0.80 excellent.
Blood Lancets and Transfer Devices
The type of blood lancet (e.g. safety lancet with retractable
needle, safety seal lancet, simple lancet) and transfer device
(pipette, straw, loop, inverted cup) was recorded. Besides, blood
lancets were assessed for possibility of reuse. The safety lancets
with retractable needle consist of a plastic casing in which a needle
is fixed. The system has to be primed and next the needle is
launched by pushing on a button. For these systems it was checked
that the needle could not be launched inadvertently (e.g. during
transport in the luggage of the traveler) before the protective cap
was removed.
Additional Analysis
To assess the presence of histidine-rich protein-2 (PfHRP2) in
one P. vivax sample showing a P. falciparum test line of strong and
weak intensity in four and one out of five PfHRP2-detecting
RDTs, a PfHRP2 ELISA (Standard Diagnostics, Hagal-Dong,
Korea) was performed.
Results
RDT Selection
During the internet search eight RDT products were encoun-
tered and ordered. Three of these products were not included in
the final selection: one (Malapack Travel test, http://www.
vaccinations.com.au/product.htm) was not marketed anymore,
the manufacturer of the second product (EZ-Trust Malaria Rapid
Screen Test Kit, CS Innovation Pte Ltd, Singapore) replied not to
start up the production for an order less than 10,000 tests. The
third product that was delivered (Unitest malaria cassette Pf-Pv,
Ciriano global S.L., Zaragoza, Spain) appeared to be an RDT
detecting malaria antibodies instead of antigens (Figure 1),
whereas the product ordered from the manufacturer’s website
clearly mentioned an antigen-detecting product.
In addition to the five ordered RDT products, the three tests
directly provided by the manufacturers (as explained above) were
also included, so that a total of eight RDT products was evaluated
(Table 2). Six RDT formats were cassettes, there was one hybrid
format (OptiMAL) and one RDT (Immunoquick) consisted of a
dipstick.
RDT Performance
The number of samples detected and the number of false
positive lines for malaria negative samples for each RDT product
are displayed in Table 3. For 6/8 RDT products 100% sensitivity
was reached for P. falciparum diagnosis, but Labstix and Onestep
showed false positive lines in respectively 80% and 70% of malaria
negative samples. Three RDT products detected all P. vivax
samples. P. ovale and P. malariae detection was in general poor,
Labstix was the only one diagnosing all samples but this was at the
expense of poor specificity as this product generated visible pan-
pLDH lines in 8/10 Plasmodium negative samples as well.
Cross-reactions of non-falciparum samples with the P. falciparum
test line occurred for the majority of samples in Labstix (94.3%)
and OneStep (80.0%). In addition for OneStep 47 P. falciparum
samples and 12 P. ovale/P. malariae samples showed a visible P. vivax
test line.
Faint Test Lines
For P. falciparum diagnosis, the median percentage of correctly
identified test lines with faint line intensity per RDT product was
3.6% (range 0.0%–14.0%). For the correctly identified non-
falciparum samples, faint line intensities occurred at a median
frequency of 23.8% (range 10%–58.3%).
Interobserver Agreement
Median k for positive/negative readings for the P. falciparum test
line was 0.95 (range 0.50–1.00, OneStep k=0.50), for the non-
falciparum test line this was 0.91 (range 0.66–1.00). For line
intensity readings median k were 0.83 (range 0.70–0.96) and 0.76
(range 0.71–0.85) for the P. falciparum and non-falciparum lines
respectively.
Reading Beyond the Recommended Reading Time
For all but one (SDFK63) products false positive test lines were
seen after reading beyond the recommended reading time among
10.0%–90.0% of the malaria negative samples and 9.4%–100% of
the non-falciparum samples with initially no false positive test lines.
Immunoquick, TODA and Labstix were mainly affected with
nearly half (.44.4%) of malaria negative samples erroneously
diagnosed as malaria and the majority (.88.2%) of non-falciparum
samples diagnosed as P. falciparum malaria upon reading beyond
the recommended time.
RDT Packaging, Content and Design
Half of RDT products assessed had inconsistencies in their
names displayed on the outer packaging, the device packaging and
the IFU. Moreover, 3/8 RDT products did not mention their
target antigens and 2/8 RDT products did not display recom-
mended storage temperature (Table 2). In general, the RDT
products contained all material needed to perform the test,
however to open the buffer vial of Labstix, a scissor was needed
but this was not mentioned among the required materials, only in
the procedural steps of the IFU. Only 2/8 (25.0%) RDT products
contained a correct desiccant – i.e. provided with a color-based
humidity indicator allowing to control for humidity saturation.
Two products did not contain a transfer device, the drop of blood
had to be applied directly to the test strip. The pipettes supplied
with Labstix and OneStep did not contain a mark for indication of
the correct volume of blood.
For 4/7 RDT devices test line labeling consisted of acronyms
(‘Pf’, ‘P’, ‘Pan’), the others used either letters (T) or numbers.
Immunoquick contained no labeling at all as it is a dipstick without
cassette. Incorrect labeling of the reading window was found for
Sanitoets: only the symbols ‘C’ and ‘T’ were displayed at either
side of the reading window while the strip contains a control line
(‘‘C’’) and two test lines. For Labstix discordances were observed
between labeling on the test device (Pf, Pan) and the pictures
displayed in the IFU (T2, T1).
Instructions for Use
OneStep did not deliver an IFU with the tests, nor a link to the
online version. On the website where the product was ordered an
IFU was found. The IFU of OptiMAL consisted only of pictures.
None of the IFUs fulfilled requirements for correct font size (.12),
median font size was 5.0 (range 4.5–9). Only two products used an
interline distance of 2 and six IFUs used an open character.
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Median Flesh Kincaid grade level was 8.32 (5.86–9.65), only
Immunoquick had a Flesh Kincaid grade level #6th grade.
Shortcomings of the IFU with regard to test procedure and
interpretation are displayed in Table 4. Several critical procedural
steps were missing in more than half of the IFUs. For three RDT
products, the correct use of the blood lancet was not clearly
described or depicted. Sanitoets depicted another type of pipette in
the IFU than was delivered in the kit. Moreover, Sanitoets
mentioned to cut the end of the sealed pipette that contained the
reagent while in the kit a buffer vial with a screw cap was included.
Four IFUs failed to mention that the test should not be read
beyond the recommended reading time and one IFU (TODA) did
Figure 1. Received product of Unitest (Ciriano global S.L., Zaragoza, Spain). The delivered Unitest malaria cassette P.f-P.v kit mentions
detection of antibodies while the almost identical kit on the website mentions detection of the Pf and Pv antigen. (http://www.clinica.co.za/index.
php?page= shop.product_details&flypage= flypage.tpl&product_id= 11&category_id = 3&option= com_virtuemart&Itemid= 90).
doi:10.1371/journal.pone.0053102.g001
Table 3. Test characteristics of the different RDT products.
Number of samples identified (%) False positive lines
P. falciparum P. vivax P. ovale P. malariae
Pv, Po and Pm
(n=35) malaria negative (n=10)
RDT product PD ,1,000/ml
(n = 15)
PD .1,000/ml
(n = 40)
(n = 15) (n = 15) (n = 5) Pf test line Pf test line Pan/Pv test
line
CareStart 15 (100) 40 (100) 15 (100) 4 (26.7) 3 (60.0) 4 (11.4)*
Immunoquick 15 (100) 40 (100) 4 (11.4)
Labstix 15 (100) 40 (100) 15 (100) 15 (100) 15 (100) 33 (94.3)* 8 (80.0) 8 (80.0)
OneStep 15 (100) 40 (100) 12 (80.0) 28 (80.0) 7 (70.0) 3 (30.0)
OptiMAL 11 (73.3) 39 (97.5){ 13 (86.7){ 1 (6.7) 3 (60.0) 2 (5.7) 1 (10.0) 1 (10.0)
Sanitoets 13 (86.7) 39 (97.5){ 12 (80.0)1 7 (46.7) 2 (40.0) 2 (5.7)*
SDFK63 15 (100) 40 (100) 15 (100) 1 (6.7) 3 (60.0) 3 (8.6)*
TODA 15 (100) 40 (100) 14 (93.3) 3 (20.0) 4 (80.0) 1 (2.9)* 1 (10.0)
PD=parasite density, Pf = P. falciparum, Pv = P. vivax, Po = P. ovale, Pm= P. malariae.
*including one P. vivax sample that generated a strong positive result upon testing PfHRP2 ELISA.
{one sample missed with parasite density 2,458/ml.
{including one invalid result. 1 including one missed sample with parasite density 3,251/ml.
doi:10.1371/journal.pone.0053102.t003
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not display a reading time at all (for this product, information
about reading time was withheld from the box that contained the
single packages used for self-diagnosis).
OneStep did not contain any pictures of possible test results in
the interpretation section. OptiMAL and TODA did not mention
a visible control line and single visible P. falciparum test line as a
possible result. Following their instructions, a P. falciparum infection
always generates both a visible P. falciparum and pan-pLDH test
line. In the present study however, OptiMAL and TODA showed
a single visible P. falciparum test line among one and three P.
falciparum samples respectively, leading to 49/55 (89.0%) and 52/
55 (94.5%) correctly identified P. falciparum samples respectively.
IFUs that did not display all possible combinations for invalid
results generally only depicted a test in which none of the lines
were visible. For TODA, an error was observed on the figure
showing the invalid results, i.e. a cassette was displayed with a
visible control line and an absent test line. Except for Labstix that
depicted a less visible test lines among the positive results, none of
the RDT products mentioned to consider a faint test line as a
positive one. Likewise, causes of false negative and false positive
results were not mentioned. SDFK63 was the single product
mentioning that a negative test does not rule out malaria. Hardly
any advices about test policy were made, except for TODA
mentioning to use the ‘pan’ line for treatment follow-up of a P.
falciparum infection and Labstix and Immunoquick advised to start
treatment in case of a positive test or in case of a negative test and
persistence of symptoms (Table 4).
Table 4. Presence of important items that need to be addressed in the instructions for use.
Procedure section
Care-
Start
Immuno-
quick Labstix OneStep OptiMAL
Sani-
toets SDFK63 TODA
Do not use the RDT if the device
package is damaged
No Yes No Yes No No Yes No
Do not use beyond the expiry date Yes No No Yes No No Yes Yes
Use the device immediately after opening No No No No No Yes Yes No
Place the device on a level surface No N.A No Yes N.A. Yes No Yes
Check the desiccant for signs of exposure
to humidity
No No No No No No No No
Disinfect finger with alcohol wipe Yes Yes Yes Yes No Yes Yes Yes
Allow the finger to dry before pricking No No No Yes No Yes No Yes
Correct use of blood lancet is clearly
described/depicted
No Yes Yes Yes No Yes No Yes
The volume of blood to be transferred is
clearly mentioned
Yes Yes Yes No Yes No Yes No
Hold the buffer vial vertically No No No No No No Yes No
Do not use another buffer than the one
provided in the kit
No No No No No No No No
Use an adequate light source for reading No No No No No No No No
Do not read beyond the recommended
reading time
No Yes Yes Yes No Yes No No
Interpretation section
All possible line combinations for invalid
test results
No No Yes Yes No Yes Yes No
All possible test line combinations for
positive test results
Yes Yes Yes Yes No Yes Yes No
Interpretation of a faint test line as positive No No Yes No No No No No
Causes of false negative results, in
particular low parasitedensities
No No No No No No No No
Causes of false positive results, e.g.
presence of the rheumatoid
factor
No No No No No No No No
A negative test does not rule out malaria No No No No No Yes No No
In case of a negative RDT result and
persistent suspicion ofmalaria repeat the
test after 6–12 h or go to a doctor
No No*{ No* No No No No No
Do not use the test to follow-up treatment No No No No No No No No{
In case of a positive RDT result consult
a doctor
No No* No* No No Yes No No
N.A. = not applicable.
*The user is advised to take the treatment included in the kit.
{Repeating the test after 12 hours is advised, independent of persistence of symptoms.
{The user is advised to use the ‘pan’ line for treatment follow-up.
doi:10.1371/journal.pone.0053102.t004
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Blood Lancets and Transfer Devices
Blood lancets and transfer devices for each RDT product are
depicted in Figure 2. Five lancets were so-called safety lancets with
a retractable needle. For two of them reuse was possible and for
the other three the needle could inadvertently be launched before
removal of the protective cap. Two products did not contain a
transfer device, the drop of blood had to be applied directly to the
test strip. The pipettes supplied with Labstix and OneStep did not
contain a mark for indication of the correct volume of blood.
Discussion
The present study assessed the diagnostic accuracy of malaria
RDT products available for self-diagnosis as well as the quality of
packaging and content, the readability level and lay-out of its IFU.
Sensitivity was variable and for two products an unacceptable high
number of false positive test lines occurred. All but one product
yielded false-positive test lines upon reading beyond the recom-
mended reading time. Major shortcomings in IFU were observed
among all RDT products and the IFUs were not user-friendly.
Limitations and Strengths
The present study used a limited and selected number of
samples, precluding calculation of predictive values and providing
wide confidence intervals for non-falciparum results. Furthermore,
RDTs were performed by trained personnel which allowed
calculation of RDT sensitivity under perfect conditions but the
study design did not include actual performance by the intended
end-user. Likewise, ease of use and potential errors of RDT
performance as well as interpretation by travelers were not
assessed. However, the present study used a collection of samples
comprising all four human Plasmodium species at different parasite
densities providing relevant data on diagnostic accuracy. Besides,
the systematic evaluation of RDT packaging and its IFU allowed
direct comparison between products and assessment of major
shortcomings.
Accuracy for the Diagnosis of Malaria
P. falciparum is the most dangerous species and accurate
diagnosis should be guaranteed, even at low parasite densities
since the non-immune traveler may already have symptoms at
Figure 2. Lancets and transfer devices delivered with the different RDT products. CareStart and OptiMAL included a simple lancet, SDFK63
a safety seal lancet and the other products safety lancets with a retractable needle. The systems of TODA and Immunoquick (SMI) do not require a
transfer device (direct contact of the test strip with the drop of blood). Sanitoets contained a calibrated pipette and OptiMAL a straw pipette. The
other products included a balloon pipette. The transfer devices of OneStep and Labstix did not display a volume mark.
doi:10.1371/journal.pone.0053102.g002
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parasite densities of 100/ml [17]. Six RDT products had a good
sensitivity for P. falciparum diagnosis. The use of Labstix and
OneStep is however precluded due to the unacceptable high
number of false positive test lines. Among the remaining four RDT
products, Immunoquick is less suitable as it only detects P.
falciparum and in most low endemic areas where SBET is
considered P. vivax is prevalent as well. SDFK63, CareStart and
TODA had good sensitivities for both P. falciparum and P. vivax
diagnosis, but detection of P. ovale and P. malariae was poor, which
is a known phenomenon among RDTs [14,18–21]. IFUs should
mention these limitations, and advise to repeat a negative test after
several hours or to seek reliable health care if symptoms persist.
The high number of false positive test lines for Labstix and
OneStep may be due to problems of non-specific binding
including buffer composition [22] and a redesign is needed.
Moreover, the high number of false positive P. vivax test lines for
OneStep may be due to wrong citing of the target antigen which
presumably detects pan-pLDH rather than P. vivax-pLDH, which
has been described previously for other products [23]. The other
false positive test lines occurred at random and may be due to non-
specific reactions [24].
The P. vivax sample showing clearly visible test lines in all
PfHRP2-detecting RDT products was probably obtained from a
patient with a recent P. falciparum infection and PfHRP2
persistence [25] as the presence of PfHRP2 in the blood was
confirmed by ELISA.
Faint test line intensity of true positive test lines occurred mainly
among the non-falciparum species, although for OptiMAL .10%
of P. falciparum samples also generated a faint P. falciparum test line.
Faint test lines are of concern as they tend to be regarded as
negative [26] and will not be visible under unfavorable light
conditions.
It is possible that the ill traveler will check his RDT again after a
few hours to make sure it was really negative. After reading
beyond the recommended reading time, false positive test lines
may occur as demonstrated in the present study, due to the back-
flow phenomenon [15]. Therefore, it is important that the IFU
clearly mentions that reading test results should be performed
within the time specified in the IFU and any test line becoming
visible beyond the recommended reading time should be ignored.
For OneStep even reading a few minutes too late resulted in some
false positive P. falciparum test lines observed by the second
observer and explaining the low interobserver agreement.
RDT Shortcomings in Labeling
The most serious encountered error in labeling was that on the
website of UNITEST malaria antigen detection was clearly
mentioned and displayed on the picture, while the product
delivered targeted malaria antibodies. Apart from errors in the
online ordering system, it is of note that both products are nearly
identical except for differences in the text present on the box
(Figure 1).
RDT Problems in Design
Some observed errors in design may affect performance under
field conditions like errors in labeling of the reading frame and the
need of scissors for opening the buffer vial while not mentioned on
the package or in the IFU. The lack of a mark on the transfer
device to indicate the correct blood volume risks the application of
too much or too little blood, leading to poor background clearance
obscuring the test lines or to false negative results respectively. The
system of direct application of the cassette on the drop of blood
looks attractive, but there are no published data about its
correctness and ease of use. The most accurate, easy to use and
preferred transfer device by health workers in malaria endemic
setting was the inverted cup [27] and it can be assumed that this
will apply to travelers too.
Instructions for Use: Procedure and Interpretation
The presently found shortcomings in the IFU are of concern as
past evaluation showed problems in RDT performance by the ill
traveler which improved after revision of the IFU [4]. None of the
IFUs was written to the level of the end-user (high readability level,
poor lay-out and user unfriendly typography), which is a crucial
requirement for products intended for self-diagnosis [28].
Many of the shortcomings mentioned in Table 4 apply to the
use of RDTs by any end-user and have been observed in products
intended for laboratory use before [12]. Of particular interest to
the layman traveler are to check integrity and expiry date of the
product as it can be assumed that – despite the long shelf-life of
RDTs, storage periods can exceed those indicated by the expiry
dates. Moreover, the traveler, and especially the backpacker, will
not always be able to adhere to storage conditions (for most RDT
products below 30uC) leading to RDT degradation. Further, the
curious traveler might open the RDT packaging before intended
use, particularly when the IFU is included in a single pouch
together with the device, and by doing so he will expose the
product to humidity degradation.
The failure to explain/depict the use of the blood lancet is a
major shortcoming as one of the major difficulties in RDT
performance by travelers observed in previous studies was the
finger prick [2,29]. Test interpretation was another frequently
observed difficulty [2,3] and therefore all possible test results
should preferably be depicted. Of note, information regarding
RDT strategic issues (repeat testing, reasons for false negative tests)
was poor and when available not always correct i.e. using the pan-
pLDH line for treatment follow-up, which is debatable, as also
gametocytes produce pLDH [30,31].
What can be Done to Improve RDTs for Self-diagnosis?
First of all, an accurate performance needs to be assured.
Products like Labstix and OneStep performed insufficiently, they
contained no CE mark but were actually delivered to users in the
European Union. Next, IFUs should give understandable infor-
mation about the product performance, including the limitations
for the diagnosis of the non-falciparum species. Furthermore, the
IFU needs to become more user-friendly and the procedure and
interpretation sections need to be completed at least with the
topics mentioned in Table 4. Also for a traveler, multiple lancets,
transfer devices and alcohol wipes are advised. A tag for
temperature control (i.e. a small device or sticker that changes
color when the maximal temperature has been exceeded) may be
of additional value. Important, fulfillment of all these requirements
does not preclude the need for training and counseling of the end-
user of these tests. Although not presently studied, previous reports
have demonstrated the needs for training and the benefits of a
comprehensive training program [29]. For expatriates and
travelers performing RDTs abroad who ask for advice, we
currently ask them to send a photograph of the RDT. Future
technical developments, such as cell-phone based RDT readers
should be assessed for applications [32].
Conclusion
Diagnostic accuracy of currently on the internet available RDTs
for self-diagnosis is variable. Based on the present study, 3/8 RDT
products are reliable for P. falciparum and P. vivax diagnosis and one
for P. falciparum diagnosis only. Instructions on test performance,
interpretation and limitations and what to do with test results were
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incomplete and unsatisfactory for all RDT products. The presently
observed shortcomings need to be urgently adapted before RDTs
can indeed be used for self-diagnosis by the traveler and
expatriate.
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Frequency of severe malaria and invasive bacterial infections among children admitted to 
a rural hospital in Burkina Faso 
 Abstract 
Background: Although severe malaria is an important cause of mortality among children in Burkina Faso, 
data on community-acquired invasive bacterial infections (IBI, bacteremia and meningitis) are lacking, as well 
as data on the involved pathogens and their antibiotic resistance rates.  
Methods: The present study was conducted in a rural hospital in Burkina Faso, in a seasonal malaria 
transmission area. Children (<15 years) presenting with fever and/or signs of severe illness were enrolled 
upon admission and examined by study nurses. Malaria diagnosis and blood culture were performed for all 
participants, lumbar puncture when clinically indicated. We assessed the frequency of severe malaria and 
IBI, and for the latter the causative pathogens and their antibiotic resistance patterns.  
Results: From July 2012 to July 2013, a total of 711 patients were included. Severe malaria was diagnosed in 
292 (41.1%) children, including 8 (2.7%) with IBI co-infection. IBI was demonstrated in 67 (9.7%) children 
(bacteremia, n=63;  meningitis, n=6), 8 (11.8%) were co-infected with malaria. Non-Typhoid Salmonella  spp. 
(NTS) was the predominant isolate from blood culture (32.8%) and mainly isolated after the rainy season, 
followed by Salmonella Typhi (18.8%), Streptococcus pneumoniae (18.8%) and Escherichia coli (12.5%). High 
antibiotic resistance rates to first line antibiotics were observed, particularly among Gram-negative 
pathogens. In addition, decreased ciprofloxacin susceptibility and extended-spectrum beta lactamase (ESBL) 
production was reported for one NTS isolate each. ESBL production in E. coli was observed in 3/8 isolates 
(37.5%). In-hospital mortality was 8.2% and case-fatality rates for IBI (23.4%) were significantly higher 
compared to severe malaria (6.8%, p < 0.001). 
Conclusions: Although severe malaria was the main cause of illness, invasive bacterial infections were not 
uncommon and had higher case-fatality rates. The high frequency and mortality rates of community 
acquired IBI require improvement in hygiene, better diagnostic methods and revision of current treatment 
guidelines. 
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Introduction 
Malaria remains a major cause of mortality in children 
in most sub-Saharan African countries, despite 
decreasing incidence rates [1]. Community-acquired
invasive bacterial infections (IBI) such as  bacteremia 
and bacterial meningitis also contribute to the under-5 
mortality in sub-Saharan Africa [2,3], although exact
data are lacking in many areas. Severe malaria and IBI 
present with similar symptoms [4,5] precluding
differential diagnosis on clinical grounds and leading to 
an overdiagnosis of malaria [6] and ignorance of IBI. In
Burkina Faso, a West African country with seasonal 
malaria transmission, malaria is reported to be 
responsible for 55% of deaths at district level [7], but
data on frequency of IBI, pathogens and susceptibility 
patterns are hardly available due to a lack of diagnostic 
microbiology facilities. We conducted a prospective 
observational study in order to assess proportions of 
severe malaria and community-acquired IBI among 
children admitted to a rural hospital and health center 
in Burkina Faso. In addition, we determined the 
causative bacteria and their antibiotic resistance 
patterns and assessed case-fatality rates of both IBI 
and severe malaria. 
Methods 
Study site 
The survey was conducted at the district hospital 
Centre Médical avec Antenne chirurgicale (CMA) Saint 
Camille of Nanoro and the health center Urbain (with 
inpatient beds), both situated in Nanoro, Burkina Faso. 
Nanoro is located in a rural area in the Center-West 
region of the country, approximately 90 km west of 
the capital Ouagadougou. The health district of Nanoro 
comprises approximately 153,259 inhabitants of whom 
35,159 (22.9%) are children <5 years of age [8]. In
Nanoro there is hyperendemic malaria transmission 
from July – November, corresponding to the rainy 
season (June – October). Meningitis epidemics may 
occur in the hot, dry season (February – April), the last 
dating from 2009, after which a mass vaccination 
campaign against Neisseria meningitidis A was 
performed [7]. Pneumococcal and meningococcal
vaccines were not included in the national extended 
program of immunization (EPI) at the time of the study 
period. Vaccination against Haemophilus influenzae 
type b was introduced into EPI in January 2006 and the 
estimated coverage of immunization was 95.2% in 
2011 [8]. In 2010, the overall under-5 mortality rate in
Burkina Faso was 129/1000 life-births and 142/1000 
life-births in the Center-West region [7]; HIV-
prevalence was 1.2% among women 15-49 years and 
0.76% among pregnant women [7].
Study population and procedures 
All admitted children <15 years of age presenting with 
axillary temperature ≥38.0°C or clinical signs of severe 
illness were enrolled, including respiratory distress, 
prostration, altered consciousness, convulsions, clinical 
jaundice, hypothermia, signs of shock or severe 
malnutrition (weight for height score <70% according 
to national guidelines or kwashiorkor) or with severe 
anemia (hemoglobin <5 g/dl). Medical history, 
including prior antibiotic (48h) and antimalarial (2 
weeks) treatment, physical examination and outcome 
of febrile episode (died, referred, discharged) were 
registered on a standardized form by trained study 
nurses. Venous blood samples for blood culture, 
malaria diagnosis, full blood count and blood glucose 
levels were collected from all participants by trained 
study staff using aseptic techniques. Lumbar puncture 
was performed in case of suspicion of cerebral malaria 
and/or bacterial meningitis, based on the decision of 
the attending health care worker. Decision for HIV 
testing or other additional testing was left to the 
discretion of attending health staff. Treatment 
decisions were made by the attending health staff 
according to national guidelines: quinine IV for severe 
malaria, ampicillin + gentamicin for neonatal infections 
and ceftriaxone for suspected sepsis or meningitis in 
older children. Laboratory results were provided 
instantly to guide treatment decisions. 
Laboratory procedures 
All laboratory analysis were performed at the Clinical 
Research Unit of Nanoro (CRUN) which is located on 
the compound of CMA. Samples were submitted 
within 15 minutes after collection.  
Thick and thin blood films were stained with 3% 
Giemsa solution (pH 7.2), examined for presence of 
Plasmodium species according to standard procedures 
[9] and results were expressed as asexual parasites per 
microliter using the patient’s white blood cell (WBC) 
count. Every slide was read by two experienced 
microscopists, and in case of discrepant results 
(positive vs. negative, different Plasmodium species, 
difference in parasite density >Log10 or ratio >2 in 
case of parasite density ≤400/µl and >400/µl 
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respectively) by a third experienced microscopist. A 
selection of slides (5%) was re-read by an expert 
microscopist whose results were considered 
conclusive. 
The malaria rapid diagnostic test (RDT) recommended 
by the national malaria control program, SD Bioline Pf 
(Standard Diagnostics, Hagal-Dong, Korea) detecting P. 
falciparum-specific histidine-rich protein-2 (PfHRP2), 
was performed on EDTA blood samples according to 
the manufacturers’ instructions. 
In all children, 1-3 ml of venous blood was collected 
into a pediatric blood culture bottle (BD BACTEC Peds 
PlusTM/F, Becton Dickinson and Company, Sparks, 
Maryland, USA). A subset of blood culture bottles was 
weighed before and after blood inoculation to 
determine the amount of blood collected. All blood 
culture bottles were incubated in a BACTEC 9050 
instrument (Becton Dickinson) for a total of 5 days. If 
flagged for growth they were Gram stained, 
subcultured on Eosin-Methylene blue (EMB) agar and 
5% Sheep Blood agar (bioMérieux, Marcy-l’Etoile, 
France) and incubated at 35-37°C for 24 hours in 
atmospheric conditions and at 5% CO2 respectively. 
Isolates were identified to the species level by 
standard biochemical methods and antibiotic 
susceptibility testing was performed by disk diffusion 
according to CLSI criteria [10] or in case of assessment
of minimal inhibitory concentration (MIC) values by E-
test macromethod (bioMérieux) [10]. For Salmonella
spp., multidrug resistance (MDR) was defined as 
resistance to the first-line antibiotics ampicillin, 
chloramphenicol and trimethoprim-sulfamethoxazole 
(TMP-SMX); reduced fluoroquinolone susceptibility 
(further referred to as decreased ciprofloxacin 
susceptibility, DCS) was defined as resistance to 
nalidixic acid [10] and/or MIC-values for ciprofloxacin
>0.06 µg/ml [11]. Enterobacteriaceae resistant to
cephalosporins were tested for Extended Spectrum 
Beta-Lactamase (ESBL) production by combined 
double-disk method (Rosco Diagnostica, Taastrup, 
Denmark) [10]. For Enterobacteriaceae, no breakpoints
have been published for azithromycin susceptibility, 
however EUCAST V 3.1. [11] suggests treatment of
infections with Salmonella Typhi at MIC-values ≤16 
mg/l and recently this value has been proposed as an 
epidemiological cutoff value for wild-type Salmonella 
spp. [12]. Non-fragile clinically significant organisms
were shipped on tryptic soy agar (TSA) at room 
temperature to the Institute of Tropical Medicine, 
Antwerp, where identification and antibiotic 
susceptibility testing were confirmed. Shigella spp. and 
a subset of Salmonella spp. isolates was confirmed at 
the National Reference Laboratory for Salmonella and 
Shigella (Institute of Public Health, Brussels) by slide 
agglutination with commercial monospecific antisera 
(Sifin, Berlin, Germany), following the Kauffmann-
White scheme [13].
Cerebrospinal fluid (CSF) was assessed for its aspect, 
cell count, Gram stain and culture. The CSF leucocyte 
count was assessed in a Nageotte counting chamber at 
x 400 magnification, and if ≥50 WBC/µl were counted a 
thin film was prepared and stained with methylene 
blue to count the percentage of neutrophils and 
lymphocytes. For culture, 1 to 2 drops of CSF were 
inoculated onto blood agar and chocolate blood agar 
supplemented with IsovitalexTM (Becton Dickinson) and 
incubated at 35-37°C at 5% CO2 for 48 hours. Any 
bacterial growth observed was further processed by 
standard microbiological techniques. CSF samples 
were further assessed by latex agglutination testing for 
Haemophilus influenzae b, Streptococcus pneumoniae, 
Streptococcus group B, Neisseria meningitidis and 
Escherichia coli K1 (PastorexTM Meningitis , BioRad, 
Marnes-la-Coquette, France). In addition if N. 
meningitidis was identified serotyping was performed 
(BioRad or Becton Dickinson). 
Full blood counts were assessed using Sysmex XS1000i 
(Sysmex Corporation, Kobe, Japan).  
For determination of glucose levels full blood was 
collected on NaF tubes and processed by Flexor Junior 
(Vital Scientific, Netherland). Screening for HIV was 
performed at the HIV center on the CMA compound 
according to national guidelines by the rapid diagnostic 
test Determine
TM
 HIV-1/2 (Alere Medical Co., Ltd, 
Chiba, Japan) and in case positive the SD Bioline HIV-
1/2 3.0 (Standard Diagnostic INC, Kyonggi-do, Korea) 
was performed.  
Case definitions 
Fever was defined as axillary temperature ≥37.5°C or 
reported history of fever in the past 48 hours.  
Malaria was defined as the presence of asexual P. 
falciparum parasites confirmed by microscopy.   
Severe malaria was defined as microscopically 
confirmed malaria and fulfillment of at least one of the 
WHO clinical or laboratory criteria of severe malaria 
[14] with slight adaptations: respiratory distress was
defined as abnormal deep breathing, subcostal 
retraction or tachypnea according to age [15]; shock
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was defined as an abnormal low systolic blood 
pressure according to age [15], or a combination of 
temperature gradient (warm trunk and cold 
extremities) and capillary refill >3 seconds.  
Cerebral malaria was defined as severe falciparum 
malaria with coma (Glasgow coma scale <11 or 
Blantyre coma score <3) or convulsions in the past 24 
hours (≥2 or postictal phase ≥30 minutes) and 
exclusion of bacterial meningitis or hypoglycemia 
alone (prompt recovery of consciousness after glucose 
infusion) as cause of symptoms [14]. 
IBI was defined as bacteremia and/or bacterial 
meningitis. Bacteremia was defined as the growth of 
clinical significant organisms from blood culture. Non-
pathogenic bacteria or skin flora were considered 
contaminants, including coagulase-negative 
Staphylococci, Bacillus spp. and Micrococcus spp. 
Bacterial meningitis was defined as i) cerebrospinal 
fluid (CSF) culture grown with an organism of known 
clinical significance, or ii) CSF white blood cell count 
>10/µl with on Gram stain slides the presence of 
organisms of known clinical significance, or iii) CSF 
white blood cell count >10/µl and blood culture grown 
with an organism of known causative role in meningitis 
or iv) positive latex agglutination. Probable meningitis 
was defined as a child with clinical signs of meningitis, 
in whom no lumbar puncture had been performed and 
a bacteria known to be a causative agent in meningitis 
was isolated from blood culture.    
Data management and analysis 
Clinical and laboratory data was double entered in Epi 
Info version 3.5.3. Statistical analysis was done with 
Stata 11 (Stata Corp., College Station, TX, USA).  
Categorical data were assessed for significance using 
the chi-square test or Fisher exact test as appropriate. 
The Wilcoxon rank sum test was used for non-
parametric data. Case-fatality rates (CFR) were 
calculated as proportions of children who died within a 
specified disease group. Only participants for whom 
the final hospital outcome was known (discharge or 
death) were included in the denominator of CFR 
calculations, referred patients were excluded.  
Ethics statement 
The study was conducted according to the principles 
expressed in the Declaration of Helsinki and was 
approved by the national ethics committee of Burkina 
Faso, the institutional review board of the Institute of 
Tropical Medicine, Antwerp and the ethics committee 
of the University Hospital of Antwerp. Written 
informed consent was given by all parents or guardians 
of children enrolled. 
Results 
Patients included  
From July 2012 to July 2013, a total of 711 admitted 
children were enrolled (hospital n=607, health center 
n=104). Another 177 eligible children were not 
included for various reasons (not proceeding to study 
nurse, no blood sampling, refusal to provide informed 
consent). For age, gender and outcome, there were no 
significant differences (p > 0.05) between included and 
eligible non-included patients, however, recorded 
axillary temperature was significantly higher among 
included patients (p < 0.001).  
Demographic data, clinical features and laboratory 
results of the children included are displayed in Table 
1. Children were included because of axillary
temperature ≥38.0°C (n = 196), signs of severe illness 
with fever (n = 494) or without fever (n = 21). Lumbar 
puncture was performed in 19 children. Six children 
were known as HIV-positive at enrolment and an 
additional two (out of five tested) were newly 
diagnosed with HIV infection at inclusion.   
Severe Malaria 
In total 378 children (53.2%) had microscopically 
confirmed malaria. Of them, 292 children fulfilled at 
least one clinical or laboratory sign of severe malaria of 
whom 48 children (16.4%) had cerebral malaria (Table 
2). Severe malaria was more common among children 
aged 1-5 years than those <1 and >5 years (both p < 
0.001). 
Of note, a positive malaria RDT was observed in 137 
children with negative microscopy, among which 106 
(77.4%) had at least one clinical or laboratory sign of 
severe malaria. Of them, 69.8% (74/106) reported 
previous antimalarial treatment, significantly higher 
compared to children with microscopically confirmed 
severe malaria (36.6%, 107/292, p < 0.001).  
Invasive bacterial infections 
Bacteremia was found in 63 (8.9%) children (Table 2), 
while contaminants were grown in another 27 (3.7%) 
samples collected. In one blood culture, two 
pathogens were isolated resulting in a total of 64 
clinically significant isolates. Proportions of bacteremia  
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Table 1. Demographic, clinical and laboratory characteristics upon admission 
All (n = 711) Hospital (n = 607) Health center (n = 104) 
Female sex, n (%) 318 (44.7) 264 (43.5) 54 (51.9) 
Age, median months (IQR) 19 (10-36) 18 (9-34) 28.5 (14-65) 
Axillary temperature ≥38.0°C  507 (71.3) 410 (67.5) 97 (93.3) 
Pretreatment with antimalarials, n (%) 305 (42.9) 245 (40.4) 60 (57.7) 
Pretreatment with antibiotics, n (%) 199 (28.0) 174 (28.7) 25 (24.0) 
Clinical features upon admission 
Altered consciousness 33 (4.6) 28 (4.6) 5 (4.8) 
 Coma, n (%) 23 (3.2) 18 (3.0) 5 (4.8) 
Convulsions, n (%) 55 (7.7) 44 (7.2) 11 (10.6) 
Prostration, n (%) 304 (42.8) 262 (43.2) 42 (40.4) 
Respiratory distress, n (%) 221 (31.1) 172 (28.3) 49 (47.1) 
Shock 48 (6.8) 40 (6.6) 8 (7.7) 
Jaundice, n (%) 30 (4.2) 30 (4.9) 0 
Hemoglobinuria, n (%) 6 (0.8) 5 (0.8) 1 (1.0) 
Severe malnutrition*, n (%)  85 (12.7) 80 (13.7) 5 (5.9) 
Laboratory features upon admission 
Severe anemia (< 5 g/dl), n (%) 191 (26.9) 186 (30.6) 5 (4.8) 
Hypoglycemia (< 2.2 mmol/l), n (%) 36 (5.1) 30 (4.9) 6 (5.8) 
Hyperparasitemia (<250,000/µl) 22 (3.1) 16 (2.6) 6 (5.8) 
Hb = hemoglobin IQR = interquartile range, 
* For 670 children data on severe malnutrition known
Table 2. Severe malaria and invasive bacterial infections by age group 
All < 1 m 1 - 11 m 12 - 23 m 24 - 59 m ≥ 60 m
n = 711 n = 15 n = 195 n = 206 n = 196 n = 99 
Severe malaria*, n (%) 292 (42.1) 62 (31.8) 101 (49.0) 101 (51.5) 28 (28.3) 
Cerebral malaria, n (%) 48 (6.8) 7 (3.6) 16 (7.8) 22 (11.2) 3 (3.0) 
IBI§, n (%) 67 (9.2) 3 (20.0) 15 (7.7) 20 (9.7) 13 (6.6) 16 (16.2) 
Bacteremia, n (%) 63 (8.9) 3 (20.0) 14 (7.2) 18 (8.7) 13 (6.6) 15 (15.2) 
Confirmed + probable 
meningitis, n (%) 
6+5 (1.5) 0+1 (6.7) 1+0 (0.5) 3+1 (1.9) 0+1 (0.5) 2+2 (4.0) 
Co-infection IBI / malaria, n (%) 8 (1.1) 1 (6.7) 1 (0.5) 3 (1.5) 3 (1.5) 
IBI = invasive bacterial infection, m = months 
* Including those with IBI co-infection, § Including those with malaria co-infection
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were highest among neonates (20.0%) and children ≥5 
years of age (15.8%). Pathogens most frequently 
isolated were non-typhoid Salmonella spp. (NTS, 
32.8%), Salmonella Typhi (18.8%) Streptococcus 
pneumoniae (18.8%) and Escherichia coli (12.5%) 
(Table 3). NTS comprised Salmonella Typhimurium (n = 
12), Salmonella Enteritidis (n = 8) and Salmonella 
Telelkibir (n = 1). E. coli, NTS and Salmonella Typhi 
were the most frequently isolated pathogens among 
children <1 year of age, 1-5 years and ≥5 years of age 
respectively (Table 3).  
The median (range) blood volume per blood culture 
vial sampled was 0.8 ml (0.3 – 1.2) and 2.1 ml (1.1 – 
3.0) for children <2 months and ≥2 months of age 
respectively. In 19/170 (11.2%) and 46/170 (27.1%) 
blood culture bottles were under-filled (<0.5 ml) and 
overfilled (>3.0 ml) respectively.  
Bacterial meningitis was confirmed in 6/19 (31.6%) 
children for whom lumbar puncture was performed; 
pathogens were Streptococcus pneumoniae (n = 3, 
identified by latex agglutination), Neisseria 
meningitidis W135 (n = 1), Haemophilus influenzae (n = 
1) and Klebsiella pneumoniae (n = 1). There were five
additional children with probable meningitis who had 
S. pneumoniae (n = 4) and N. meningitidis W135 (n = 1) 
isolated from blood cultures.  
Figure 1. Numbers of children with positive 
microscopy, RDT and IBI 
TBF, RDT and IBI results for all children (n = 711), 169 children 
tested negative on all three items. Areas in Venn-diagram 
approximately to scale. TBF = thick blood film, RDT = rapid 
diagnostic test, IBI = invasive bacterial infection,  SM = severe 
malaria, UM = uncomplicated malaria. 
Co-infections of severe malaria and invasive bacterial 
disease  
Distribution of positive microscopy, RDT and IBI among 
children included are displayed in Figure 1. P. 
falciparum parasites were present in 7/63 (11.1%) and 
1/6 (16.7%) children with bacteremia and meningitis 
respectively. Conversely, among the children with 
severe malaria 8/299 (2.7%) had IBI. No significant 
difference in parasite densities between children with 
severe malaria (median 38,319/µl, range 25 – 702,500) 
and severe malaria / IBI co-infection (79,365.5/µl, 
range 271 – 338,000) was observed (p = 0.5).  
The RDT was positive in 30/63 (47.6%) children with 
bacteremia and was significantly more frequent among 
children with NTS (17/21, 81.0%) compared to children 
with other pathogens isolated (13/42, 31.0%, p < 
0.001). 
Figure 2. Distribution of severe malaria (SM) and 
invasive bacterial infection (IBI) by month 
IBI = invasive bacterial infection, SM = severe malaria, RDT-
SM = signs of severe malaria with negative microscopy and 
positive RDT, UM = uncomplicated malaria, Other = all other 
children included not fulfilling criteria of SM or IBI 
Proportions of malaria and invasive bacterial 
infections 
The proportion of severe malaria per month ranged 
from 0.0% - 62.7% among all children included with a 
peak from August to October (Figure 2), while the 
proportion of IBI ranged from 0.0% - 24.1% per month 
with a peak in November – January  after the rainy 
season, mainly due to a high number of NTS infections 
(62.5%, 15/24 bacteremia cases), and a smaller 
increase in May.  
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Table 3. Clinically significant organisms isolated from blood culture and age-specific frequencies 
Data displayed are numbers and percentages of clinically significant bacteria isolated. 
M = months, IQR = interquartile range 
* In one patient 2 pathogens were isolated (E. coli and Leuconostoc)
Table 4. Antibiotic resistance patterns of Enterobacteriaceae 
Non-typhoid 
Salmonella 
Salmonella 
Typhi 
Shigella 
spp. 
Escherichia 
coli 
Klebsiella 
pneumoniae* 
n = 21 n = 12 n = 2 n = 8 n = 1 
Antibiotic n (%) resistant isolates 
Ampicillin 19 (90.5) 0 2 7 (87.5) 1 
Chloramphenicol 19 (90.5) 10 (83.3) 1 2 (25.0) 1 
TMP-SMX 19 (90.5) 10 (83.3) 2 6 (75.0) 1 
MDR 19 (90.5) 0 NA NA NA 
Nalidixic acid 1 (4.8) 0 0 NA NA 
Ciprofloxacin NA NA 0 5 (62.5) 0 
DCS 1 (4.8) 0 NA NA NA 
ESBL confirmed 1 (4.8) 0 0 3 (37.5) 0 
Azithromycin 0 0 0 NA NA 
Gentamicin NA NA NA 4 (50.0) 0 
Meropenem / Ertapenem NA NA NA 0 0 
DCS = decreased ciprofloxacin susceptibility, ESBL = extended-spectrum beta-lactamase, MDR = multidrug resistant, NA = non 
applicable, TMP-SMX = trimethoprim-sulfamethoxazole 
* Isolated from CSF
All < 1 m 1 - 11 m 12 - 23 m 24 - 59 m ≥ 60 m
Age in months, 
median (IQR) 
All pathogenic bacteria 64 3 14 18 13 16 21 (9 – 54) 
Non-typhoid Salmonella 21 (32.8) 5 (35.7) 8 (44.4) 6 (46.2) 2 (12.5) 19 (10 – 36) 
Salmonella Typhi 12 (18.8) 1 (5.6) 3 (23.1) 8 (50.0) 75.5 (45 – 114) 
Streptococcus pneumoniae 12 (18.8) 1 (33.3) 3 (21.4) 5 (27.8) 2 (15.4) 1 (6.3) 12.5 (8.5 – 25) 
Escherichia coli 8 (12.5) 1 (33.3) 5 (35.7) 1 (7.7) 1 (6.3) 7.5 (4 – 16.5) 
Staphylococcus aureus 3 (4.7) 1 (7.1) 1 (6.3) 
Shigella spp. 2 (3.1) 1 (5.6) 1 (7.7) 1 (6.3) 
Neisseria meningitidis 2 (3.1) 1 (5.6) 1 (6.3) 
Haemophilus influenzae 1 (1.6) 1 (6.3) 
Streptococcus pyogenes 1 (1.6) 1 (33.3) 
Aerococcus viridans 1 (1.6) 1 (5.6) 
Leuconostoc 1 (1.6) 1 (6.3) 
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Antibiotic resistance patterns of bacterial pathogens 
Table 4 displays the antibiotic resistance rates of the 
Enterobacteriaceae: 19/21 NTS isolates were MDR, of 
them one Salmonella Typhimurium was in addition 
ESBL producing and one Salmonella Enteritidis isolate 
showed DCS (ciprofloxacin MIC-value 0.25 µg/ml, 
nalidixic acid MIC-value >256 µg/ml). All other NTS 
isolates were susceptible to ciprofloxacin (MIC-values 
≤0.023 µg/ml). Salmonella Telelkibir was susceptible to 
all antibiotics tested. Among the Salmonella Typhi 
isolates, 10/12 (83.3%) were resistant to both 
chloramphenicol and TMP-SMX but all were 
susceptible to ampicillin and ciprofloxacin (MIC-values 
≤0.008 µg/ml). Shigella flexneri was resistant to 
ampicillin, chloramphenicol and TMP-SMX, Shigella 
dysenteriae was resistant to ampicillin and TMP-SMX. 
All NTS, Salmonella Typhi and Shigella isolates  were 
susceptible to azithromycin (MIC-values ≤6.0, ≤2.0 and 
≤1.0 µg/ml respectively). Three E. coli isolates were 
confirmed ESBL producers and co-resistant to 
ciprofloxacin, two of them were also co-resistant to 
gentamicin. No resistance to the carbapenem 
antibiotics tested was detected.  
All S. pneumoniae isolates (n = 11, isolated from blood) 
were susceptible to ceftriaxone (MIC values ≤0.047 
µg/ml in 10/11 and 0.19 µg/ml in the remaining one) 
and 10/11 were susceptible to penicillin (MIC-values 
≤0.032 µg/ml in 9/10 isolates and 0.064 in one). The 
remaining isolate had MIC-values (0.094 µg/ml) above 
the CLSI meningitis susceptibility breakpoint (0.06 
µg/ml). All S. pneumoniae isolates were susceptible to 
erythromycin but most 9/11 (81.8%) were resistant to 
TMP-SMX. The N. meningitidis isolates were 
susceptible to penicillin (MIC-values 0.047 and 0.064 
µg/ml) and ceftriaxone (MIC-values 0.002 µg/ml for 
both isolates) as was H. influenzae (MIC-value 0.006 
µg/ml) 
All three S. aureus isolates were methicillin susceptible 
as well as susceptible to clindamycin, gentamicin and 
TMP-SMX; three and one of them were resistant to 
tetracycline and erythromycin respectively.  
A total of 28.2% (205/728) children reported antibiotic 
use <48h prior to sampling; most frequently 
administered antibiotics were TMP-SMX (35.1%) and 
amoxicillin or ampicillin (45.9%). Bacteria were 
significantly more frequently isolated among children 
on antibiotics (13.1%, 26/199) compared to those who 
reported no prior antibiotic use (7.3%, 37/510, p = 
0.015). 
Case-fatality rates 
For 697 (98.0%) children hospital outcome was known: 
58/697 (8.3%) children died, of them 20 (34.5%) and 
15 (25.9%) were diagnosed with severe malaria and IBI 
respectively. CFR were significantly higher among 
children with IBI (23.4%) versus severe malaria (6.8%, p 
< 0.001), none of the children with severe malaria/IBI 
co-infection (n = 8) died. Among children with a 
positive RDT and negative microscopy with signs of 
severe malaria 11/110 (10.0%) died, of them six had 
IBI.  
CFR for IBI was highest among children <1 year of age 
(52.9%, 9/17). Among children with bacteremia, 
deaths occurred among children infected by S. 
pneumoniae (4/12), E. coli (4/8), NTS (3/20), S. aureus 
(2/3) and N. meningitidis (1/2). None of the patients 
with Salmonella Typhi bacteremia died. Among 
children with confirmed and probable meningitis 4/10 
(40.0%) died (three S. pneumoniae, one N. 
meningitidis), while 8/46 (17.4%) children with 
cerebral malaria died.  
Discussion 
The present study showed that, among children ill 
enough to be admitted to  rural health facilities in 
Burkina Faso, severe malaria was the leading cause of 
morbidity (one half of the admissions) and mortality 
(one third of the deaths). However IBI were not 
uncommon and were associated with a significantly 
higher mortality rate compared to malaria cases. The 
relative proportions of severe malaria and IBI in febrile 
and/or severely ill children differed dramatically 
according to the seasons as well as the bacterial 
pathogens isolated, with a peak of severe malaria 
during the rainy season and a relative increase of IBI 
(mainly due to NTS) shortly thereafter. High antibiotic 
resistance rates to first line antibiotics were observed, 
particularly among Gram-negative pathogens.  
This study has several limitations. First, a substantial 
proportion of children fulfilling inclusion criteria was 
not included. As age and mortality rate did not differ 
significantly, non-inclusion probably occurred at 
random although the lower body temperatures may 
suggest less severe disease in non-included patients. 
Second, there are the intrinsic limitations of blood 
cultures such as the moderate sensitivity (e.g. 40 – 
80% in the case of typhoid fever [16]), further lowered
by antibiotic exposure prior to sampling. In the present 
study, the first-line antibiotics used prior to sampling 
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(ampicillin and TMP-SMX) were mostly ineffective to 
the pathogens retrieved and the percentage of 
bacteremia was higher among children who were on 
antibiotics before sampling. Nevertheless, more 
susceptible and fragile strains, like S. pneumoniae, may 
have been missed. Quality indicators of the current 
blood culture system were satisfying: the percentage 
of contaminants (3.7%) was acceptable and  lower 
compared to other studies performed in malaria 
endemic settings (8 – 14.3%) [2,17–20]. Despite the
limited number of isolates, the present study is the 
first to present surveillance data on antibiotic 
resistance rates in blood culture isolates in Burkina 
Faso to the knowledge of the authors. Furthermore, 
performance of a lumbar puncture was left to the 
decision of the health care worker, and the actual 
number of meningitis cases may have been higher as 
in only nineteen children with clinical signs of cerebral 
malaria and/or meningitis a lumbar puncture was 
performed. Health care workers in rural Africa may be 
reluctant to perform a lumbar puncture, because of 
little experience, lack of appropriate materials and lack 
of microbiological facilities. In addition, the case 
definition of severe malaria might have been too 
stringent: indeed, some children may have been 
erroneously excluded from the diagnosis of severe 
malaria as no parasites were seen by microscopy, 
whereas the PfHRP2-detecting RDT was positive. This 
was supported by the significantly higher proportion of 
antimalarial treatment prior to admission in this group 
compared to microscopy positive children. On the 
other hand, some children may have had 
asymptomatic carriage of P. falciparum parasites while 
being ill due to bacterial or viral infection [21,22].
Furthermore, with the available diagnostic methods 
we could not establish a final diagnosis for all children 
included. Finally, the limited number of children for 
whom HIV testing was performed precluded 
assessment of associations with IBI and/or severe 
malaria.     
Bacterial co-infections among children with severe 
malaria were less frequent (2.7%) compared to those 
reported from other studies (4.6% – 8.3.%) [2,17,23–
27] as was P. falciparum co-infection among children
with bacteremia (11.1% versus 14.7% – 21.6%) 
[2,19,28]. One of the explanations may be the frequent
use of antimalarial treatment before admission. When 
considering also cases with positive RDT results, the 
proportion of co-infections was substantially higher 
(49.2% of children with bacteremia had positive RDT), 
although still lower than in a  recent study from 
Tanzania (56.9%) [26].
Except for surveillance of meningitis epidemics and a 
single study on blood culture isolates in a tertiary care 
urban center [29], there were no previous data about
the burden of community acquired bacteremia in 
Burkina Faso, in particular from rural areas. The high 
proportion of NTS isolates is consistent with studies 
performed in other rural malaria endemic settings in 
sub-Saharan Africa [18,19,24–27,30], although most of
them reported NTS infections mainly during (and after) 
the rainy season [18,24,25], while in the present study
NTS was scarce during the rainy season with a peak 
just after it. Recent reviews found Salmonella Typhi to 
be uncommon in children in rural malaria endemic 
areas in sub-Saharan Africa [31,32], but this pathogen
was relatively frequent in our study compared to 
others performed in similar settings [2,30,33]. This
may be due to specific local environment conditions or 
to the inclusion of children ≥5 years of age. Salmonella 
Typhi is more common in older children [16,26], but
may also occur in children ≤5 [26,34] as shown in the
present study. Two recent studies performed in sub-
Saharan Africa even found higher incidence rates of 
Salmonella Typhi bacteremia among children 2-5 years 
compared to children ≥5 [35,36].
Resistance rates among community-acquired 
pathogens were high, particularly among the 
Enterobacteriaceae. The majority of NTS was MDR as 
reported previously for other countries in sub-Saharan 
Africa [19,37–40]. In line with recent findings from DR
Congo [40], we observed isolates with DCS and ESBL.
Although limited to a single isolate each, this warrants 
further microbiological surveillance. For Salmonella 
Typhi, high resistance rates to TMP-SMX 
(recommended as alternative treatment for typhoid 
fever by the ministry of health of Burkina Faso [41])
and amoxicillin/ampicillin were observed, which were 
the antibiotics most frequently prescribed at the 
health center level in our study population. No MDR 
nor DCS was found for Salmonella Typhi, in contrast to 
reports from other sub-Saharan countries [40,42–45].
This may reflect differences in antibiotic use, but also 
differences in prevailing isolates. Unlike recent reports 
from DR Congo [34,40], no resistance was observed for
azithromycin, which is an oral reserve antibiotic useful 
in the treatment of salmonellosis and shigellosis [46].
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Of concern was the presence of ESBL with co-
resistance to gentamicin and fluoroquinolone 
antibiotics among E. coli (precluding treatment options 
with commonly available antibiotics), which is in line 
with ESBL producing pathogens in the environment 
and community in sub-Saharan Africa [47–49].
All S. pneumoniae, N. meningitidis and H. influenzae 
isolates were susceptible to ceftriaxone, which is the 
recommended treatment for bacterial meningitis in 
Burkina Faso.  
The high number of resistance to first-line antibiotics 
(ampicillin, TMP-SMX) requires extension of 
surveillance studies to other populations (e.g. adults, 
outpatients) and regions in the country and evaluation 
of the current national treatment guidelines.  
CFR for IBI were significantly higher compared to 
severe malaria (23.4% and 6.8% respectively) and 
existence of IBI as well as appropriate case 
management should be more emphasized at all levels 
of health care. CFR for IBI were in line with those 
found in rural Kenya (28%) [2] and rural DR Congo
(19%) [30], but lower than those in urban Malawi
(38%) [50] and Tanzania (35%) [28] which may be due
to low HIV-positive rate in Burkina Faso [7]; they were
higher than those in rural Mozambique (12%) [20] and
rural Ghana (9%) studies [19], but this is probably due
to the broader inclusion criteria (inclusion of in- and 
outpatients) in the latter studies. Previous studies 
reported 4-6 fold higher mortality rates among 
malaria/bacteremia co-infected children versus 
children with severe malaria only [17,23]. In the
present study none of the children with 
malaria/bacteremia co-infection died, but  the number 
of co-infections was low. For the RDT positive / IBI co-
infections, CFR increased to 7.4% but remained lower 
than reported in previous studies [17,25].
As malaria may predispose to NTS bacteremia [51,52],
reduction of malaria transmission would not only lead 
to a reduction in morbidity and mortality due to 
malaria but could also reduce the burden of NTS 
bacteremia [52]. As main reservoirs for human invasive
NTS have to date not been explored extensively [53],
containment of risk factors (malaria, HIV, malnutrition 
[53]) appears the best preventive measure.
Introduction of the 13-polyvalent pneumococcal 
vaccine and vaccination against typhoid fever as well 
as improved hygiene could further reduce the burden 
of community-acquired childhood bacteremia in this 
area.  
In conclusion, although severe malaria was the main 
cause of disease among children admitted to a rural 
hospital in Burkina Faso, invasive bacterial infections 
were not uncommon and had higher CFR. The high 
proportion and case-fatality rate of community 
acquired bacteremia as well as the high antibiotic 
resistance rates of the pathogens require 
improvement in hygiene, better diagnostic methods 
and emphasize the need of blood culture surveillance 
and revision of current antibiotic guidelines. 
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Accuracy of PfHRP2 versus Pf-pLDH antigen detection by malaria rapid diagnostic tests in 
children presenting with severe febrile illness in a seasonal hyperendemic malaria 
transmission area in Burkina Faso 
 
Abstract 
Background: In most Sub-Saharan African countries malaria rapid diagnostic tests (RDTs) are now used for
the diagnosis of malaria. Most RDTs used detect Plasmodium falciparum Histidine rich protein-2 (PfHRP2), 
though P. falciparum-specific parasite lactate dehydrogenase (Pf-pLDH)-detecting RDTs may have 
advantages over PfHRP2-detecting RDTs. Only few data are available on the use of RDTs in severe illness 
and we therefore compared Pf-pLDH to PfHRP2-detection.  
Methods: Hospitalized children aged 1 month – 14 years presenting with fever or severe illness were
included over one year. Venous blood samples were drawn for malaria diagnosis (microscopy and RDT), 
culture and complete blood count. Leftovers were stored at -80 °C and used for additional RDT analysis and 
PCR. An RDT targeting both PfHRP2 and Pf-pLDH was performed on all samples for direct comparison of 
diagnostic accuracy with microscopy as reference method. PCR was performed to explore false-positive 
RDT results. 
Results: In 376/694 (54.2%) children included malaria was microscopically confirmed. Sensitivity,
specificity, positive predictive value (PPV) and negative predictive value were 100.0%, 70.9%, 69.4% and 
100.0% respectively for PfHRP2-detection and 98.7%, 94.0%, 91.6% and 99.1% respectively for Pf-pLDH-
detection. Specificity and PPV were significantly lower for PfHRP2-detection (p < 0.001). For both detection 
antigens specificity was lowest for children 1 – 5 years and in the rainy season. PPV for both antigens was 
highest in the rainy season, because of higher malaria prevalence. False positive PfHRP2 results were 
associated with prior antimalarial treatment and positive PCR results (98/114 (86.0%) samples tested).  
Conclusion: Among children presenting with severe febrile illness in a seasonal hyperendemic malaria
transmission area, we observed similar sensitivity but lower specificity and PPV of PfHRP2 compared to Pf-
pLDH-detection. Further studies should assess the diagnostic accuracy and safety of an appropriate Pf-
pLDH-detecting RDT in field settings and if satisfying replacement of PfHRP2 by Pf-pLDH-detecting RDTs 
should be considered. 
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Background 
Malaria rapid diagnostic tests (RDTs) are currently 
rolled out in Sub-Saharan Africa to fulfill the need of 
parasite based diagnosis e.g. the parasitological 
confirmation of malaria before start of treatment [1]. 
The operational characteristics of RDTs have been 
extensively evaluated for uncomplicated malaria [2] 
and the parasite-based diagnosis strategy has proven 
to be safe in uncomplicated malaria [3]. In contrast, 
only few studies addressed the use of RDTs in children 
presenting with severe illness. Those performed 
reported low specificity of Plasmodium falciparum 
Histidine-rich protein-2 (PfHRP2)-detecting RDTs [4,5], 
which is most probably due to PfHRP2 persistence after 
clearance of infection [6]. An alternative would be an 
RDT detecting P. falciparum-specific parasite lactate 
dehydrogenase (Pf-pLDH), which is more rapidly 
cleared from the bloodstream, but lower sensitivities 
compared to PfHRP2 have been reported [4]. However 
recent evaluations of other Pf-pLDH-detecting RDT 
products have shown better performance, also at low 
parasite densities [7-9]. The RDT used by the national 
malaria control program of Burkina Faso detects 
PfHRP2, which is recommended by the World Health 
Organization (WHO) [10] and used in most Sub-Saharan 
African countries. The current diagnostic algorithm in 
Burkina Faso recommends treatment of malaria in case 
of a positive test and search for other causes of disease 
when negative [11], but does not differentiate between 
severe and non-severe disease. The aim of this study 
was to compare Pf-pLDH to PfHRP2-detecting RDTs in 
children presenting with severe febrile illness in a 
seasonal hyperendemic malaria transmission area.   
Methods 
Study site and population 
A one year survey (July 2012 – 2013) to assess 
proportions and incidence rates of invasive bacterial 
infections and severe malaria was performed in a rural 
area in the Center-west region of Burkina Faso. In this 
region there is seasonal hyperendemic malaria 
transmission and the estimated under-5 mortality in 
2010 was 142/1,000 live births [12]. Details of the study 
have been published elsewhere [13]. In summary, 
children (< 15 years) presenting with axillary 
temperature ≥ 38.0°C and/or clinical signs of severe 
illness who were admitted to the hospital or health 
center were enrolled. Signs of severe illness included 
convulsions, altered consciousness, prostration, 
respiratory distress, shock, hypothermia and severe 
malnutrition. For the present study children < 1 month 
of age were not considered.  
Sample collection 
In all children enrolled blood culture was performed 
and EDTA-anticoagulated venous blood samples were 
drawn for malaria diagnosis (both microscopy and rapid 
diagnostic test). Laboratory analysis was performed in 
the clinical research unit of Nanoro (CRUN), located on 
the compound of the district hospital. Leftovers of 
EDTA blood samples were stored at -80°C within a 
maximum of 2 hours after sampling until further 
analysis. Medical history, including previous 
antimalarial treatment, and clinical examination were 
registered on standardized forms by trained study staff.  
Laboratory procedures 
Thick blood films (TBF) were stained with Giemsa and 
assessed for the presence of Plasmodium parasites 
according to standard procedures [14]. Parasite density 
was expressed as asexual parasites per microliter using 
the patient’s white blood cell (WBC) count. TBF was 
considered negative if no parasites were seen on 100 
fields. Every slide was read by two experienced 
microscopists blinded to each other’s results and in 
case of discrepant results (positive vs. negative, 
different Plasmodium species, difference in parasite 
density >Log10 or ratio >2 in case of parasite density 
≤400/µl and >400/µl respectively) by a third 
experienced microscopist.  
The RDT SD Bioline Malaria Antigen P.f (Standard 
Diagnostics, Hagal-Dong, Korea), further referred to as 
SD50 (LOT 082160), is the RDT recommended by the 
national malaria control program of Burkina Faso and 
detects the protein PfHRP2. SD50 was performed on 
EDTA blood samples by trained CRUN laboratory staff 
before slides were read and within a maximum of 2 
hours after sampling.  
Blood culture work-up and cerebrospinal fluid analysis 
was performed according to standard microbiological 
procedures as described previously [13].  
Malaria rapid diagnostic test evaluated 
The RDT SD Bioline Malaria Antigen P.f (HRP2/pLDH) 
(Standard Diagnostics, Hagal-Dong, Korea), further 
referred to as SD90 (LOT RDT12002), is a three-band 
test consisting of a control line and two test lines 
targeting PfHRP2 and Pf-pLDH respectively. Good 
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performance was reported in previous evaluations 
[15,16].   
SD90 was performed on EDTA blood samples according 
to the manufacturer’s instructions except for 
replacement of the transfer device by a micropipette. 
From February to July (n = 276), SD90 was performed 
on fresh samples side-to-side to SD50 by CRUN 
laboratory staff. For the remaining samples (n = 420) 
SD90 was performed on stored samples at the end of 
the study period by the investigator.  
In case of absence of the control line the test was 
considered invalid and repeated. Test line intensities 
were scored as negative, faint, weak, medium or strong 
compared to the control line by a single observer who 
was blinded to the result of microscopy. After reading, 
photographs were taken. 
 
Monitoring and Quality control  
A selection of slides (5%) was sent to the Institute of 
Tropical Medicine (ITM) and again read by an expert 
microscopist whose results were considered conclusive.  
SD50 and SD90 were ordered at ITM Belgium and 
shipped to Burkina Faso where they were stored in a 
temperature controlled room. The actual kit in use was 
stored in the parasitology laboratory. Temperature and 
humidity during shipment and storage were monitored 
using loggers (Ebro Electronic GmBH, Ingolstadt, 
Germany).  
 
For discordant results between either SD50 or SD90 
and microscopy, samples were retrieved from -80°C 
storage and both RDTs were repeated by the 
investigator blinded to microscopy results. The result of 
the repeat testing was considered for analysis in case 
the first result was performed by CRUN staff. If both 
the first and repeat testing was performed by the 
investigator the first result was considered. 
Photographs taken were verified to exclude clerical 
errors.  
In order to compare PfHRP2 results of SD50 and SD90, 
the RDTs were performed side to side on 10% randomly 
selected stored samples. For SD50, these 10% of stored 
samples were also compared to results obtained when 
prospectively performed on fresh samples.  
 
Additional analysis: PCR 
Real-time polymerase chain reaction (PCR) was 
performed in case of discordant results between 
microscopy and RDT. DNA was extracted from 200 ml 
whole blood using QIAamp DNA blood Mini kit 
(QIAGEN, Venlo, The Netherlands) or from TBF if 
needed [17]. DNA was amplified by a species-specific 
18S rRNA real-time PCR (P. falciparum/P. vivax [18]), 
the P. ovale/P. malariae duplex was run simultaneously 
to confirm microscopically identified non-falciparum 
species. 
 
Data management, definitions and analysis 
Data were double-entered in Epi info software (version 
3.5.3). Statistical analysis was done with Stata 11 (Stata 
Corp., College Station, TX, USA). For the purpose of this 
study, microscopy was considered as the gold standard. 
Samples with asexual P. falciparum parasites seen on 
TBF (irrespective of parasite density and either as 
mono-infection or as mixed infection with P. ovale or P. 
malariae) were categorized as P. falciparum positive. 
The remaining samples, including samples with pure P. 
falciparum gametocytemia, P. ovale or P. malariae as 
well as those with no parasites seen, were categorized 
as P. falciparum negative. For SD90, sensitivity and 
specificity were calculated for both PfHRP2 and Pf-
pLDH test lines. A visible test line in case of P. 
falciparum positive samples was considered true 
positive, no visible test line false negative. For P. 
falciparum negative samples, the absence of a visible 
test line was labeled as true negative, a visible line was 
labeled as false positive. Sensitivity, specificity and 
predictive values were calculated by age group and 
season and expressed with 95% C.I.. Differences were 
assessed for statistical significance using the chi-square 
test, or Fisher exact test when appropriate, in case of 
independent data (e.g. comparison between the 
seasons) and with the McNemar test or paired 
proportion test for dependent data (PfHRP2 vs. Pf-
pLDH).  
 
Ethical issues 
The study was approved by the ethical committee of 
Burkina Faso and the University Hospital of Antwerp 
and by the institutional review board of ITM. Written 
informed consent was obtained from the parent or 
guardian of each child included.  
 
Results 
Study population and malaria microscopy results 
During the one-year study period 696 children aged 1 
month – 14 years were included [13]. For two children 
(both P. falciparum positive with parasite densities of 
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62/µl and 35194/µl respectively) there was evidence of 
a sample switch during storage, both samples were 
excluded from analysis. The final collection consisted of 
694 samples.  
Demographic data of participants during the different 
seasons are displayed in Table 1. Seasons were divided 
in Rainy season (July – October, monthly microscopy 
positivity rate 67.9% - 87.9%) post-rainy season 
(November – February, monthly microscopy positivity 
rate 31.4% - 40.0%) and hot dry season (March – June, 
monthly microscopy positivity rate 2.9% - 17.2%).  
In 376 (54.0%) children, samples were P. falciparum 
positive, five of them had a mixed infection with 
Plasmodium malariae (n = 3) and Plasmodium ovale (n 
= 2). Median P. falciparum parasite density was 
43,231.5/µl (25 - 702,500). Among the P. falciparum 
negative samples (318/694, 45.8%), two had P. ovale 
infection and 13 had pure P. falciparum 
gametocytemia.  
Diagnostic accuracy of PfHRP2 and Pf-pLDH  
No invalid results were observed for SD90. PfHRP2 and 
Pf-pLDH positivity rates are displayed in Figure 1.  
Among the P. falciparum-positive samples, PfHRP2 was 
positive in all samples while Pf-pLDH missed one 
(parasite density 62/µl, Table 2), resulting in an overall 
sensitivity of 100% and 99.5% for PfHRP2 and Pf-pLDH 
respectively (p = 1.0). Among the P. falciparum-
negative samples, there were 139 and 29 false-positive 
PfHRP2 and Pf-pLDH lines respectively, corresponding 
to specificities of 56.3% and 90.9% respectively (p < 
0.001). In 25 (7.9%) P. falciparum-negative samples  
Figure 1. Microscopy, PfHRP2 and Pf-pLDH positivity 
rate by month 
Micro = microscopy positivity rate, PfHRP2 = positive rate of 
PfHRP2, Pf-pLDH = positivity rate of Pf-pLDH  
both test lines were visible: they included eight 
samples with pure gametocytemia. PfHRP2 was 
positive in an additional 114 samples, including another 
four samples with pure gametocytemia. False positive 
Pf-pLDH test lines in the absence of PfHRP2 lines 
occurred in four samples of which two were P. ovale 
infection and one pure gametocytemia. 
Overall, positive predictive value (PPV) for PfHRP2-
detection (73.0%), was significantly lower compared to 
Pf-pLDH detection (92.8%, p < 0.001) while negative 
predictive values (NPV) were similar (Table 3).  
PfHRP2 and Pf-pLDH performance by age group  
PfHRP2 specificity was significantly lower among 
children aged 1 – 5 years (39.6%) compared to children 
<1 year (70.9%) or > 5 years (68.4%, p < 0.001 for both), 
for Pf-pLDH differences among age groups were not 
significant (p = 0.053 and p = 0.134 respectively, Table 
4). As the slide-positivity rate was highest among 
children 1-5 years of age, PPV for PfHRP2 in this age 
group did not differ significantly from the others 
despite lower specificity (p = 0.428 and p = 0.255).  
PfHRP2 and Pf-pLDH seasonal performance 
Sensitivity of PfHRP2 and Pf-pLDH detection did not 
differ throughout the year (Table 4). PfHRP2 specificity 
was significantly higher in the hot dry season (78.9%) 
compared to the rainy and post-rainy season (35.1% 
and 46.9% respectively, both p < 0.001). As slide 
positivity-rate was highest in the rainy season, PPV of 
PfHRP2 was highest in the rainy season (83.3%), 
despite lowest specificity, and decreased to 51.9% and  
Figure 2. False positive RDT results per month 
compared to microscopy positivity rate 
Micro = microscopy positivity rate, FP PfHRP2 = % false 
positive results among total PfHRP2 positive, FP Pf-pLDH =% 
false positive Pf-pLDH among total Pf-pLDH positive 
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Table 1. Demographic profile and diagnosis of children included during the different seasons 
 
All year Rainy season  Post-rainy season Hot dry season 
 
n = 694 n = 398 n = 151 n = 145 
Age, median months (IQR) 20 (11 - 37) 21 (12 - 37) 16 (9 - 35) 17 (9 - 39) 
Female sex, n (%) 310 (44.7) 176 (44.2) 79 (52.3) 55 (37.9) 
Prior antimalarial treatment, n (%) 302 (43.5) 156 (39.2) 87 (57.6) 59 (40.7) 
Microscopy Pf positive 376 (54.2) 304 (76.4) 55 (36.4) 17 (11.7) 
Pf parasite density (/µl),  
median (range) 
42,331  
(25 - 702,500) 
49,962.5   
(62 - 702,500) 
18,256  
(99 - 259,685) 
7,549  
(25 - 112,465) 
Blood culture positive, n (%) 60 (8.7%) 19 (4.8) 27 (17.9) 14 (9.7) 
Confirmed meningitis, n (%) 6 (0.9) 1 (0.3) 2 (1.3) 3 (2.1) 
Co-infections 7 (1.0) 4 (1.0) 3 (2.0) 0 
IQR = interquartile range, n = number, Pf = P. falciparum 
 
 
Table 2. PfHRP2 and Pf-pLDH results according to parasite density 
    PfHRP2 pos PfHRP2 neg 
Microscopy Number Pf-pLDH pos Pf-pLDH neg Pf-pLDH pos Pf-pLDH neg 
1 - 100 3 2 1 
  100 - 1,000 25 25       
1,001 - 10,000 66 66 
   10,001 - 100,000 199 199       
> 100,000 83 83 
   pure gametocytemia 13 8 4 1   
Microscopy negative 303 17 110 1 175 
P. ovale 2     2   
Total 694 400 115 4 175 
Neg = negative, pos = positive, PfHRP2 = P. falciparum Histidine-rich protein-2, Pf-pLDH = P. falciparum-specific 
parasite lactate dehydrogenase  
 
 
Table 3. Diagnostic accuracy of PfHRP2- compared to Pf-pLDH-detection 
  PfHRP2 Pf-pLDH p-value 
RDT pos, n (%) 515 (74.2) 404 (54.2)   
SE 100.0 (94.7 - 100.0) 98.7 (93.5-99.9) 1.0 
Sp 70.9 (67.4 - 70.9) 94.0 (90.6 - 94.8) < 0.001 
PPV 69.4 (65.7 - 69.4) 91.6 (86.8 - 92.7) < 0.001 
NPV 100.0 (95.1 - 100.0) 99.1 (95.5 - 100.0) 1.0 
N = number, NPV = negative predictive value, PfHRP2 = P. falciparum Histidine-rich protein-2, Pf-pLDH = P. 
falciparum-specific parasite lactate dehydrogenase pos = positive, PPV = positive, predictive value SE = sensitivity, 
Sp = specificity  
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Table 4. Diagnostic accuracy of PfHRP2 versus Pf-pLDH by age group and by season 
Number 
Slide Pf 
pos (%) 
PfHRP2 Pf-pLDH 
SE (95% C.I.) Sp (95% C.I.) PPV (95% C.I.) NPV (95% C.I.) SE (95% C.I.) Sp (95% C.I.) PPV (95% C.I.) NPV (95% C.I.) 
Age group 
< 1 year 194 39.7 100.0 70.9 69.4 100.0 98.7 94.0 91.6 99.1 
(94.7 - 100.0) (67.4 - 70.9) (65.7 - 69.4) (95.1 - 100.0) (93.5 - 99.9) (90.6 - 94.8) (86.8 - 92.7) (95.5 - 100.0) 
1 – 5 years 401 64.1 100.0 39.6 74.7 100.0 100.0 86.8 93.1 100.0 
(98.3 - 100.0) (36.6 - 39.6) (73.5 -74.7) (92.5 - 100.0) (98.4 - 100.0) (84.0 - 86.8) (91.6 - 93.1) (96.7 - 100.0) 
≥ 5 years 99 42.4 100.0 68.4 70.0 100.0 100.0 94.7 93.3 100.0 
(91.1 - 100.0) (61.9 - 68.4) (63.8 - 70.0) (90.4 - 100.0) (92.3 - 100.0) (89.1 - 94.7) (86.2 - 93.3) (94.0 - 100.0) 
Season 
Rainy 398 76.4 100.0 35.1 83.3 100.0 99.7 85.1 95.6 98.8 
(98.7 - 100.0) (30.8 - 35.1) (82.2 - 83.3) (87.6 - 100.0) (98.2 - 100.0) (80.5 - 86.1) (94.2 - 95.9) (93.4 - 99.9) 
Past-rainy 151 36.4 100.0 46.9 51.9 100.0 100.0 87.5 82.1 100.0 
(92.7 - 100.0) (42.7 - 46.9) (48.1 - 51.9) (91.1 - 100.0) (93.2 - 100.0) (83.6 - 87.5) (76.5 - 82.1) (95.5 - 100.0) 
Hot dry 145 11.7 100.0 78.9 38.6 100.0 100.0 97.7 85.0 100.0 
(78.7 - 100.0) (76.1 - 78.9) (30.4 - 38.6) (96.4 - 100.0) (81.7 - 100.0) (95.2 - 97.7) (69.5 - 85.0) (97.5 - 100.0) 
Pf = P. falciparum, PfHRP2 = P. falciparum Histidine-rich protein-2, Pf-pLDH = P. falciparum-specific parasite lactate dehydrogenase, pos = positive, SE = sensitivity, Sp = specificity, PPV = 
positive predictive value, NPV = negative predictive value
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38.6% in the other two seasons. Specificity of Pf-pLDH 
detection was in all seasons higher compared to 
PfHRP2 (Table 4, p < 0.001 for each season). Also for Pf-
pLDH-detection PPV was highest in the rainy season, 
though differences were smaller: 95.6% in the rainy 
season compared to 82.1% (p < 0.001) and 85.0% (p = 
0.071) in the post-rainy and hot dry season 
respectively.  
RDT positivity among children with invasive bacterial 
infections 
Microscopy was positive in 8/64 (12.5%) children with 
invasive bacterial infections (IBI), PfHRP2 and Pf-pLDH 
were positive in 33/64 (51.6%) and 12/64 (18.8%) 
respectively. As described previously [13] non-typhoid
Salmonella spp. (NTS) were most frequently isolated 
from blood culture (21/60, 35.0%). PfHRP2 was positive 
among 17/21 (81.0%) NTS which was significantly more 
frequent compared to Pf-pLDH (6/21, 28.6%, p = 0.002) 
and microscopy (2/21, 9.5%, p < 0.001).  
RDT line intensity 
For Pf-pLDH, 2.4% (9/375) of true positive test lines was 
of faint intensity, for PfHRP2 this was 0.5% (2/376). For 
the P. falciparum positive samples, the PfHRP2 test line 
compared to the corresponding Pf-pLDH test line for 
the same sample was of stronger and weaker intensity 
in 179/376 (47.6%) and 31/376 (8.2%) samples 
respectively. For seven samples with high parasite 
density (82,080 – 392,535/µl) PfHRP2 was of weak 
intensity while Pf-pLDH was of strong intensity. Among 
the false positive test lines (excluding pure 
gametocytemia), 2/20 (10%) Pf-pLDH and 67/126 
(53.2%) PfHRP2 lines were of medium or strong 
intensity.  
RDT results of retesting and quality control 
During the side to side comparison of PfHRP2 of SD50 
and SD90 no discordances between positive and 
negative results were observed and differences in line 
intensity were limited to one category. 
When comparing results of SD50 performed on fresh 
and stored samples, no differences in positive / 
negative results nor major differences in line intensities 
(more than one category) were observed, except for 
one originally strong result which was faint on repeat 
testing but for which clerical error could not be 
excluded.  
Further analysis of the false positive samples 
In 139/318 P. falciparum-negative samples the PfHRP2 
line was visible, including 12 samples with pure 
gametocytemia. For the latter, 10/12 were obtained in 
children reporting previous antimalarial treatment and 
8/12 had a visible Pf-pLDH line. Figure 3 summarizes 
the results of PCR, Pf-pLDH and previous antimalarial 
treatment for the false positive PfHRP2 results 
(excluding pure gametocytemia) for which PCR was 
performed (n = 114): Pf-pLDH was positive in 16 
(14.0%) samples, PCR in 98 (86.0%) and previous 
antimalarial treatment was reported in 75 (65.8%). For 
five samples, none of the aforementioned items was 
positive.  
Among both PfHRP2 and Pf-pLDH false positive results, 
report of previous antimalarial treatment was 
significantly higher (66.2% and 86.2% respectively) 
compared to microscopy positive samples (33.3%, p < 
0.001 for both).     
Figure 3. Positive PCR and Pf-pLDH results and report 
of previous antimalarial treatment for false-positive 
PfHRP2 samples 
Only those samples with false positive PfHRP2 for which PCR 
was performed are displayed (n = 114). AM Tx = previous 
antimalarial treatment, PfpLDH = positive Pf-pLDH test line, 
PCR = positive PCR result. For 5 children none of the 
aforementioned was positive.  
Discussion 
The present study assessed the diagnostic accuracy of 
PfHRP2 compared to Pf-pLDH antigen detection in 
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children presenting with severe febrile illness in a rural 
area with seasonal malaria transmission. Both antigens 
had excellent sensitivity and similar negative predictive 
values, but PfHRP2 had a lower specificity resulting in a 
significantly lower positive predictive value. Specificity 
was lowest in the rainy season, but due to the high 
malaria prevalence PPV was highest in the rainy 
season. The majority of false-positive PfHRP2 lines 
were PCR positive and/or reported recent antimalarial 
treatment, part of them were also Pf-pLDH positive or 
had pure gametocytemia.  
Limitations 
A number of limitations need to be considered. First, 
although the present study allowed reliable 
comparison between Pf-pLDH and PfHRP2-detection, 
which was the study objective, the RDT evaluated is not 
a format that is likely to be used in field settings. 
However, the simultaneous side-to-side testing of SD90 
and SD50 showed similar results, reason why we feel 
confident to extrapolate the data about PfHRP2 
performance to the actual situation in Burkina Faso. 
Second, RDTs were performed and interpreted by an 
experienced investigator using a calibrated pipette 
which may have generated higher sensitivities than 
would have been obtained under field conditions. 
Furthermore, 60% of SD90 was performed on stored 
samples, though samples had been stored for a 
maximum of one year and had not been thawed prior 
to testing; in addition, repeat testing on a subset of 
samples showed no difference in results when 
performed on fresh or stored samples. 
Sensitivity 
So far, only two large studies evaluated the diagnostic 
accuracy of RDTs in children suspected of severe 
malaria, one in Mozambique and Tanzania [4] and
another in Tanzania [5]. The former compared a Pf-
pLDH with a PfHRP2-detecting RDT: they observed a 
significant lower sensitivity for the Pf-pLDH-detecting 
RDT (88.0% versus 94.0%), especially at low (< 1000/µl) 
parasite densities. Of note however, the test used 
(Optimal-IT) is a multistep RDT with reported lower 
sensitivities compared to more recent one-step Pf-
pLDH-detecting RDT products [8,19]. In the present
study there was excellent sensitivity of Pf-pLDH 
detection, also at low parasite densities. Only one 
sample was missed by Pf-pLDH detection and  this 
sample had a parasite density of 62/µl, which is below 
the detection threshold of routine microscopy [20].
Faint test lines, which are prone to be disregarded by 
health workers [21-23], only occurred in 0.5% and 2.4% 
of the true positive PfHRP2 and Pf-pLDH lines 
respectively. The co-presence of weak PfHRP2 and 
strong Pf-pLDH lines at high parasite densities (n = 7), 
may be caused by the prozone effect (false 
negative/low test lines due to an antigen excess [24]),
but was presently not further assessed. Only PfHRP2-
detecting RDTs are affected by the prozone effect, not 
Pf-pLDH [24,25]. The degree to which RDTs are affected
by prozone is product dependent and in some products 
PfHRP2 lines may be completely absent [24], leading to
false negative results. The weak line intensities at high 
parasite densities are also of concern, as they may be 
considered as non-severe disease [23,26].
Specificity 
When interpreting specificity several factors should be 
addressed: first, although in the present study slides 
were double read by experienced microscopists, very 
low parasite densities may have been missed. Next, 
exclusive presence of gametocytes was considered as 
P. falciparum negative (as they do not cause clinical 
infection) but they produce PfHRP2 and Pf-pLDH 
[27,28] explaining the apparent false positive results.
For the purpose of this study we did not consider PCR 
as the reference method, because it may detect 
submicroscopic infections (reflecting asymptomatic 
carriage) which do not explain clinical symptoms [29].
The false positive Pf-pLDH lines observed in the present 
study can in part be explained by a (on-going and 
partly) treated malaria infection from the previous days 
as Pf-pLDH becomes negative in a median of 2-7 days 
after start of effective treatment [30,31].This was
presently supported by its association with a history of 
recent antimalarial treatment. In addition, there were 
three false positive Pf-pLDH results for which both 
PfHRP2 and PCR were negative. Possible explanations 
may be cross-reaction with pLDH produced by P. ovale 
(n = 2) or other interfering factors [32].
The interpretation of false positive PfHRP2 lines is more 
complex. The most common cause of false positive 
PfHRP2 results, especially in high-transmission areas, is 
PfHRP2 persistence. Other possibilities, though rare, 
are nonspecific bindings or interference with other 
immunological or infectious factors such as the 
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rheumatoid factor, hepatitis C, schistosomiasis, 
toxoplasmosis, dengue, leishmaniasis, Chagas disease 
and human African trypanosomiasis [19,33-36].  
For the PCR negative samples we can reasonably 
assume that the false positive PfHRP2 lines were due to 
past infection, approximately two – six weeks ago. For 
the PCR positive samples, the subsequent  question 
arises  whether the children were  actually suffering 
from malaria at the time of sampling and had negative 
microscopy because of recently (<2 days) started 
antimalarial treatment (ongoing infection) [37] or
whether it was a recently cleared infection with the 
child now suffering from another disease. Indeed, 
microscopy turns negative within 1-2 days after start of 
artemisinin-based combination therapy (ACT) [38], but
the time of PCR to become negative after start of 
treatment has not yet been studied, although one 
study reported that upon completion of supervised ACT 
treatment a third of children were still positive by real 
time PCR [39]. As the proportion of positive PCR results
among false positive PfHRP2 samples was high in our 
study, we speculate that at least part of the false-
positive PfHRP2 lines can be explained by ongoing and 
partly treated infection, especially in those samples 
which showed false positive Pf-pLDH results as well.  
Prior use of antimalarial treatment (either by self-
medication or prescription) reflects real-life situation in 
malaria endemic settings. To know if the child is 
actually suffering from malaria, an ideal RDT should be 
able to differentiate ongoing infection from a 
previously currently cured episode of infection, but 
PfHRP2 is not capable to do so. Pf-pLDH RDTs seem to 
be more promising in that respect  – as they turn 
negative in 2 – 7 days - but future studies should assess 
their evolution over time after start of treatment.  
Influence of age and season on specificity 
The low PfHRP2 specificity in the rainy and post-rainy 
season compared to the dry season has been observed 
before [40] and may be explained by malaria infection
in the weeks prior to enrolment as malaria 
transmission is high in these months. In addition 
children may have had an actual infection and been 
(partly) treated before enrolment, which also explains 
the decreased Pf-pLDH specificity in the rainy and post-
rainy season. For children aged 1 – 5 years, specificity 
for PfHRP2-detection was extremely low which may be 
ascribed to their high vulnerability to malaria which 
was reflected by the high prevalence in this age group. 
The relation has been observed before [5] while no
such association was observed for Pf-pLDH-detection, 
probably due to the more rapid clearance from the 
blood stream [41-43].  
What if treatment is based on RDT results 
In children with severe malaria it is crucial that the 
diagnosis is not missed: a negative RDT should safely 
exclude malaria. However, overdiagnosis of malaria by 
diagnostic testing does not only lead to a waste of 
antimalarial drugs but also increases the risk of 
ignorance of other possible life threatening diseases 
like invasive bacterial infections, which is especially 
true for PfHRP2-detecting RDTs. Even though WHO 
mentions to look for other causes of severe illness 
(including IBI) in case of a positive RDT, this strategy is 
not yet clearly implemented in the diagnostic algorithm 
of Burkina Faso [11] and may be overlooked in daily
reality, especially since tools for diagnosis of other 
diseases are lacking.  
Pf-pLDH versus PfHRP2-detecting RDTs 
The present data adds to the debate about Pf-pLDH 
versus PfHRP2-detecting RDTs. The previously reported 
lower sensitivity and lower heat stability of Pf-pLDH-
detecting RDTs appeared to be product dependent 
[19]. Unlike PfHRP2, Pf-pLDH-detection is not affected
by the prozone effect [24], no gene deletions [15] or
antigen polymorphisms [44-47] have been reported 
and it is rapidly cleared from the blood stream [41,42].
Especially because of its higher specificity, Pf-pLDH-
detecting RDTs may be more useful in malaria endemic 
areas. In addition it may be that Pf-pLDH-detecting 
RDTs are more cost-beneficial compared to 
presumptive diagnosis in high-transmission settings, 
which was not the case for PfHRP2-detecting RDTs as 
concluded by Bisoffi et al. [48]. This needs however to
be further evaluated. 
Future perspectives 
To what extent can the present study findings be 
applied? First, an appropriate Pf-pLDH-detecting RDT 
should be selected and assessed for its diagnostic 
accuracy and robustness in field studies. Currently only 
few Pf-pLDH-detecting RDT products are available on 
the international market [32], and only one 3-band RDT
targeting Pf-pLDH and pan-pLDH and one 2-band RDT 
targeting pan-pLDH fulfilled WHO criteria of good 
performance [49]. More emphasis should be on
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development and optimization of Pf-pLDH-detecting 
RDTs, and it should be evaluated how fast they become 
negative during antimalarial treatment. If future field 
evaluations of Pf-pLDH-detecting RDTs are satisfying, 
the recommendation of the WHO to use PfHRP2-
detecting RDTs in P. falciparum endemic areas in Sub-
Saharan Africa [10] should be reconsidered. In the
meantime, diagnostic algorithms should better 
highlight the possibility of invasive bacterial infections 
in spite of a positive RDT result.   
Conclusion 
Among children presenting with severe febrile illness in 
a region with seasonal hyperendemic malaria 
transmission, we observed similar sensitivity but lower 
specificity of PfHRP2 compared to Pf-pLDH-detection. 
Specificity of PfHRP2 was lowest in the rainy season but 
positive predictive value was highest in this season due 
to the high malaria prevalence. For each season and 
age group, the positive predictive value of PfHRP2 was 
lower compared to Pf-pLDH. Part of the apparent false-
positive PfHRP2 samples might however be due to 
parasite clearance after (incomplete or ongoing)  
treatment with antimalarials at home or at the 
referring health center. Further studies should assess 
the diagnostic accuracy and safety of an appropriate Pf-
pLDH-detecting RDT in field settings and its capacity to 
distinguish ongoing malaria from recently cleared 
infections. If satisfying, replacement of PfHRP2-
detecting RDTs by Pf-pLDH-detecting RDTs should be 
considered.  
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Parts of this discussion have been adapted from 
 Maltha J, Gillet P, Jacobs J. Malaria rapid diagnostic tests in endemic settings. Clin Microbiol
Infect 2013, 19: 399-407.
 Maltha J, Gillet P, Jacobs J. Malaria rapid diagnostic tests in travel medicine. Clin Microbiol
Infect 2013, 19: 408-415.
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General discussion and future perspectives 
Malaria RDTs have been developed more than 20 years ago and have undergone many 
improvements since then and the number of available products has multiplied enormously. 
Although RDTs are widely available and used on large scale, we observed several shortcomings 
regarding diagnostic accuracy, appropriateness for end-users and place in the diagnostic algorithm. 
Here we will discuss our findings with regard to more recently available data and current evolutions 
in policy. Some of the data presented below have been adapted from two recent reviews we were 
invited to write about RDTs in travel medicine and RDTs in endemic setting [1,2].
Cross-reactions between the different Plasmodium antigens and antibodies  
In Chapter 2 of this thesis, we observed false-positive Pv-pLDH lines (targeting P. vivax) in 6/9 RDT 
products which were tested against a panel of P. falciparum samples at high parasite density [3]. A
more recent study by Piper et al. found however that, when using antibody combinations most 
commonly incorporated in RDTs, P. falciparum samples with high parasite densities did not generate 
false positive Pv-pLDH lines [4]. If this is the case, then there may be two other possible
explanations. First, non-specific bindings may have occurred, as was shown for some RDT products 
in Chapter 5 of this thesis which generated positive results in nearly all samples [5]. In our study we
did not test the RDTs with Plasmodium negative samples to exclude non-specific bindings. However, 
three out of six RDT products generating false positive Pv-pLDH lines have been evaluated against a 
panel of Plasmodium positive and negative samples. Interestingly, only P. falciparum samples 
generated false positive Pv-pLDH lines, not the P. ovale, P. malariae or Plasmodium negative samples 
[6–8]. It may be that the P. falciparum samples used in chapter 3 contained other interfering factors
that have caused false positive results, such as rheumatoid factor, hepatitis C, schistosomiasis, 
toxoplasmosis, dengue, leishmaniasis, Chagas disease and Human African trypanosomiasis [9–13].
However, as these diseases are rare in the travel population, the expected frequency of these 
factors among the P. falciparum samples tested is much lower than the observed false positive Pv-
pLDH lines (8.2 – 29.1%). Therefore it seems plausible that indeed the ‘P. vivax specific’ antibodies 
on the RDT test strip have bound Pf-pLDH. Why this was not found by Piper et al. may be due to the 
use of different antibody combinations than the ones used in the RDT products we evaluated. In 
addition Piper et al. used an extra ‘washing’ step in their analysis which is known to remove weak 
antibody-antigen bindings. Besides the cross-reactions of P. falciparum samples with the Pv-pLDH 
line, we also observed false positive Pf-pLDH lines in case of P. vivax samples [14] and in case of P.
ovale infection (Chapter 7). Incorrect species diagnosis may lead to incorrect treatment, as discussed 
in Chapters 2 and 3. Therefore, manufacturers should try to improve the accuracy of their RDT 
products, which can be done by selection of an ideal combination of detection and capture 
antibodies [4]. 
Pfhrp2 gene deletions – local or global problem? 
Pfhrp2 gene deletions have first been described in P. falciparum laboratory strains in the eighties 
[15], but recently the absence of this gene has been confirmed in P. falciparum field isolates [16]. For 
how long P. falciparum strains with gene deletions have been present in Peru is unknown, although 
it seems a quite recent phenomenon: a field evaluation of a PfHRP2-detecting RDT in Iquitos in 1998 
– 1999 found excellent sensitivity [17]. This study was performed in the same area as where we
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observed poor sensitivity of PfHRP2-detecting RDTs due to pfrhp2 gene deletions. This implies that  
P. falciparum strains lacking pfhrp2 were only introduced after this period.  
Are these gene deletions restricted to the Peruvian Amazon? As the Amazon region where malaria 
transmission occurs is not only confined to Peru, it would be expected that other South-American 
countries are affected as well. Indeed, pfhrp2 gene deletions have been reported from Brazil [18] 
and the Colombian Amazon [19] and the Centers for Disease Control and prevention (CDC) found 
pfhrp2 and pfhrp3  gene deletions in Bolivia, coastal Colombia and Suriname (Table 1 [20]).  
Table 1. Pfhrp2 and pfhrp3 gene deletions in different countries assessed by CDC 
Country Samples pfhrp2 (%) pfhrp3 (%) 
Bolivia 27 4 68 
Colombia 40 7.5 45 
Guyana 100 0 0 
Peru 94 33 53.8 
Suriname 78 14.1 3.84 
Honduras 68 0 44 
Data retrieved from CDC [20] 
More recently, reports from Africa [21,22] and India [23] have appeared. The study in Mali [22] 
concluded that pfhrp2 gene deletions only occur in asymptomatic patients, in contrast to our 
findings [14]. This study was performed 15 years ago,  using different techniques and materials. In
addition, to conclude that the pfhrp2 gene was absent, only one PCR was performed: this is of 
concern as sequence variation at the binding site or low DNA concentration/quality by itself may 
have caused the negative PCR reaction. By contrast, in other studies and ours we performed two 
PCRs across the pfhrp2 gene. Further investigation is warranted to assess if pfhrp2 gene deletions 
are indeed present in Mali and how frequently they occur. A recent evaluation of a PfHRP2-detecting 
RDT performed in Mali found high sensitivities (96% and 95% [24]), making widespread pfhrp2 gene
deletions less plausible. It needs however to be said that in high endemic settings, children are often 
infected by different P. falciparum strains [25]. Therefore, it is possible that many children actually
do carry P. falciparum strains with pfhrp2 gene deletions but because of simultaneous infection by P. 
falciparum strains with intact pfhrp2, the RDTs remain positive.  
In India, in two symptomatic patients with parasite density of 47,136 and 6,952/µl the deletion of 
pfhrp2 and pfhrp3 was confirmed [23] as well as in three patients from Senegal [21]. 
These findings indicate that pfhrp2 gene deletions are more widespread than previously thought and 
the frequency may further increase. Further investigation to identify the extent of the problem are 
needed and possibly a switch to Pf-pLDH-detecting RDTs if the spread of pfhrp2 gene deletions 
increases. 
How can end-user performance be improved? [2] 
Table 2 lists the most frequent errors committed by end-users in remote settings; they include 
critical steps related to safety and accuracy of procedure and interpretation. Reading beyond the 
recommended reading time proves to be a persistent error: at warm ambient temperatures, the 
excess sample with unbound conjugate flows back by capillary action of the sample/buffer pad and 
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gets passively deposited on the test band, thereby generating a false positive line, a so-called 
“Backflow” phenomenon [26].
Many errors by end-users can be explained by shortcomings in packaging, labeling, correctness and 
readability of instructions [27], as was described in this thesis [5,28], and unsatisfactory
comprehension of “universal” ISO15223-based graphical symbols [29]. In addition, shortcomings in
other contents of RDT kits may add to poor performance, such as desiccants with absent or difficult 
to assess humidity indicator [30], tiny alcohol swabs [27], pipette transfer devices with no volume
mark and incorrectly packaged lancets. Combined efforts from (repeat) training, clear and simple 
bench-site job aids (in local language) and supervision visits are effectively and sustainably 
contributing to correct end-user’s performance [31–33].
The currently available RDT products differ from each other on many aspects, e.g. lay-out and 
labeling of RDT device, transfer device to be used and procedure. In countries where two or more 
tests are deployed or where new different RDT product will replace the old specific training is 
needed. Similarities between RDT products would facilitate procurement and supply management, 
as well as training/re-training and supervision. In addition, it is expected that harmonization of RDT 
products will improve general end-user performance of malaria RDTs in the field. Therefore, the 
diagnostic work stream of the Roll Back Malaria partnership has developed an action plan for RDT 
harmonization which is executed by ITM. 
Table 2. Errors committed by RDT end-users in malaria endemic settings. 
Errors ranked according to chronology 
of test procedure 
Effects/Comments Countries References 
Not checking expiration date of the 
device 
Confusion may arise from the way of 
displaying the expiry date [27]
Lao PDR, The 
Philippines, Uganda, 
Zambia 
[27,31–33]
Not checking the humidity indicator of 
the desiccant 
Humidity weakens the bonds 
between antibodies and 
nitrocellulose strip and delays 
particle resolubilisation [30]
Laos PDR, The 
Philippines, Zambia 
[32,33]
Not using gloves Gloves protect from blood borne 
infection transmission 
Zambia [31,32]
Reusing the same gloves for different 
patients 
Uganda, Zambia [27,31]
Not identifying  the cassette with the 
patients’ name or laboratory number 
Risk of inversion of results between 
patients 
Zambia [31,32]
Not cleaning/disinfecting the  finger 
before pricking 
Zambia [27,31–33]
Not allowing the finger to dry after 
cleaning and before pricking 
Antiseptic needs enough action time Lao PDR, The 
Philippines, Zambia 
[31–33]
Reusing  a lancet for a next patient Zambia [31]
Desterilizing the lancet before use (by 
touching the bench or hands) 
Zambia [31]
Pricking the wrong place of the finger 
(palmar instead of lateral side) 
Pricking the palmar side of the finger 
is more painful than pricking at the 
side 
Zambia [31]
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Not throwing the lancet in a sharps 
container 
Zambia [31,32]
Dispensing the wrong volume of blood 
or transferring the blood not completely 
to the sample well (leaving blood on the 
wall of the well) 
1. Insufficient volume of blood may
cause false negative results, 2. Too 
much blood may increase the risk or 
the intensity of a prozone effect [34],
3. Too much blood will cause
decreased clearance of the strip 
Malawi, Sudan, 
Uganda, Zambia 
[27,31,32,35,36]
Distributing blood into the buffer well 
and/or buffer into the sample well 
Sample and buffer well are not 
always unequivocally labeled [28]
Laos PDR, The 
Philippines 
[33]
Substituting the buffer by another liquid 
(e.g. distilled water) 
Use of any other liquid than the 
buffer provided in the RDT's kit may 
cause false positive results [37]
Mali, Mozambique [38]
Dispensing the wrong volume of buffer 1. Insufficient volume of buffer will
impede clearance of the strip and/or 
slow down migration with failure to 
generate a control line (invalid test 
results)  
2. Too high volume of buffer may
cause false positive results due to 
non-specific bindings 
Lao PDR, Sudan, The 
Philippines, Uganda, 
Zambia 
[27,31–33,36]
Not using a leveled surface to place the 
cassette 
Decreasing  the migration time may 
cause false negative results [39]
DR Congo, Lao PDR, 
Sudan 
[31,33,36]
Not discarding  the used materials 
correctly 
Lao PDR, The 
Philippines, Zambia 
[31–33]
Not respecting the correct reading time 1. Reading too early may cause false-
negative results, 2. Reading too late 
may cause false-positive results due 
to a backflow phenomenon [40]
Lao PDR, Malawi, 
Sudan, The 
Philippines, Uganda, 
Zambia 
[27,31–33,35,36]
Disregarding faint or weak test lines  Faint test lines may be difficult to see 
particularly in unfavorable light 
conditions (night shifts) and by 
elderly readers [27,41]
DR Congo, Lao PDR, 
The Philippines, 
Zambia 
[31–33,42]
Not recognizing invalid test results DR Congo, Zambia [32,42]
Interpreting line intensities as indicative 
for disease severity (and installing 
treatment accordingly) 
Line intensity is not related to 
severity 
Lao PDR, The 
Philippines, Uganda 
[27,33]
Not interpreting correctly a three- band 
RDT 
Difficulties to define the species 
involved based on the test line 
results 
DR Congo, Sudan [36,42]
Study subjects were village or community health workers (Cambodia, Lao PDR, Mali, The Philippines and 
Zambia), staff of peripheral health centers (Malawi, Sudan and Uganda) and hospital laboratory staff 
(Mozambique and DR Congo). All subjects had been trained in RDT use and performance. 
Adapted from Maltha et al. malaria RDTs in endemic setting [2] 
Although RDTs were initially mostly performed by laboratory technicians, RDT use is now 
increasingly expanding to community health workers [43]. Home-based management of malaria
(HMM), i.e. the diagnosis and treatment of malaria by trained community members, has been 
recommended by WHO to improve access to effective antimalarial treatment [44]. Promising results
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have been reported [45], although appropriate training and continued supervision is needed [31].
Training and supervision may be feasible in research settings, but in remote settings this may be 
hard to obtain. For example, in DR Congo 50% of health facilities using RDTs had not received any 
training [42]. Therefore, when implementing RDTs, more emphasis should be put on training and
continued supervision of end-users. 
Worldwide, approximately 40% of patients with suspected malaria seek treatment in the private 
sector [43]. RDT regulation and quality control is however lacking in the private sector [46]. This may
lead to the use of inaccurate RDT products or inaccurate performance and interpretation due to 
incomplete or incorrect instructions [28]. Consequently, incorrect diagnosis may be made and the
recommended test and treat strategy may not be safe anymore. Therefore, private sectors should 
be incorporated in the roll-out of malaria RDTs and training of health staff should include those from 
the private sector. 
How can quality of RDTs be guaranteed? [2]
Substandard malaria RDTs are widespread in resource limited settings [47,48] and lot-to-lot
variations may affect performance of RDTs [49]. Regulatory approvals from high-income countries
are of limited help: for instance, the requirements for the European Union’s conformity label (CE 
Mark) in the case of malaria RDTs are purely administrative [47]. To overcome this vacuum, WHO
and partners organized the “Prequalification of Diagnostics Programme”: in addition to RDT product 
dossier assessments, manufacturing sites are inspected for compliance with ISO13485 standards and 
an active post-marketing surveillance system has been installed [50]. The increasing demand of RDTs
(annually need of 1.5 billion RDTs forecasted) may however lead to supply interruptions or 
decreased quality due to scale-up of the production processes. Further, the so-called WHO/FIND 
Rounds assess RDTs also for diagnostic accuracy (P. falciparum and P. vivax) and heat stability [51]
and WHO/FIND further offer a lot testing program.  
Should RDTs be promoted for self-use by travelers? [1]
As written in Chapter 5, several improvements in RDTs for travelers are necessary with regard to 
diagnostic accuracy and IFU. The IFU should become more user-friendly, clear information on test 
accuracy and limitations should be given, and test procedure and interpretation should be 
completed. In addition we suggested multiple lancets, transfer devices and alcohol wipes as the first 
attempt may be unsuccessful. However, even with these improvements, we suggest a 
comprehensive training program and follow-up of results.  
In our setting, we offer a training of RDT self-diagnosis to travelers referred by physicians during pre-
travel consultations. Travelers are provided with a simple layman-directed step-by-step procedure of 
the RDT product [52] which includes comments on limitations of RDTs and on what to do with the 
test results (e.g. repeat testing in case of negative result but persistence of symptoms). The training 
comprises hands-on practice as well as a photo-based quiz about RDT interpretation. Participants 
are further invited to email photographs of the RDTs they performed on-site for follow-up and 
advice. To facilitate finger pricking, we replaced the simple “plain lancet” provided in the RDT kit by 
a “safety lancet” (Sarstedt, Nümbrecht, Germany). Furthermore we provide extra safety lancets, 
alcohol wipes and transfer devices, as repeat finger pricking and transfer attempts may be expected. 
From our training sessions, we learned that repeat hands-on practice is essential for acquiring 
dexterity in finger pricking and transfer of blood; therefore we advise RDT self-testing only to those 
who have been trained or have practiced RDTs appropriately – it goes without saying that stressful 
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CAS SUSPECTS 
Test de diagnostic rapide 
POSITIF NEGATIF 
TRAITEMENT Rechercher D’AUTRES 
MALADIES 
Ne pas utiliser 
d’antipaludiques
conditions may decrease the actual performance (Figure 1). RDTs for self-diagnosis may be useful for 
the traveler when comprehensive instructions and a training program are guaranteed, but further 
study needs to assess its value under field settings.   
Figure 1: Picture of a RDT performed by an expatriate and sent by email 
A woman performed the RDT on her 9-year old son in Ivory Coast and sent the picture by email. She had 
attended the RDT training three months earlier. The cassette is placed on the printed outlines of the layman-
directed Standard Operating Procedure [52]. From the picture it is clear that the user had difficulties applying 
the blood into the sample well (S), as much blood sticks to the plastic casing. Applying a too low volume of 
blood on the test strip may result in false-negative RDT results. The visible control line (C) only testifies that 
migration of the colloidal gold complex occurred, but not that the correct sample volume has been applied.   
Adapted from Maltha et al. Malaria RDTs in travel medicine [1] 
Some reflections on the  current diagnostic algorithm 
The current diagnostic algorithm used in Burkina Faso includes treatment of malaria in case of a 
positive RDT and withholding antimalarial drugs in RDT negative cases while searching for other 
causes of disease (Figure 2 [53]). Below, the findings of Chapters 6 and 7 will discussed with respect
to the current diagnostic algorithm and current practice in sub-Saharan Africa.    
Figure 2 Diagnostic algorithm as displayed in most health facilities in Burkina Faso [53].
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Problem 1: “a positive test is malaria” 
The above quote reflects current practice in many sub-Saharan countries. The recommended RDT 
type in sub-Saharan Africa detects PfHRP2. As shown in chapter 6 and 7 of the present study and in 
many others, false positive RDT results are frequent in high-transmission settings due to PfHRP2 
persistence after treatment [54–57]. This leads to an overuse of ACTs and it was shown that 
presumptive diagnosis and treatment of malaria in hyperendemic areas may be more cost-effective 
than treatment based on PfHRP2-detecting RDTs [58]. Moreover, false positive RDTs lead to 
ignorance of other diseases that may become fatal. During our study in Burkina Faso, a child had 
been tested for malaria at a health center and was treated on outpatient basis with intramuscular 
quinine. On day 2 of treatment the child  had become severely ill and was referred to the hospital 
where the child died upon arrival. It is possible that this child had a bacterial infection with a (false) 
positive malaria RDT (Chapter6/7), but this could not be confirmed as the child had died before 
blood sampling could have been done. 
Potential measures to prevent overlooking of other diseases include increasing the awareness of 
other possible life threatening diseases (see below) by training and supervision. In addition, 
appropriate tools for diagnosis of non-malaria febrile illness should be developed. Another 
possibility can be the use of malaria Pf-pLDH-detecting RDTs, which are more specific compared to 
PfHRP2 (see Table 3 for an overview of advantages and disadvantages of Pf-pLDH versus PfHRP2). 
Due to a higher specificity of Pf-pLDH (because of faster decline and clearance compared to PfHRP2 
[54–56,59,60]), less children with bacterial diseases will have false positive RDT results. However, 
this does not resolve the problem of the ‘true’ malaria/bacterial co-infections. Of note, Pf-pLDH RDT 
products consistently showed lower sensitivity compared to Pf-HRP2 RDTs, but recent studies show 
that well performing Pf-pLDH-detecting RDTs can reach equal sensitivity compared to PfHRP2 
(Chapter 7, [54,61]). However, their usefulness in settings where a high number of children are 
already (partially) treated at the moment of testing needs to be assessed, as  discussed in Chapter 7.  
Table 3. Advantages and disadvantages of PfHRP2 versus Pf-pLDH-detection (Chapter 6) 
Item PfHRP2 Pf-pLDH 
Sensitivity Generally high, also at low 
parasite densities 
Lower at low parasite densities, 
though product-dependent 
Specificity In high endemic settings low 
due to slow clearance after 
treatment (> 5 weeks) 
Excellent, could be used for 
treatment follow-up (although 
debated) 
High parasite densities False negative results may 
occur (prozone effect) 
Not affected by prozone effect 
Gene deletions Reported in South-America 
and evidence from India and 
Africa as well 
No gene deletions reported 
Sequence variation Highly variable between and 
within regions, may affect 
RDT sensitivity 
Not reported 
Heat stability Usually up to 45°C Usually up to 30°C though some 
products up to 45°C 
Problem 2: “a negative test safely excludes malaria” 
The safety of withholding antimalarial treatment in RDT or microscopy negative children was 
confirmed in several studies, which reported that withholding antimalarial treatment in test negative 
children never resulted in severe disease [62–65]. Indeed, most of the RDT products evaluated in
              89
field settings have a very high negative predictive value. In addition, most false negative results 
occur at very low parasite densities which either may be cleared by the patient himself or may be 
detected at subsequent testing when the patient consults again with persisting or aggravating 
symptoms. However, PfHRP2-detecting RDTs may also be negative in case of high parasite densities 
[66–68], most likely due to the prozone effect [34,69]. And although the prozone effect is relatively 
rare, missing high parasite densities may become fatal.  
 
Problem 3: adherence to test results 
The test and treat strategy has been implemented to restrict malaria treatment only to RDT positive 
patients. Some studies have reported good adherence to test results [45,62], while in other studies 
many of the RDT negative patients still received antimalarial treatment [70–74]. In high-transmission 
settings low adherence to test results may be influenced by initial training, opinion of colleagues, 
confusing guidelines and patient preference [75]. These factors should be taken into account when 
implementing RDTs and regular training as well as education of the community may be needed. 
Moreover, guidance on non-malaria febrile illness may further improve adherence to test results 
[76].  
 
Problem 4: no alternative diagnosis available 
The lack of alternative diagnostic test or clear guidelines may lead to an over-prescription of 
antibiotics in RDT negative children, as was observed in several studies [62,77,78], probably due to 
the absence of alternative diagnosis. Over-prescription of antibiotics may further increase antibiotic 
resistance rates, while the resistance to first line antibiotics is already high in sub-Saharan Africa, as 
observed in our study and others [79–84]. Clear guidelines on clinical management are needed while 
RDTs for other causes of febrile illness should be developed and implemented.  
 
Problem 5: diagnostic algorithm for severe malaria 
Although children with suspicion of severe malaria should be referred to the hospital urgently, this is 
not always possible. Long distances, lack of transport facilities, bad road and weather conditions and 
poor economic circumstances make that some children with ‘less’ severe disease are diagnosed and 
treated at health center level. Since RDTs are available, the diagnosis of malaria can now be 
confirmed at health center level and intravenous quinine can be started. However, as shown in our 
studies, there is a high number of false positive RDT results and more than half of the children with 
confirmed bacteremia had a positive RDT. Although training instructions include that a positive thick 
blood film or RDT does not mean that malaria is the only cause of disease, the possibility of 
concomitant bacterial infection is not clearly incorporated in the diagnostic algorithm of Burkina 
Faso and a positive RDT may distract the health care worker from other possible life-threatening 
diagnosis. A RDT detecting bacteremia would be highly beneficial in these settings to identify those 
in need of antibiotics, especially since timely diagnosis and treatment for bacterial sepsis is needed 
to prevent mortality. Existing diagnostic tests for detection of bacteremia (culture, PCR) are time 
consuming, require special equipment and often fail to detect the low number of bacteria circulating 
in the blood [85].  
An alternative to diagnosis of bacteremia may be provided by the host himself: indeed, 
metabolomics i.e. the study of small molecules released during biochemical processes by the host, 
can identify specific markers of bacteremia which can be used as basis for an antigen detection test.   
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Recently we performed a pilot study on the metabolomics-based approach of detecting bacteria in 
blood. The first results are promising, showing a distinct metabolomics profile in children with 
bacteremia compared to severe malaria [86]. However, as development and implementation of a 
RDT may take up to ten years, some other solutions should be sought in the meantime. First, the 
diagnostic algorithm should emphasize the possibility of a positive RDT with concomitant 
bacteremia. Second, blood culture surveillance studies, as performed in Chapter 6, should continue 
and extend to other sites as well, to assess the burden of bacteremia, to identify the most commonly 
isolated pathogens and to evaluate their antibiotic resistance pattern. This can help to improve 
clinical guidelines on when to use the appropriate antibiotics.   
In conclusion, we provided information with regard to diagnostic accuracy, end-user performance 
and diagnostic practice, which when addressed by the respective manufacturers, health regulatory 
authorities or health care workers, can improve malaria diagnosis in children. 
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Summary 
 
Malaria is an infectious disease caused by the Plasmodium parasite which replicates in red blood 
cells. Almost half of the world population is at risk of acquiring malaria and 660,000 persons died 
from malaria in 2010, most of whom were children under the age of five. The World Health 
Organization (WHO) recommends to confirm the diagnosis of malaria before start of treatment. This 
confirmation can be done by microscopy, which is often unavailable or of low quality in endemic 
settings, or by malaria rapid diagnostic tests (RDTs). RDTs are hand-held cassettes that detect 
malaria by an antigen-antibody reaction. They are easy to use and provide results within 15-20 
minutes. Different formats detecting different antigens exist: Plasmodium falciparum Histidine-rich 
protein-2 (PfHRP2), parasite lactate dehydrogenase (pLDH) which can be specific for P. falciparum 
(Pf-pLDH), Plasmodium vivax (Pv-pLDH) or common to all  Plasmodium species (pan-pLDH) and 
aldolase (all Plasmodium species).  
 
In 2010, 88 million RDTs were used worldwide and more than 200 different products from 60 
manufacturers were available. Although worldwide used, we hypothesized several limitations and 
shortcomings regarding i) diagnostic accuracy, ii) appropriateness for end-users and iii) place in 
diagnostic algorithms.  
 
In Chapter 2 we showed that in 6/9 RDT products evaluated, Plasmodium falciparum samples at high 
parasite density generated false positive Pv-pLDH lines in 9 – 28% of samples tested, thereby leading 
to incorrect species diagnosis. In Chapters 3 and 6 we observed as well false positive P. falciparum 
results in case of P. vivax or P. ovale samples respectively.  
 
In Peru RDTs could be highly beneficial, especially in remote areas of the Peruvian Amazon where it 
may take several days before a health center can be reached; however no RDT has been 
incorporated in the national malaria control program yet. In Chapter 3 we evaluated a panel of RDTs 
in the Peruvian amazon and found that PfHRP2-detecting RDTs had low diagnostic sensitivity due to 
pfhrp2 gene deletion, which encodes the protein PfHRP2. We showed that Pf-pLDH-detecting RDTs 
are accurate and hence promising for this region; the Ministry of Health is actually in the decision 
process upon which RDT product to use. 
 
Clear and complete instructions are crucial to correct performance and interpretation of RDTs by 
end-users. We assessed a large panel of RDT products for the quality and completeness of their 
instructions, packaging and labeling (Chapter 4). Shortcomings were observed in all RDT products, 
including some with CE label. Some of the major shortcomings included ambiguous labeling of the 
reading window, incomplete information about test interpretation and critical differences between 
depicted device in the instructions and the device present in the RDT kit. Most of these 
shortcomings can be corrected at low cost and investment and will help to improve end-user’s 
performance.   
 
Nowadays RDTs for self-use by travelers are available through the internet. There is increasing 
interest in the self-use of RDTs, but quality of these products is unknown. We found that only half of 
the RDT products advertised for self-testing and purchased through internet could reliably diagnose 
P. falciparum and P. vivax. Two products showed positive test lines in nearly all samples, including 
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the Plasmodium negative ones, thereby prohibiting their use. (Chapter 5). All products had major 
shortcomings in the instructions for use with regard to description of test procedure and 
interpretation, poor readability and lay-out and user-unfriendly typography. Importantly, strategic 
issues (‘what to do if your test is positive or negative’) were incomplete or not mentioned at all. 
Before RDTs can be recommended for self-use by travelers, major improvements need to be done 
and we only recommend RDTs for travelers when comprehensive instructions and a training 
program are guaranteed.  
 
Malaria is often over-diagnosed in endemic settings. Severe malaria may present with similar 
symptoms as invasive bacterial infections, such as bacteremia or meningitis. Co-infections of malaria 
and bacterial infections may occur as well. In order to improve treatment guidelines in children 
presenting with severe febrile illness in malaria endemic areas, it is important to know to which 
extent malaria and invasive bacterial infections occur and what the antibiotic resistance rates are. In 
a group of severely ill children in a seasonal hyperendemic malaria transmission area in Burkina 
Faso, we observed severe malaria in 50% of the admissions and invasive bacterial infections in 9%. 
However, case-fatality rates of invasive bacterial infections were four-fold higher compared to 
severe malaria. Furthermore, many of the bacteria isolated were resistant against first line 
antibiotics commonly used in Burkina Faso (Chapter 6).  
 
As malaria rapid diagnostic tests are used in children presenting with severe febrile illness, and as 
they are the only diagnostic tool available in health centers, we assessed the diagnostic accuracy and 
predictive value of PfHRP2 versus Pf-pLDH detection in the children studied in Chapter 6. We 
observed similar (high) sensitivities, but the specificity of PfHRP2-detection was significantly lower 
compared to Pf-pLDH detection, which was reflected by a lower positive predictive value of PfHRP2 
detection for all ages and seasons (Chapter 7). Positive PfHRP2 results do not distinguish between 
recent (<1 week) or ongoing P. falciparum infections versus past en cured P. falciparum infections 
more than one week ago. Pf-pLDH probably will be better suited for this purpose as it is rapidly 
cleared from the bloodstream and should be further studied.   
 
In conclusion, we provided information with regard to diagnostic accuracy, end-user performance 
and diagnostic practice of malaria RDTs, which when addressed by the respective manufacturers, 
health regulatory authorities and  health care professionals  can improve malaria diagnosis in 
children. 
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Samenvatting 
Malaria is een infectieziekte die veroorzaakt wordt door de Plasmodium parasiet die zich in de rode 
bloedcellen vermenigvuldigt. Bijna de helft van de wereldbevolking loopt risico om malaria te krijgen 
en in 2010 stierven er 660.000 personen aan malaria, hoofdzakelijk kinderen onder de vijf jaar. De 
Wereld Gezondheidsorganisatie (WHO) adviseert om de diagnose van malaria te bevestigen alvorens 
te starten met de behandeling. Deze bevestiging kan gebeuren door middel van microscopie, welke 
in endemische gebieden zelden beschikbaar is of van lage kwaliteit, of door middel van malaria 
sneltesten  (Rapid Diagnostic Tests, RDTs). RDTs zijn kleine cassettes die malaria detecteren door 
antigen-antilichaam reactie. Ze zijn gemakkelijk in gebruik en geven een resultaat binnen 15-20 
minuten. Er bestaan verschillende formaten die verschillende antigenen detecteren: Plasmodium 
falciparum Histidine-rich protein-2 (PfHRP2), parasiet lactaat dehydrogenase (pLDH) dat specifiek 
kan zijn voor P. falciparum (Pf-pLDH) en voor Plasmodium vivax (Pv-pLDH) ofwel gemeenschappelijk 
kan zijn aan alle Plasmodium species  (pan-pLDH); daarnaast is er nog aldolase, welke voorkomt bij 
alle Plasmodium species.  
In 2010 werden wereldwijd 88 miljoen RDTs gebruikt en er waren meer dan 200 verschillende 
producten van 60 fabrikanten beschikbaar op de markt. Hoewel RDTs wereldwijd gebruikt worden, 
vermoedden we een aantal beperkingen en tekortkomingen betreffende i) de diagnostische 
nauwkeurigheid, ii) de geschiktheid voor eindgebruikers en iii) de positionering van RDTs in 
diagnostische algoritmes. 
In Hoofdstuk 2 tonen we aan dat  Plasmodium falciparum stalen met een hoge parasietdensiteit vals
positieve Pv-pLDH testlijnen veroorzaakten in 9-28% van de geteste stalen, hetgeen leidde tot een 
incorrecte diagnose van de Plasmodium species, en dit voor 6 van de 9 geëvalueerde RDT producten. 
In Hoofdstuk 3 en 6 observeerden we ook vals positieve P. falciparum resultaten voor respectievelijk
P. vivax en P. ovale stalen.  
In Peru zouden RDTs van groot nut kunnen zijn, voornamelijk in de afgelegen gebieden van het 
Peruviaanse Amazonegebied waar het verschillende dagen kan duren voordat een 
gezondheidscentrum kan bereikt worden;  toch zijn de RDTs er nog niet opgenomen in het nationale 
malaria controle programma. In Hoofdstuk 3 evalueerden we een panel van RDTs in het Peruviaanse
Amazonegebied en we stelden vast dat de RDTs die PfHRP2 detecteren een lage diagnostische 
gevoeligheid hadden omwille van een pfhrp2 gen-deletie, het gen dat codeert voor het eiwit  
PfHRP2. We toonden aan dat RDTs die Pf-pLDH detecteren wel accuraat zijn en dus veelbelovend 
zijn voor dit gebied; het ministerie van volksgezondheid is momenteel in de beslissingsfase over 
welke RDT producten zullen gebruikt worden. 
Duidelijke en volledige gebruiksinstructies zijn cruciaal voor een correcte uitvoering en interpretatie 
van RDTs door de eindgebruikers. We hebben een groot panel van RDT producten geanalyseerd voor 
de kwaliteit en de volledigheid van de gebruiksinstructies in de bijsluiter, hun verpakking en hun 
etikettering (Hoofdstuk 4).  We stelden tekortkomingen vast voor alle RDT producten, waaronder
ook een aantal met CE label. De meest belangrijke tekortkomingen waren onder meer de 
dubbelzinnige etikettering van het leesvenster, de onvolledige informatie over de interpretatie van 
de test en de belangrijke verschillen tussen de weergave van de test in de instructies en de 
werkelijke presentatie van de test in de RDT kit. In de meeste gevallen kunnen deze tekortkomingen 
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gecorrigeerd worden aan een lage kost en investering , waardoor de uitvoering van de test door de 
eindgebruiker gevoelig kan verbeteren. 
Tegenwoordig zijn er steeds meer zelftesten voor reizigers beschikbaar op het internet. Er is een 
verhoogde interesse voor deze zelftesten, maar de kwaliteit van deze producten is nog ongekend. 
We hebben vastgesteld dat slechts de helft van de RDT producten die op het internet geadverteerd 
en verkocht werden als malaria zelftesten, een betrouwbare diagnose van  P. falciparum en P. vivax 
konden geven. Twee producten gaven positieve testlijnen voor bijna alle stalen, ook voor de 
Plasmodium negatieve, waardoor ze niet gebruikt kunnen worden (Hoofdstuk 5). Alle producten
hadden belangrijke tekortkomingen in de beschrijving van de test procedure en de test interpretatie, 
de leesbaarheid, de lay-out en de typografie van de gebruiksinstructies. Belangrijker was dat 
strategische instructies (“Wat te doen als je test resultaat positief of negatief is”) onvolledig waren 
of zelfs helemaal niet genoemd werden. Voordat RDTs aanbevolen kunnen worden als zelftesten 
voor reizigers moeten er belangrijke aanpassingen gebeuren en ze kunnen enkel aanbevolen worden 
indien de gebruiksinstructies volledig zijn en indien een trainingsprogramma voor de reizigers kan 
gegarandeerd worden.   
Malaria wordt vaak over-gediagnostiseerd in endemische gebieden. Ernstige malaria kan 
gelijkaardige symptomen geven dan een invasieve bacteriële infectie, zoals bacteriëmie of 
meningitis. Co-infecties van malaria en bacteriële infecties kunnen ook voorkomen. Om de 
richtlijnen voor de behandeling van kinderen met ernstige koorts in endemische gebieden te kunnen 
verbeteren, is het belangrijk om te weten in welke verhouding malaria en invasieve bacteriële 
infecties voorkomen en hoe groot de antibiotica resistentie is. Bij een groep van ernstig zieke 
kinderen in een hyper-endemisch malaria-gebied met seizoensgebonden transmissie in Burkina Faso 
stelden we bij 50% van de gevallen malaria vast tegenover bij 9% een invasieve bacteriële infectie. 
De sterfte bij invasieve bacteriële infecties was echter vier keer hoger dan die voor malaria. 
Bovendien waren vele van de geïsoleerde bacteriën resistent tegen de eerstelijns antibiotica die 
algemeen gebruikt worden in Burkina Faso (Hoofdstuk 6).
Malaria RDTs worden gebruikt voor kinderen met ernstige koorts, en zijn de enige diagnostische 
methode aanwezig zijn in gezondheidscentra. Daarom evalueerden we de diagnostische 
nauwkeurigheid en predictieve waarde van PfHRP2 versus Pf-pLDH detectie in dezelfde groep 
kinderen die bestudeerd werden in Hoofdstuk 6. We observeerden vergelijkbare (hoge) 
gevoeligheden, maar de specificiteit van de PfHRP2-detectie was significant lager in vergelijking met 
de Pf-pLDH detectie, wat weerspiegeld werd in een lagere positieve predictieve waarde van PfHRP2 
detectie voor alle leeftijden en seizoenen (Hoofdstuk 7). Met een positief PfHRP2 resultaat kan geen
onderscheid gemaakt worden tussen een actieve of een recent opgelopen infectie (< 1 week) versus 
een afgelopen en behandelde P. falciparum infectie van meer dan 1 week geleden. Pf-pLDH 
waarschijnlijk meer geschikt om dit onderscheid te kunnen maken, omdat dit eiwit sneller wordt 
verwijderd uit de bloedbaan. Deze hypothese moet verder onderzocht worden. 
Ter conclusie, we hebben informatie verkregen betreffende de diagnostische nauwkeurigheid, de 
kwaliteit van de uitvoering door de eindgebruikers  en op welke manier de RDTs in de praktijk 
worden gebruikt. Wanneer deze informatie wordt aangeboden aan de respectievelijke fabrikanten, 
de regelgevende instanties omtrent gezondheid en de gezondheidsmedewerkers, kan dit de malaria 
diagnosis voor kinderen verbeteren.    
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